US20080131455A1 - Antigen Delivery Compositions And Methods Of Use - Google Patents
Antigen Delivery Compositions And Methods Of Use Download PDFInfo
- Publication number
- US20080131455A1 US20080131455A1 US11/944,912 US94491207A US2008131455A1 US 20080131455 A1 US20080131455 A1 US 20080131455A1 US 94491207 A US94491207 A US 94491207A US 2008131455 A1 US2008131455 A1 US 2008131455A1
- Authority
- US
- United States
- Prior art keywords
- antigen
- lpd
- tumor
- peptide
- mice
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 239000000427 antigen Substances 0.000 title claims abstract description 170
- 108091007433 antigens Proteins 0.000 title claims abstract description 170
- 102000036639 antigens Human genes 0.000 title claims abstract description 170
- 238000000034 method Methods 0.000 title claims abstract description 43
- 239000000203 mixture Substances 0.000 title abstract description 27
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 131
- 208000035473 Communicable disease Diseases 0.000 claims abstract description 6
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 108
- 210000004027 cell Anatomy 0.000 claims description 101
- 108090000623 proteins and genes Proteins 0.000 claims description 55
- 150000002632 lipids Chemical class 0.000 claims description 54
- 125000002091 cationic group Chemical group 0.000 claims description 43
- 102000004169 proteins and genes Human genes 0.000 claims description 43
- 230000000694 effects Effects 0.000 claims description 41
- ATUOYWHBWRKTHZ-UHFFFAOYSA-N Propane Chemical compound CCC ATUOYWHBWRKTHZ-UHFFFAOYSA-N 0.000 claims description 34
- -1 cationic lipid Chemical class 0.000 claims description 34
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims description 32
- 230000028993 immune response Effects 0.000 claims description 27
- 208000015181 infectious disease Diseases 0.000 claims description 24
- 239000001294 propane Substances 0.000 claims description 17
- 201000011510 cancer Diseases 0.000 claims description 16
- 235000012000 cholesterol Nutrition 0.000 claims description 16
- 244000052769 pathogen Species 0.000 claims description 15
- 241000700605 Viruses Species 0.000 claims description 14
- 230000000813 microbial effect Effects 0.000 claims description 12
- 241000701806 Human papillomavirus Species 0.000 claims description 11
- 210000004881 tumor cell Anatomy 0.000 claims description 11
- 239000002671 adjuvant Substances 0.000 claims description 10
- 230000002163 immunogen Effects 0.000 claims description 10
- 230000000890 antigenic effect Effects 0.000 claims description 9
- 230000003308 immunostimulating effect Effects 0.000 claims description 9
- 101000767631 Human papillomavirus type 16 Protein E7 Proteins 0.000 claims description 8
- 150000002430 hydrocarbons Chemical group 0.000 claims description 8
- 230000001717 pathogenic effect Effects 0.000 claims description 8
- 241000894007 species Species 0.000 claims description 8
- LDGWQMRUWMSZIU-LQDDAWAPSA-M 2,3-bis[(z)-octadec-9-enoxy]propyl-trimethylazanium;chloride Chemical compound [Cl-].CCCCCCCC\C=C/CCCCCCCCOCC(C[N+](C)(C)C)OCCCCCCCC\C=C/CCCCCCCC LDGWQMRUWMSZIU-LQDDAWAPSA-M 0.000 claims description 7
- 230000002246 oncogenic effect Effects 0.000 claims description 7
- XULFJDKZVHTRLG-JDVCJPALSA-N DOSPA trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F.CCCCCCCC\C=C/CCCCCCCCOCC(C[N+](C)(C)CCNC(=O)C(CCCNCCCN)NCCCN)OCCCCCCCC\C=C/CCCCCCCC XULFJDKZVHTRLG-JDVCJPALSA-N 0.000 claims description 6
- 210000003719 b-lymphocyte Anatomy 0.000 claims description 5
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 5
- 230000012010 growth Effects 0.000 claims description 5
- 239000004094 surface-active agent Substances 0.000 claims description 5
- 239000004215 Carbon black (E152) Substances 0.000 claims description 4
- 241000590002 Helicobacter pylori Species 0.000 claims description 4
- 241000700721 Hepatitis B virus Species 0.000 claims description 4
- 241000701044 Human gammaherpesvirus 4 Species 0.000 claims description 4
- 108010048684 O,O'-dimyristyl-N-lysyl aspartate Proteins 0.000 claims description 4
- 108010047807 O,O'-dimyristyl-N-lysyl glutamate Proteins 0.000 claims description 4
- 241000194017 Streptococcus Species 0.000 claims description 4
- AJOVHKRJQWSZLE-PXLJZGITSA-N ditetradecyl (2s)-2-[[(2s)-2,6-diaminohexanoyl]amino]butanedioate Chemical compound CCCCCCCCCCCCCCOC(=O)C[C@H](NC(=O)[C@@H](N)CCCCN)C(=O)OCCCCCCCCCCCCCC AJOVHKRJQWSZLE-PXLJZGITSA-N 0.000 claims description 4
- 229930195733 hydrocarbon Natural products 0.000 claims description 4
- 102000015728 Mucins Human genes 0.000 claims description 3
- 108010063954 Mucins Proteins 0.000 claims description 3
- 239000013592 cell lysate Substances 0.000 claims description 3
- 230000004069 differentiation Effects 0.000 claims description 3
- 201000010099 disease Diseases 0.000 claims description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 3
- 150000002270 gangliosides Chemical class 0.000 claims description 3
- 229940051875 mucins Drugs 0.000 claims description 3
- 231100000590 oncogenic Toxicity 0.000 claims description 3
- 229920000642 polymer Polymers 0.000 claims description 3
- 230000004936 stimulating effect Effects 0.000 claims description 3
- 230000000381 tumorigenic effect Effects 0.000 claims description 3
- 230000003612 virological effect Effects 0.000 claims description 3
- 241000711549 Hepacivirus C Species 0.000 claims description 2
- 208000005176 Hepatitis C Diseases 0.000 claims description 2
- 108010043496 Immunoglobulin Idiotypes Proteins 0.000 claims description 2
- 241000712464 Orthomyxoviridae Species 0.000 claims description 2
- 241000606860 Pasteurella Species 0.000 claims description 2
- 241000709664 Picornaviridae Species 0.000 claims description 2
- 241000589516 Pseudomonas Species 0.000 claims description 2
- 241000712907 Retroviridae Species 0.000 claims description 2
- 241000607142 Salmonella Species 0.000 claims description 2
- 210000002752 melanocyte Anatomy 0.000 claims description 2
- 230000035755 proliferation Effects 0.000 claims description 2
- 210000002307 prostate Anatomy 0.000 claims description 2
- 210000001550 testis Anatomy 0.000 claims description 2
- 150000002148 esters Chemical class 0.000 claims 6
- KSXTUUUQYQYKCR-LQDDAWAPSA-M 2,3-bis[[(z)-octadec-9-enoyl]oxy]propyl-trimethylazanium;chloride Chemical compound [Cl-].CCCCCCCC\C=C/CCCCCCCC(=O)OCC(C[N+](C)(C)C)OC(=O)CCCCCCC\C=C/CCCCCCCC KSXTUUUQYQYKCR-LQDDAWAPSA-M 0.000 claims 3
- DTQVDTLACAAQTR-UHFFFAOYSA-M Trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-M 0.000 claims 3
- 150000002576 ketones Chemical class 0.000 claims 3
- 125000001453 quaternary ammonium group Chemical group 0.000 claims 3
- 150000004671 saturated fatty acids Chemical class 0.000 claims 3
- 230000003637 steroidlike Effects 0.000 claims 3
- 235000021122 unsaturated fatty acids Nutrition 0.000 claims 3
- 150000004670 unsaturated fatty acids Chemical class 0.000 claims 3
- 229960001438 immunostimulant agent Drugs 0.000 claims 2
- 239000003022 immunostimulating agent Substances 0.000 claims 2
- 230000001939 inductive effect Effects 0.000 claims 2
- 230000002401 inhibitory effect Effects 0.000 claims 2
- 241000700586 Herpesviridae Species 0.000 claims 1
- 239000000654 additive Substances 0.000 claims 1
- 230000000996 additive effect Effects 0.000 claims 1
- 229940037467 helicobacter pylori Drugs 0.000 claims 1
- 208000005252 hepatitis A Diseases 0.000 claims 1
- 208000002672 hepatitis B Diseases 0.000 claims 1
- 241000699670 Mus sp. Species 0.000 description 108
- 239000002502 liposome Substances 0.000 description 59
- 239000002245 particle Substances 0.000 description 56
- 108020004414 DNA Proteins 0.000 description 31
- 238000011282 treatment Methods 0.000 description 31
- 102000004196 processed proteins & peptides Human genes 0.000 description 29
- 238000002255 vaccination Methods 0.000 description 27
- 210000000952 spleen Anatomy 0.000 description 26
- 229920001184 polypeptide Polymers 0.000 description 24
- 238000002347 injection Methods 0.000 description 23
- 239000007924 injection Substances 0.000 description 23
- 229960005486 vaccine Drugs 0.000 description 21
- 230000014509 gene expression Effects 0.000 description 19
- 239000013612 plasmid Substances 0.000 description 19
- 230000002458 infectious effect Effects 0.000 description 18
- 238000002474 experimental method Methods 0.000 description 15
- KWVJHCQQUFDPLU-YEUCEMRASA-N 2,3-bis[[(z)-octadec-9-enoyl]oxy]propyl-trimethylazanium Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC(C[N+](C)(C)C)OC(=O)CCCCCCC\C=C/CCCCCCCC KWVJHCQQUFDPLU-YEUCEMRASA-N 0.000 description 14
- 238000009472 formulation Methods 0.000 description 14
- 210000004988 splenocyte Anatomy 0.000 description 14
- 238000011740 C57BL/6 mouse Methods 0.000 description 13
- 239000002105 nanoparticle Substances 0.000 description 13
- 102100022297 Integrin alpha-X Human genes 0.000 description 12
- 150000001413 amino acids Chemical class 0.000 description 12
- 101001046686 Homo sapiens Integrin alpha-M Proteins 0.000 description 11
- 101000914484 Homo sapiens T-lymphocyte activation antigen CD80 Proteins 0.000 description 11
- 102100022338 Integrin alpha-M Human genes 0.000 description 11
- 108010007568 Protamines Proteins 0.000 description 11
- 102000007327 Protamines Human genes 0.000 description 11
- 102100027222 T-lymphocyte activation antigen CD80 Human genes 0.000 description 11
- 230000000259 anti-tumor effect Effects 0.000 description 11
- 239000002953 phosphate buffered saline Substances 0.000 description 11
- 238000007920 subcutaneous administration Methods 0.000 description 11
- 229940024606 amino acid Drugs 0.000 description 10
- 210000001165 lymph node Anatomy 0.000 description 10
- 230000004614 tumor growth Effects 0.000 description 10
- 230000009089 cytolysis Effects 0.000 description 9
- 238000011081 inoculation Methods 0.000 description 9
- 244000005700 microbiome Species 0.000 description 9
- 210000000822 natural killer cell Anatomy 0.000 description 9
- 230000007935 neutral effect Effects 0.000 description 9
- 229940048914 protamine Drugs 0.000 description 9
- 230000000638 stimulation Effects 0.000 description 8
- 230000001225 therapeutic effect Effects 0.000 description 8
- 241001465754 Metazoa Species 0.000 description 7
- 241000699666 Mus <mouse, genus> Species 0.000 description 7
- 229940037003 alum Drugs 0.000 description 7
- 238000003556 assay Methods 0.000 description 7
- MWRBNPKJOOWZPW-CLFAGFIQSA-N dioleoyl phosphatidylethanolamine Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC(COP(O)(=O)OCCN)OC(=O)CCCCCCC\C=C/CCCCCCCC MWRBNPKJOOWZPW-CLFAGFIQSA-N 0.000 description 7
- 238000000684 flow cytometry Methods 0.000 description 7
- 230000035772 mutation Effects 0.000 description 7
- 229940046166 oligodeoxynucleotide Drugs 0.000 description 7
- 239000000047 product Substances 0.000 description 7
- 125000000539 amino acid group Chemical group 0.000 description 6
- 125000000637 arginyl group Chemical group N[C@@H](CCCNC(N)=N)C(=O)* 0.000 description 6
- 230000015572 biosynthetic process Effects 0.000 description 6
- 229940022399 cancer vaccine Drugs 0.000 description 6
- 238000009566 cancer vaccine Methods 0.000 description 6
- 150000001720 carbohydrates Chemical class 0.000 description 6
- 229940079593 drug Drugs 0.000 description 6
- 239000003814 drug Substances 0.000 description 6
- 239000012636 effector Substances 0.000 description 6
- 239000012634 fragment Substances 0.000 description 6
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 6
- 230000006698 induction Effects 0.000 description 6
- 238000004519 manufacturing process Methods 0.000 description 6
- 230000005740 tumor formation Effects 0.000 description 6
- 102100034540 Adenomatous polyposis coli protein Human genes 0.000 description 5
- 206010008342 Cervix carcinoma Diseases 0.000 description 5
- 241000588724 Escherichia coli Species 0.000 description 5
- 229930186217 Glycolipid Natural products 0.000 description 5
- 241000282412 Homo Species 0.000 description 5
- 108060001084 Luciferase Proteins 0.000 description 5
- 241000124008 Mammalia Species 0.000 description 5
- 108010060818 Toll-Like Receptor 9 Proteins 0.000 description 5
- 102100033117 Toll-like receptor 9 Human genes 0.000 description 5
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 5
- HIHOWBSBBDRPDW-PTHRTHQKSA-N [(3s,8s,9s,10r,13r,14s,17r)-10,13-dimethyl-17-[(2r)-6-methylheptan-2-yl]-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1h-cyclopenta[a]phenanthren-3-yl] n-[2-(dimethylamino)ethyl]carbamate Chemical compound C1C=C2C[C@@H](OC(=O)NCCN(C)C)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HIHOWBSBBDRPDW-PTHRTHQKSA-N 0.000 description 5
- 235000014633 carbohydrates Nutrition 0.000 description 5
- 201000010881 cervical cancer Diseases 0.000 description 5
- 150000001875 compounds Chemical class 0.000 description 5
- 239000002609 medium Substances 0.000 description 5
- 206010061289 metastatic neoplasm Diseases 0.000 description 5
- 150000007523 nucleic acids Chemical class 0.000 description 5
- 230000003389 potentiating effect Effects 0.000 description 5
- 241000894006 Bacteria Species 0.000 description 4
- VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 description 4
- 108090000695 Cytokines Proteins 0.000 description 4
- 102000004127 Cytokines Human genes 0.000 description 4
- 241000701022 Cytomegalovirus Species 0.000 description 4
- 241000233866 Fungi Species 0.000 description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 4
- 102100037850 Interferon gamma Human genes 0.000 description 4
- 108010074328 Interferon-gamma Proteins 0.000 description 4
- 206010061309 Neoplasm progression Diseases 0.000 description 4
- 108010004729 Phycoerythrin Proteins 0.000 description 4
- 125000002252 acyl group Chemical group 0.000 description 4
- 230000006023 anti-tumor response Effects 0.000 description 4
- 210000000612 antigen-presenting cell Anatomy 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 229910052804 chromium Inorganic materials 0.000 description 4
- 239000011651 chromium Substances 0.000 description 4
- 210000004443 dendritic cell Anatomy 0.000 description 4
- PSLWZOIUBRXAQW-UHFFFAOYSA-M dimethyl(dioctadecyl)azanium;bromide Chemical compound [Br-].CCCCCCCCCCCCCCCCCC[N+](C)(C)CCCCCCCCCCCCCCCCCC PSLWZOIUBRXAQW-UHFFFAOYSA-M 0.000 description 4
- 238000009826 distribution Methods 0.000 description 4
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 4
- 230000036039 immunity Effects 0.000 description 4
- 230000003053 immunization Effects 0.000 description 4
- 238000002649 immunization Methods 0.000 description 4
- 238000007912 intraperitoneal administration Methods 0.000 description 4
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 4
- 108020004707 nucleic acids Proteins 0.000 description 4
- 102000039446 nucleic acids Human genes 0.000 description 4
- 230000001681 protective effect Effects 0.000 description 4
- 150000003839 salts Chemical class 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 238000003860 storage Methods 0.000 description 4
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 4
- 238000002560 therapeutic procedure Methods 0.000 description 4
- 230000005751 tumor progression Effects 0.000 description 4
- 239000004475 Arginine Substances 0.000 description 3
- 108010022366 Carcinoembryonic Antigen Proteins 0.000 description 3
- 102100025475 Carcinoembryonic antigen-related cell adhesion molecule 5 Human genes 0.000 description 3
- 102000003886 Glycoproteins Human genes 0.000 description 3
- 108090000288 Glycoproteins Proteins 0.000 description 3
- 239000005089 Luciferase Substances 0.000 description 3
- 108700020796 Oncogene Proteins 0.000 description 3
- 101710172711 Structural protein Proteins 0.000 description 3
- 229930006000 Sucrose Natural products 0.000 description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
- 210000001744 T-lymphocyte Anatomy 0.000 description 3
- 0 [1*]CC([2*])[3*] Chemical compound [1*]CC([2*])[3*] 0.000 description 3
- 102000013529 alpha-Fetoproteins Human genes 0.000 description 3
- 108010026331 alpha-Fetoproteins Proteins 0.000 description 3
- 238000000540 analysis of variance Methods 0.000 description 3
- 230000005975 antitumor immune response Effects 0.000 description 3
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 3
- 108010005774 beta-Galactosidase Proteins 0.000 description 3
- 230000004071 biological effect Effects 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 238000001125 extrusion Methods 0.000 description 3
- 239000012091 fetal bovine serum Substances 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 229940084986 human chorionic gonadotropin Drugs 0.000 description 3
- 230000005934 immune activation Effects 0.000 description 3
- 210000000987 immune system Anatomy 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 210000004072 lung Anatomy 0.000 description 3
- 210000002540 macrophage Anatomy 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 230000001404 mediated effect Effects 0.000 description 3
- 238000012737 microarray-based gene expression Methods 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012243 multiplex automated genomic engineering Methods 0.000 description 3
- 238000002559 palpation Methods 0.000 description 3
- 244000045947 parasite Species 0.000 description 3
- 150000003904 phospholipids Chemical class 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 238000010254 subcutaneous injection Methods 0.000 description 3
- 239000005720 sucrose Substances 0.000 description 3
- 230000004083 survival effect Effects 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- OPCHFPHZPIURNA-MFERNQICSA-N (2s)-2,5-bis(3-aminopropylamino)-n-[2-(dioctadecylamino)acetyl]pentanamide Chemical compound CCCCCCCCCCCCCCCCCCN(CC(=O)NC(=O)[C@H](CCCNCCCN)NCCCN)CCCCCCCCCCCCCCCCCC OPCHFPHZPIURNA-MFERNQICSA-N 0.000 description 2
- PORPENFLTBBHSG-MGBGTMOVSA-N 1,2-dihexadecanoyl-sn-glycerol-3-phosphate Chemical group CCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(O)=O)OC(=O)CCCCCCCCCCCCCCC PORPENFLTBBHSG-MGBGTMOVSA-N 0.000 description 2
- SNKAWJBJQDLSFF-NVKMUCNASA-N 1,2-dioleoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/CCCCCCCC SNKAWJBJQDLSFF-NVKMUCNASA-N 0.000 description 2
- WALUVDCNGPQPOD-UHFFFAOYSA-M 2,3-di(tetradecoxy)propyl-(2-hydroxyethyl)-dimethylazanium;bromide Chemical compound [Br-].CCCCCCCCCCCCCCOCC(C[N+](C)(C)CCO)OCCCCCCCCCCCCCC WALUVDCNGPQPOD-UHFFFAOYSA-M 0.000 description 2
- 241001227615 Bovine foamy virus Species 0.000 description 2
- 241000714266 Bovine leukemia virus Species 0.000 description 2
- 201000009030 Carcinoma Diseases 0.000 description 2
- 102000011022 Chorionic Gonadotropin Human genes 0.000 description 2
- 108010062540 Chorionic Gonadotropin Proteins 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 101150029707 ERBB2 gene Proteins 0.000 description 2
- 238000011510 Elispot assay Methods 0.000 description 2
- 241000709661 Enterovirus Species 0.000 description 2
- 241000713730 Equine infectious anemia virus Species 0.000 description 2
- 241000713800 Feline immunodeficiency virus Species 0.000 description 2
- 241000192125 Firmicutes Species 0.000 description 2
- 241000713813 Gibbon ape leukemia virus Species 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 241000856850 Goose coronavirus Species 0.000 description 2
- 229920000209 Hexadimethrine bromide Polymers 0.000 description 2
- 241000713772 Human immunodeficiency virus 1 Species 0.000 description 2
- 241000248484 Ichthyophthirius Species 0.000 description 2
- 101001056675 Klebsiella pneumoniae Ferric aerobactin receptor Proteins 0.000 description 2
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 2
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 2
- 102000007330 LDL Lipoproteins Human genes 0.000 description 2
- 108010007622 LDL Lipoproteins Proteins 0.000 description 2
- 239000004472 Lysine Substances 0.000 description 2
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 2
- 102000043129 MHC class I family Human genes 0.000 description 2
- 108091054437 MHC class I family Proteins 0.000 description 2
- 241000713821 Mason-Pfizer monkey virus Species 0.000 description 2
- 102100022430 Melanocyte protein PMEL Human genes 0.000 description 2
- 241000713333 Mouse mammary tumor virus Species 0.000 description 2
- 102000007298 Mucin-1 Human genes 0.000 description 2
- 108010008707 Mucin-1 Proteins 0.000 description 2
- 241000714177 Murine leukemia virus Species 0.000 description 2
- 102000043276 Oncogene Human genes 0.000 description 2
- 229930182555 Penicillin Natural products 0.000 description 2
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 229920002873 Polyethylenimine Polymers 0.000 description 2
- 206010060862 Prostate cancer Diseases 0.000 description 2
- 108010072866 Prostate-Specific Antigen Proteins 0.000 description 2
- 102100038358 Prostate-specific antigen Human genes 0.000 description 2
- 241000711798 Rabies lyssavirus Species 0.000 description 2
- 241000606701 Rickettsia Species 0.000 description 2
- 241001529934 Simian T-lymphotropic virus 3 Species 0.000 description 2
- 241000700584 Simplexvirus Species 0.000 description 2
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 2
- 241000711975 Vesicular stomatitis virus Species 0.000 description 2
- 108010067390 Viral Proteins Proteins 0.000 description 2
- 229960000723 ampicillin Drugs 0.000 description 2
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000005875 antibody response Effects 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 239000006285 cell suspension Substances 0.000 description 2
- 230000007969 cellular immunity Effects 0.000 description 2
- 229940032077 cervical cancer vaccine Drugs 0.000 description 2
- WLNARFZDISHUGS-MIXBDBMTSA-N cholesteryl hemisuccinate Chemical compound C1C=C2C[C@@H](OC(=O)CCC(O)=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 WLNARFZDISHUGS-MIXBDBMTSA-N 0.000 description 2
- 239000000287 crude extract Substances 0.000 description 2
- 239000012228 culture supernatant Substances 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 239000008121 dextrose Substances 0.000 description 2
- 238000012377 drug delivery Methods 0.000 description 2
- 238000002296 dynamic light scattering Methods 0.000 description 2
- 210000002889 endothelial cell Anatomy 0.000 description 2
- 238000003114 enzyme-linked immunosorbent spot assay Methods 0.000 description 2
- 108091006104 gene-regulatory proteins Proteins 0.000 description 2
- 102000034356 gene-regulatory proteins Human genes 0.000 description 2
- 150000004676 glycans Chemical class 0.000 description 2
- 125000003827 glycol group Chemical group 0.000 description 2
- 244000052637 human pathogen Species 0.000 description 2
- 230000036571 hydration Effects 0.000 description 2
- 238000006703 hydration reaction Methods 0.000 description 2
- 125000001165 hydrophobic group Chemical group 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 239000002479 lipoplex Substances 0.000 description 2
- 210000002751 lymph Anatomy 0.000 description 2
- 230000002101 lytic effect Effects 0.000 description 2
- MCIDNMJNWYUTMB-UHFFFAOYSA-N n-tert-butyl-n'-tetradecyl-3-(tetradecylamino)propanimidamide Chemical compound CCCCCCCCCCCCCCNCCC(NC(C)(C)C)=NCCCCCCCCCCCCCC MCIDNMJNWYUTMB-UHFFFAOYSA-N 0.000 description 2
- 230000001338 necrotic effect Effects 0.000 description 2
- 229940049954 penicillin Drugs 0.000 description 2
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 description 2
- 229920000729 poly(L-lysine) polymer Polymers 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 238000003752 polymerase chain reaction Methods 0.000 description 2
- 229920001282 polysaccharide Polymers 0.000 description 2
- 239000005017 polysaccharide Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 230000037452 priming Effects 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 229940070353 protamines Drugs 0.000 description 2
- DAEPDZWVDSPTHF-UHFFFAOYSA-M sodium pyruvate Chemical compound [Na+].CC(=O)C([O-])=O DAEPDZWVDSPTHF-UHFFFAOYSA-M 0.000 description 2
- ATHGHQPFGPMSJY-UHFFFAOYSA-N spermidine Chemical compound NCCCCNCCCN ATHGHQPFGPMSJY-UHFFFAOYSA-N 0.000 description 2
- PFNFFQXMRSDOHW-UHFFFAOYSA-N spermine Chemical compound NCCCNCCCCNCCCN PFNFFQXMRSDOHW-UHFFFAOYSA-N 0.000 description 2
- 229960005322 streptomycin Drugs 0.000 description 2
- 230000008685 targeting Effects 0.000 description 2
- 239000010409 thin film Substances 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 230000002476 tumorcidal effect Effects 0.000 description 2
- 210000003462 vein Anatomy 0.000 description 2
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
- KZKAYEGOIJEWQB-UHFFFAOYSA-N 1,3-dibromopropane;n,n,n',n'-tetramethylhexane-1,6-diamine Chemical compound BrCCCBr.CN(C)CCCCCCN(C)C KZKAYEGOIJEWQB-UHFFFAOYSA-N 0.000 description 1
- RUAUPNFNQOGIFF-UHFFFAOYSA-N 1-(4-tert-butyl-2,5-dimethoxyphenyl)propan-2-amine Chemical compound COC1=CC(C(C)(C)C)=C(OC)C=C1CC(C)N RUAUPNFNQOGIFF-UHFFFAOYSA-N 0.000 description 1
- LUNCLNIYHUMRFU-UHFFFAOYSA-N 1-(trimethylazaniumyl)butan-2-yl hydrogen phosphate Chemical compound C[N+](C)(C)CC(CC)OP(O)([O-])=O LUNCLNIYHUMRFU-UHFFFAOYSA-N 0.000 description 1
- YAMUFBLWGFFICM-PTGWMXDISA-N 1-O-oleoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](O)COP([O-])(=O)OCC[N+](C)(C)C YAMUFBLWGFFICM-PTGWMXDISA-N 0.000 description 1
- RYCNUMLMNKHWPZ-SNVBAGLBSA-N 1-acetyl-sn-glycero-3-phosphocholine Chemical compound CC(=O)OC[C@@H](O)COP([O-])(=O)OCC[N+](C)(C)C RYCNUMLMNKHWPZ-SNVBAGLBSA-N 0.000 description 1
- FJUOBOJIJWDANZ-UHFFFAOYSA-N 2-[(4-anilinophenyl)iminomethyl]-5-(diethylamino)phenol Chemical compound CCN(CC)C1=CC(=C(C=C1)C=NC2=CC=C(C=C2)NC3=CC=CC=C3)O FJUOBOJIJWDANZ-UHFFFAOYSA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- DHSXKGQVDZYBPG-MHCSTSKJSA-N 2-[[(3s,10r,13r,17r)-10,13-dimethyl-17-[(2r)-6-methylheptan-2-yl]-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1h-cyclopenta[a]phenanthrene-3-carbonyl]amino]ethyl-trimethylazanium;iodide Chemical compound [I-].C1C=C2C[C@@H](C(=O)NCC[N+](C)(C)C)CC[C@]2(C)C2C1C1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 DHSXKGQVDZYBPG-MHCSTSKJSA-N 0.000 description 1
- LKKMLIBUAXYLOY-UHFFFAOYSA-N 3-Amino-1-methyl-5H-pyrido[4,3-b]indole Chemical compound N1C2=CC=CC=C2C2=C1C=C(N)N=C2C LKKMLIBUAXYLOY-UHFFFAOYSA-N 0.000 description 1
- HVCOBJNICQPDBP-UHFFFAOYSA-N 3-[3-[3,5-dihydroxy-6-methyl-4-(3,4,5-trihydroxy-6-methyloxan-2-yl)oxyoxan-2-yl]oxydecanoyloxy]decanoic acid;hydrate Chemical compound O.OC1C(OC(CC(=O)OC(CCCCCCC)CC(O)=O)CCCCCCC)OC(C)C(O)C1OC1C(O)C(O)C(O)C(C)O1 HVCOBJNICQPDBP-UHFFFAOYSA-N 0.000 description 1
- WEVYNIUIFUYDGI-UHFFFAOYSA-N 3-[6-[4-(trifluoromethoxy)anilino]-4-pyrimidinyl]benzamide Chemical compound NC(=O)C1=CC=CC(C=2N=CN=C(NC=3C=CC(OC(F)(F)F)=CC=3)C=2)=C1 WEVYNIUIFUYDGI-UHFFFAOYSA-N 0.000 description 1
- 101710163881 5,6-dihydroxyindole-2-carboxylic acid oxidase Proteins 0.000 description 1
- OPIFSICVWOWJMJ-AEOCFKNESA-N 5-bromo-4-chloro-3-indolyl beta-D-galactoside Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1OC1=CNC2=CC=C(Br)C(Cl)=C12 OPIFSICVWOWJMJ-AEOCFKNESA-N 0.000 description 1
- 241000186046 Actinomyces Species 0.000 description 1
- 102000007469 Actins Human genes 0.000 description 1
- 108010085238 Actins Proteins 0.000 description 1
- 241000701242 Adenoviridae Species 0.000 description 1
- 208000009746 Adult T-Cell Leukemia-Lymphoma Diseases 0.000 description 1
- 208000016683 Adult T-cell leukemia/lymphoma Diseases 0.000 description 1
- 101000689231 Aeromonas salmonicida S-layer protein Proteins 0.000 description 1
- 241000701386 African swine fever virus Species 0.000 description 1
- 102100024321 Alkaline phosphatase, placental type Human genes 0.000 description 1
- 241000712892 Arenaviridae Species 0.000 description 1
- 102100024003 Arf-GAP with SH3 domain, ANK repeat and PH domain-containing protein 1 Human genes 0.000 description 1
- 241001167018 Aroa Species 0.000 description 1
- 108010002913 Asialoglycoproteins Proteins 0.000 description 1
- 241000714230 Avian leukemia virus Species 0.000 description 1
- 241000713826 Avian leukosis virus Species 0.000 description 1
- 241000713838 Avian myeloblastosis virus Species 0.000 description 1
- 102100035526 B melanoma antigen 1 Human genes 0.000 description 1
- 208000003950 B-cell lymphoma Diseases 0.000 description 1
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 description 1
- 102000052609 BRCA2 Human genes 0.000 description 1
- 108700020462 BRCA2 Proteins 0.000 description 1
- 241000193830 Bacillus <bacterium> Species 0.000 description 1
- 241001148536 Bacteroides sp. Species 0.000 description 1
- 108060000903 Beta-catenin Proteins 0.000 description 1
- 102000015735 Beta-catenin Human genes 0.000 description 1
- 102100026189 Beta-galactosidase Human genes 0.000 description 1
- 241000702628 Birnaviridae Species 0.000 description 1
- 241000228405 Blastomyces dermatitidis Species 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 208000011691 Burkitt lymphomas Diseases 0.000 description 1
- LRHPLDYGYMQRHN-UHFFFAOYSA-N Butanol Natural products CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 1
- FERIUCNNQQJTOY-UHFFFAOYSA-M Butyrate Chemical compound CCCC([O-])=O FERIUCNNQQJTOY-UHFFFAOYSA-M 0.000 description 1
- 101100400624 Caenorhabditis elegans mbr-1 gene Proteins 0.000 description 1
- 101100314454 Caenorhabditis elegans tra-1 gene Proteins 0.000 description 1
- 241000589994 Campylobacter sp. Species 0.000 description 1
- 241000222122 Candida albicans Species 0.000 description 1
- 102000003846 Carbonic anhydrases Human genes 0.000 description 1
- 108090000209 Carbonic anhydrases Proteins 0.000 description 1
- 102100027668 Carboxy-terminal domain RNA polymerase II polypeptide A small phosphatase 1 Human genes 0.000 description 1
- 101710134395 Carboxy-terminal domain RNA polymerase II polypeptide A small phosphatase 1 Proteins 0.000 description 1
- 108090000538 Caspase-8 Proteins 0.000 description 1
- 102000004091 Caspase-8 Human genes 0.000 description 1
- 102100025064 Cellular tumor antigen p53 Human genes 0.000 description 1
- 101710150820 Cellular tumor antigen p53 Proteins 0.000 description 1
- 241000606153 Chlamydia trachomatis Species 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 241000193403 Clostridium Species 0.000 description 1
- 241000193449 Clostridium tetani Species 0.000 description 1
- 241000223205 Coccidioides immitis Species 0.000 description 1
- 108091026890 Coding region Proteins 0.000 description 1
- 108020004705 Codon Proteins 0.000 description 1
- 241000711573 Coronaviridae Species 0.000 description 1
- 102100028233 Coronin-1A Human genes 0.000 description 1
- 241000186227 Corynebacterium diphtheriae Species 0.000 description 1
- 241000186249 Corynebacterium sp. Species 0.000 description 1
- 241000709687 Coxsackievirus Species 0.000 description 1
- 201000007336 Cryptococcosis Diseases 0.000 description 1
- 241000221204 Cryptococcus neoformans Species 0.000 description 1
- 108010025464 Cyclin-Dependent Kinase 4 Proteins 0.000 description 1
- 102000013701 Cyclin-Dependent Kinase 4 Human genes 0.000 description 1
- 101710112752 Cytotoxin Proteins 0.000 description 1
- 241000710829 Dengue virus group Species 0.000 description 1
- 102100036912 Desmin Human genes 0.000 description 1
- 108010044052 Desmin Proteins 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 101150013359 E7 gene Proteins 0.000 description 1
- 241001115402 Ebolavirus Species 0.000 description 1
- 241001466953 Echovirus Species 0.000 description 1
- 241000607471 Edwardsiella tarda Species 0.000 description 1
- 101100491986 Emericella nidulans (strain FGSC A4 / ATCC 38163 / CBS 112.46 / NRRL 194 / M139) aromA gene Proteins 0.000 description 1
- 241000194032 Enterococcus faecalis Species 0.000 description 1
- 241001495410 Enterococcus sp. Species 0.000 description 1
- 241000991587 Enterovirus C Species 0.000 description 1
- 208000000832 Equine Encephalomyelitis Diseases 0.000 description 1
- 241000186810 Erysipelothrix rhusiopathiae Species 0.000 description 1
- 108050001049 Extracellular proteins Proteins 0.000 description 1
- 241000714165 Feline leukemia virus Species 0.000 description 1
- 241000711950 Filoviridae Species 0.000 description 1
- 241000604777 Flavobacterium columnare Species 0.000 description 1
- 102000001390 Fructose-Bisphosphate Aldolase Human genes 0.000 description 1
- 108010068561 Fructose-Bisphosphate Aldolase Proteins 0.000 description 1
- 206010017553 Furuncle Diseases 0.000 description 1
- 241000605986 Fusobacterium nucleatum Species 0.000 description 1
- 102000002464 Galactosidases Human genes 0.000 description 1
- 108010093031 Galactosidases Proteins 0.000 description 1
- 102000000805 Galectin 4 Human genes 0.000 description 1
- 108010001515 Galectin 4 Proteins 0.000 description 1
- 102100031351 Galectin-9 Human genes 0.000 description 1
- 101710121810 Galectin-9 Proteins 0.000 description 1
- 208000005577 Gastroenteritis Diseases 0.000 description 1
- 102100041003 Glutamate carboxypeptidase 2 Human genes 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 241001506229 Goose reovirus Species 0.000 description 1
- 102000009465 Growth Factor Receptors Human genes 0.000 description 1
- 108010009202 Growth Factor Receptors Proteins 0.000 description 1
- 208000031886 HIV Infections Diseases 0.000 description 1
- 241000606790 Haemophilus Species 0.000 description 1
- 206010061192 Haemorrhagic fever Diseases 0.000 description 1
- 241000150562 Hantaan orthohantavirus Species 0.000 description 1
- 108010006464 Hemolysin Proteins Proteins 0.000 description 1
- 241000700739 Hepadnaviridae Species 0.000 description 1
- 208000005331 Hepatitis D Diseases 0.000 description 1
- 241000709721 Hepatovirus A Species 0.000 description 1
- 108010033040 Histones Proteins 0.000 description 1
- 241000228404 Histoplasma capsulatum Species 0.000 description 1
- 101000874316 Homo sapiens B melanoma antigen 1 Proteins 0.000 description 1
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 description 1
- 101000892862 Homo sapiens Glutamate carboxypeptidase 2 Proteins 0.000 description 1
- 101001011441 Homo sapiens Interferon regulatory factor 4 Proteins 0.000 description 1
- 101000620359 Homo sapiens Melanocyte protein PMEL Proteins 0.000 description 1
- 101001131670 Homo sapiens PWWP domain-containing DNA repair factor 3A Proteins 0.000 description 1
- 101000880770 Homo sapiens Protein SSX2 Proteins 0.000 description 1
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 description 1
- 241000714260 Human T-lymphotropic virus 1 Species 0.000 description 1
- 241000714259 Human T-lymphotropic virus 2 Species 0.000 description 1
- 241000701085 Human alphaherpesvirus 3 Species 0.000 description 1
- 241000713673 Human foamy virus Species 0.000 description 1
- 241000725303 Human immunodeficiency virus Species 0.000 description 1
- 241000713340 Human immunodeficiency virus 2 Species 0.000 description 1
- 101100540311 Human papillomavirus type 16 E6 gene Proteins 0.000 description 1
- 101000622322 Human papillomavirus type 16 Regulatory protein E2 Proteins 0.000 description 1
- 241000714192 Human spumaretrovirus Species 0.000 description 1
- 241000601977 Ignatius Species 0.000 description 1
- 101800000324 Immunoglobulin A1 protease translocator Proteins 0.000 description 1
- 102100023915 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 102100030126 Interferon regulatory factor 4 Human genes 0.000 description 1
- 241000701377 Iridoviridae Species 0.000 description 1
- 102100033421 Keratin, type I cytoskeletal 18 Human genes 0.000 description 1
- 102100033420 Keratin, type I cytoskeletal 19 Human genes 0.000 description 1
- 102100023972 Keratin, type II cytoskeletal 8 Human genes 0.000 description 1
- 108010066327 Keratin-18 Proteins 0.000 description 1
- 108010066302 Keratin-19 Proteins 0.000 description 1
- 108010070511 Keratin-8 Proteins 0.000 description 1
- 241000588915 Klebsiella aerogenes Species 0.000 description 1
- 241000588747 Klebsiella pneumoniae Species 0.000 description 1
- 102100031413 L-dopachrome tautomerase Human genes 0.000 description 1
- 101710093778 L-dopachrome tautomerase Proteins 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- 229930182816 L-glutamine Natural products 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 1
- 101710128836 Large T antigen Proteins 0.000 description 1
- 241000589248 Legionella Species 0.000 description 1
- 208000007764 Legionnaires' Disease Diseases 0.000 description 1
- 241000713666 Lentivirus Species 0.000 description 1
- 241000589902 Leptospira Species 0.000 description 1
- 241000186779 Listeria monocytogenes Species 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 241000712079 Measles morbillivirus Species 0.000 description 1
- 241000713862 Moloney murine sarcoma virus Species 0.000 description 1
- 241000711386 Mumps virus Species 0.000 description 1
- 101100346932 Mus musculus Muc1 gene Proteins 0.000 description 1
- 241000186367 Mycobacterium avium Species 0.000 description 1
- 241000187484 Mycobacterium gordonae Species 0.000 description 1
- 241000186364 Mycobacterium intracellulare Species 0.000 description 1
- 241000186363 Mycobacterium kansasii Species 0.000 description 1
- KWYHDKDOAIKMQN-UHFFFAOYSA-N N,N,N',N'-tetramethylethylenediamine Chemical compound CN(C)CCN(C)C KWYHDKDOAIKMQN-UHFFFAOYSA-N 0.000 description 1
- 208000001894 Nasopharyngeal Neoplasms Diseases 0.000 description 1
- 241000588652 Neisseria gonorrhoeae Species 0.000 description 1
- 241000588650 Neisseria meningitidis Species 0.000 description 1
- 208000034176 Neoplasms, Germ Cell and Embryonal Diseases 0.000 description 1
- 208000009277 Neuroectodermal Tumors Diseases 0.000 description 1
- 108010077850 Nuclear Localization Signals Proteins 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 241000150218 Orthonairovirus Species 0.000 description 1
- 101710116435 Outer membrane protein Proteins 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 102000036673 PRAME Human genes 0.000 description 1
- 108060006580 PRAME Proteins 0.000 description 1
- 241001631646 Papillomaviridae Species 0.000 description 1
- 241000711504 Paramyxoviridae Species 0.000 description 1
- 208000002606 Paramyxoviridae Infections Diseases 0.000 description 1
- 206010034107 Pasteurella infections Diseases 0.000 description 1
- 241000713137 Phlebovirus Species 0.000 description 1
- 206010035148 Plague Diseases 0.000 description 1
- 241000224016 Plasmodium Species 0.000 description 1
- 241000223960 Plasmodium falciparum Species 0.000 description 1
- 241000223821 Plasmodium malariae Species 0.000 description 1
- 241001505293 Plasmodium ovale Species 0.000 description 1
- 241000223810 Plasmodium vivax Species 0.000 description 1
- 229920000362 Polyethylene-block-poly(ethylene glycol) Polymers 0.000 description 1
- 108010039918 Polylysine Proteins 0.000 description 1
- 241001505332 Polyomavirus sp. Species 0.000 description 1
- 208000024777 Prion disease Diseases 0.000 description 1
- 102100039310 Probable serine carboxypeptidase CPVL Human genes 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 102100037686 Protein SSX2 Human genes 0.000 description 1
- 102000052575 Proto-Oncogene Human genes 0.000 description 1
- 108700020978 Proto-Oncogene Proteins 0.000 description 1
- 241000125945 Protoparvovirus Species 0.000 description 1
- 239000012979 RPMI medium Substances 0.000 description 1
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 description 1
- 241000186812 Renibacterium salmoninarum Species 0.000 description 1
- 241000702247 Reoviridae Species 0.000 description 1
- 241000725643 Respiratory syncytial virus Species 0.000 description 1
- 241000712909 Reticuloendotheliosis virus Species 0.000 description 1
- 241000711931 Rhabdoviridae Species 0.000 description 1
- 239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 1
- 241000702670 Rotavirus Species 0.000 description 1
- 241000714474 Rous sarcoma virus Species 0.000 description 1
- 241000710799 Rubella virus Species 0.000 description 1
- 206010039491 Sarcoma Diseases 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 241000713656 Simian foamy virus Species 0.000 description 1
- 241000714229 Simian retrovirus 1 Species 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 241000713896 Spleen necrosis virus Species 0.000 description 1
- 241000295644 Staphylococcaceae Species 0.000 description 1
- 241000191967 Staphylococcus aureus Species 0.000 description 1
- 241001478880 Streptobacillus moniliformis Species 0.000 description 1
- 241000193985 Streptococcus agalactiae Species 0.000 description 1
- 241000194049 Streptococcus equinus Species 0.000 description 1
- 241000193998 Streptococcus pneumoniae Species 0.000 description 1
- 241000193996 Streptococcus pyogenes Species 0.000 description 1
- 241001505901 Streptococcus sp. 'group A' Species 0.000 description 1
- 241000193990 Streptococcus sp. 'group B' Species 0.000 description 1
- 102000004874 Synaptophysin Human genes 0.000 description 1
- 108090001076 Synaptophysin Proteins 0.000 description 1
- 230000006044 T cell activation Effects 0.000 description 1
- 230000005867 T cell response Effects 0.000 description 1
- 208000000389 T-cell leukemia Diseases 0.000 description 1
- 208000028530 T-cell lymphoblastic leukemia/lymphoma Diseases 0.000 description 1
- 102000003627 TRPC1 Human genes 0.000 description 1
- 108010006785 Taq Polymerase Proteins 0.000 description 1
- 101000748795 Thermus thermophilus (strain ATCC 27634 / DSM 579 / HB8) Cytochrome c oxidase polypeptide I+III Proteins 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- 241000710924 Togaviridae Species 0.000 description 1
- 241000223997 Toxoplasma gondii Species 0.000 description 1
- 241000589886 Treponema Species 0.000 description 1
- 241000589904 Treponema pallidum subsp. pertenue Species 0.000 description 1
- 108700025716 Tumor Suppressor Genes Proteins 0.000 description 1
- 102000044209 Tumor Suppressor Genes Human genes 0.000 description 1
- 102100039094 Tyrosinase Human genes 0.000 description 1
- 108060008724 Tyrosinase Proteins 0.000 description 1
- 241000700618 Vaccinia virus Species 0.000 description 1
- 241000700647 Variola virus Species 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 241001135139 Vibrio ordalii Species 0.000 description 1
- 241000713325 Visna/maedi virus Species 0.000 description 1
- 241000714205 Woolly monkey sarcoma virus Species 0.000 description 1
- 241000120645 Yellow fever virus group Species 0.000 description 1
- 206010048249 Yersinia infections Diseases 0.000 description 1
- 208000025079 Yersinia infectious disease Diseases 0.000 description 1
- ATBOMIWRCZXYSZ-XZBBILGWSA-N [1-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-3-hexadecanoyloxypropan-2-yl] (9e,12e)-octadeca-9,12-dienoate Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(COP(O)(=O)OCC(O)CO)OC(=O)CCCCCCC\C=C\C\C=C\CCCCC ATBOMIWRCZXYSZ-XZBBILGWSA-N 0.000 description 1
- QKAHUWGYVDCLQF-UHFFFAOYSA-N [2-hexadecanoyloxy-3-(1-methylimidazol-4-yl)propyl] hexadecanoate Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCCCC)CC1=CN(C)C=N1 QKAHUWGYVDCLQF-UHFFFAOYSA-N 0.000 description 1
- HMNZFMSWFCAGGW-XPWSMXQVSA-N [3-[hydroxy(2-hydroxyethoxy)phosphoryl]oxy-2-[(e)-octadec-9-enoyl]oxypropyl] (e)-octadec-9-enoate Chemical compound CCCCCCCC\C=C\CCCCCCCC(=O)OCC(COP(O)(=O)OCCO)OC(=O)CCCCCCC\C=C\CCCCCCCC HMNZFMSWFCAGGW-XPWSMXQVSA-N 0.000 description 1
- 230000035508 accumulation Effects 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 108700010877 adenoviridae proteins Proteins 0.000 description 1
- 230000000240 adjuvant effect Effects 0.000 description 1
- 201000006966 adult T-cell leukemia Diseases 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- MGSDFCKWGHNUSM-QVPNGJTFSA-N alpha-L-Fucp-(1->2)-beta-D-Galp-(1->3)-beta-D-GlcpNAc Chemical compound O[C@H]1[C@H](O)[C@H](O)[C@H](C)O[C@H]1O[C@H]1[C@H](O[C@@H]2[C@H]([C@H](O)O[C@H](CO)[C@H]2O)NC(C)=O)O[C@H](CO)[C@H](O)[C@@H]1O MGSDFCKWGHNUSM-QVPNGJTFSA-N 0.000 description 1
- AWUCVROLDVIAJX-UHFFFAOYSA-N alpha-glycerophosphate Natural products OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 229940107816 ammonium iodide Drugs 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 230000005809 anti-tumor immunity Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 101150037081 aroA gene Proteins 0.000 description 1
- 244000309743 astrovirus Species 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- OBUOQZXTPAZQNP-UHFFFAOYSA-N butan-1-ol;propane-1,2,3-triol Chemical compound CCCCO.OCC(O)CO OBUOQZXTPAZQNP-UHFFFAOYSA-N 0.000 description 1
- 229940095731 candida albicans Drugs 0.000 description 1
- 229920006317 cationic polymer Polymers 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000022534 cell killing Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000005482 chemotactic factor Substances 0.000 description 1
- 229940038705 chlamydia trachomatis Drugs 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 238000011254 conventional chemotherapy Methods 0.000 description 1
- 230000000139 costimulatory effect Effects 0.000 description 1
- 230000001461 cytolytic effect Effects 0.000 description 1
- 231100000599 cytotoxic agent Toxicity 0.000 description 1
- 239000002619 cytotoxin Substances 0.000 description 1
- 230000002498 deadly effect Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 239000000412 dendrimer Substances 0.000 description 1
- 229920000736 dendritic polymer Polymers 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 210000005045 desmin Anatomy 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 230000001236 detergent effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000009699 differential effect Effects 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 238000001493 electron microscopy Methods 0.000 description 1
- 230000009881 electrostatic interaction Effects 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 238000005538 encapsulation Methods 0.000 description 1
- 206010014599 encephalitis Diseases 0.000 description 1
- 229940092559 enterobacter aerogenes Drugs 0.000 description 1
- 230000007515 enzymatic degradation Effects 0.000 description 1
- RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 1
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 1
- 229940014144 folate Drugs 0.000 description 1
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- 239000012737 fresh medium Substances 0.000 description 1
- 208000003512 furunculosis Diseases 0.000 description 1
- 201000011587 gastric lymphoma Diseases 0.000 description 1
- 238000001641 gel filtration chromatography Methods 0.000 description 1
- PEDCQBHIVMGVHV-UHFFFAOYSA-N glycerol Substances OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 1
- 239000003228 hemolysin Substances 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 208000029570 hepatitis D virus infection Diseases 0.000 description 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 1
- 231100000844 hepatocellular carcinoma Toxicity 0.000 description 1
- 229950007870 hexadimethrine bromide Drugs 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 230000005745 host immune response Effects 0.000 description 1
- 235000020256 human milk Nutrition 0.000 description 1
- 210000004251 human milk Anatomy 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 239000012642 immune effector Substances 0.000 description 1
- 230000006058 immune tolerance Effects 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 229940121354 immunomodulator Drugs 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 230000002601 intratumoral effect Effects 0.000 description 1
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 1
- 239000000644 isotonic solution Substances 0.000 description 1
- 229930027917 kanamycin Natural products 0.000 description 1
- 229960000318 kanamycin Drugs 0.000 description 1
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 1
- 229930182823 kanamycin A Natural products 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 238000011813 knockout mouse model Methods 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 239000006193 liquid solution Substances 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 210000003563 lymphoid tissue Anatomy 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 208000025848 malignant tumor of nasopharynx Diseases 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 230000001394 metastastic effect Effects 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 238000009126 molecular therapy Methods 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000001114 myogenic effect Effects 0.000 description 1
- DAZXVJBJRMWXJP-UHFFFAOYSA-N n,n-dimethylethylamine Chemical compound CCN(C)C DAZXVJBJRMWXJP-UHFFFAOYSA-N 0.000 description 1
- DDBRXOJCLVGHLX-UHFFFAOYSA-N n,n-dimethylmethanamine;propane Chemical compound CCC.CN(C)C DDBRXOJCLVGHLX-UHFFFAOYSA-N 0.000 description 1
- PUPNJSIFIXXJCH-UHFFFAOYSA-N n-(4-hydroxyphenyl)-2-(1,1,3-trioxo-1,2-benzothiazol-2-yl)acetamide Chemical compound C1=CC(O)=CC=C1NC(=O)CN1S(=O)(=O)C2=CC=CC=C2C1=O PUPNJSIFIXXJCH-UHFFFAOYSA-N 0.000 description 1
- 201000011216 nasopharynx carcinoma Diseases 0.000 description 1
- 230000000955 neuroendocrine Effects 0.000 description 1
- 201000011519 neuroendocrine tumor Diseases 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000003071 parasitic effect Effects 0.000 description 1
- 201000005115 pasteurellosis Diseases 0.000 description 1
- 238000010647 peptide synthesis reaction Methods 0.000 description 1
- 229940023041 peptide vaccine Drugs 0.000 description 1
- 210000004303 peritoneum Anatomy 0.000 description 1
- 210000001539 phagocyte Anatomy 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 108010031345 placental alkaline phosphatase Proteins 0.000 description 1
- 229940118768 plasmodium malariae Drugs 0.000 description 1
- 229920000724 poly(L-arginine) polymer Polymers 0.000 description 1
- 229920001481 poly(stearyl methacrylate) Polymers 0.000 description 1
- 229920000768 polyamine Polymers 0.000 description 1
- 108010011110 polyarginine Proteins 0.000 description 1
- 229920000656 polylysine Polymers 0.000 description 1
- 108010055896 polyornithine Proteins 0.000 description 1
- 229920002714 polyornithine Polymers 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 108040000983 polyphosphate:AMP phosphotransferase activity proteins Proteins 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 208000017805 post-transplant lymphoproliferative disease Diseases 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 101150002764 purA gene Proteins 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 230000008707 rearrangement Effects 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 238000009877 rendering Methods 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 229940054269 sodium pyruvate Drugs 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000000527 sonication Methods 0.000 description 1
- 229940063673 spermidine Drugs 0.000 description 1
- 229940063675 spermine Drugs 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 229940031000 streptococcus pneumoniae Drugs 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 150000003467 sulfuric acid derivatives Chemical class 0.000 description 1
- 150000003512 tertiary amines Chemical class 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- NRWCNEBHECBWRJ-UHFFFAOYSA-M trimethyl(propyl)azanium;chloride Chemical compound [Cl-].CCC[N+](C)(C)C NRWCNEBHECBWRJ-UHFFFAOYSA-M 0.000 description 1
- GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical group CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 1
- 230000001573 trophoblastic effect Effects 0.000 description 1
- 208000029387 trophoblastic neoplasm Diseases 0.000 description 1
- 201000008827 tuberculosis Diseases 0.000 description 1
- 230000004565 tumor cell growth Effects 0.000 description 1
- 230000005909 tumor killing Effects 0.000 description 1
- 230000037455 tumor specific immune response Effects 0.000 description 1
- 241000724775 unclassified viruses Species 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 241001529453 unidentified herpesvirus Species 0.000 description 1
- 241000712461 unidentified influenza virus Species 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
- 244000052613 viral pathogen Species 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/385—Haptens or antigens, bound to carriers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
- A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6018—Lipids, e.g. in lipopeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6093—Synthetic polymers, e.g. polyethyleneglycol [PEG], Polymers or copolymers of (D) glutamate and (D) lysine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/20011—Papillomaviridae
- C12N2710/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S977/00—Nanotechnology
- Y10S977/902—Specified use of nanostructure
- Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
- Y10S977/906—Drug delivery
- Y10S977/907—Liposome
Definitions
- the new generation vaccine has many advantages over traditional vaccine. However, the potency of the new generation vaccine needs to be enhanced. Unfortunately, after 80 some years of development, Alum is still the only single adjuvant approved by the Food and Drug Administration (FDA) in the United States for use in humans. Therefore, novel vaccine delivery systems and/or adjuvants are urgent needed and desired.
- FDA Food and Drug Administration
- the present invention provides antigen delivery compositions/adjuvants and methods of using same to prevent or to treat cancers and other infectious diseases. More particularly, the present invention provides a lipid-protamine-DNA (LPD) vaccine delivery system/adjuvant and methods of using such LPD vaccine delivery system/adjuvant for the prevention and treatment of cancer and other infectious diseases.
- LPD lipid-protamine-DNA
- the LPD vaccines of the present invention can induce strong cellular immunity to cause complete regression of established tumors and to prevent the formation of new tumors.
- FIG. 1 One time treatment of LPD/E7 nanoparticles eradicates established tumors.
- C57BL/6 mice were s.c. inoculated with 1 ⁇ 10 5 TC-1 cells on day 4, 6, 8, or 12, mice were s.c. injected with LPD nanoparticles containing 10 ⁇ g of E7 peptide.
- Tumor growth was measured three times per week. Mean ⁇ SD, 5 mice per group.
- One representative of three experiments showing similar tumor growth kinetics is shown.
- FIG. 2 LPD/E7 vaccination prevents tumor establishment after i.p. injection of TC-1 cells (A) and induces tumor specific immune response (B).
- FIG. 3 All E7 peptide containing LPD nanoparticles can induce antigen specific anti tumor effect.
- FIG. 4 The role of TLR9 on the antigen specific immune response induced by LPD/E7 nanoparticles.
- the splenocytes from wild type or TLR9 ⁇ / ⁇ mouse were re-stimulated with 1 ⁇ g/ml of E7 peptide for 24 h.
- the culture supernatants were collected and IFN-.alpha. levels were measured using ELISA.
- FIG. 5 IFN- ⁇ ELISPOT assay.
- Mice were s.c. injected with LPD nanoparticles containing 10 ⁇ g of E7 peptide or LPD nanoparticles without E7 peptide on day 0 and 5.
- lymph node cells were isolated, re-stimulated with 1 ⁇ g/ml of E7 peptide for 24 h for tumor specific T cell expansion.
- NK cells were depleted by injection with 100 ⁇ g anti-NK1.1 starting 2 days before the first vaccination and ending 2 days after the last vaccination.
- FIG. 6 The expression of co-stimulatory molecules, CD80 and CD86, on DC2.4 cells after stimulation by LPD or the components of LPD.
- FIG. 7 Expression of co-stimulatory molecules, CD80 and CD86, on DC2.4 cells after stimulation with different cationic liposomes.
- FIG. 8 Hydrocarbon chain length dependence of cationic lipids on the expression of co-stimulatory molecule (CD 80) on DC 2.4 cells.
- FIG. 9 Tumor growth kinetics on mice treated with LPD/E7 and other different formulations.
- the letters a, b, and c indicate that the final mean tumor sizes were significantly different between the groups, but not different within the group.
- FIG. 10 Specific IgG level in serum after diluted for 1.000-fold.
- As control one group of mice was left untreated. Mice were immunized on day 0 and 14. On day 28, mice were bled via tail vein. ANOVA analysis on the three treatments showed a p value of 0.001. * indicates that the value from E7/LPD is significantly different from that of the others.
- FIG. 12 Treatment with E7/LPD caused regression of tumors.
- FIG. 15 E7m/LPD and E7/LPD are equally effective in treating tumor.
- FIG. 16 Distribution of LPD/E7 particles in the spleen following IV administration. Spleens from mice that were injected with LPD/E7 particles containing Cy3 labeled ODN were visualized at the indicated times after administration.
- FIGS. 17A and 17B Uptake of LPD/E7 particles by CD11b+ and CD11c+ cells. Mice were injected with LPD particles containing 25 ⁇ g pNGVL3, 0.1 ⁇ g FITC labeled ODN and 10 ⁇ g E7 peptide in 150 ⁇ l 5% dextrose.
- A Splenocytes were collected 24 h later, stained with PE labeled anti-CD11b or CD11c antibodies and analyzed by flow cytometry.
- FIGS. 18A and 18B Tumor specific CTL activity induced by LPD/E7 vaccination.
- Mice were IV (A) or SC (B) injected with either LPD particles containing 0 ( ⁇ ), 1 ( ⁇ ), 10 ( ⁇ ), or 20 ( ⁇ ) ⁇ g of E7 peptide, SL liposomes containing 20 ⁇ g E7 peptide ( ⁇ .largecircle.), or 20 ⁇ g E7 peptide in PBS (*) on days 0 and 5.
- splenocytes were isolated, restimulated for 4 days and used as effectors in a chromium release assay. Non-specific lysis was ⁇ 8% in all groups. Mean ⁇ SD, 2 mice/group. One representative of 2 experiments is shown.
- FIGS. 19A and 19B LPD/E7 vaccination prevents tumor establishment.
- Mice were IV (A) or SC (B) injected with LPD particles with ( ⁇ ) or without ( ⁇ ) 20 ⁇ g E7 peptide, or 20 ⁇ g E7 peptide in PBS ( ⁇ ) on days 0 and 5 or left untreated ( ⁇ ).
- the mice were SC challenged with 0.5 ⁇ 10 6 TC-1 cells. Tumor formation was monitored twice per week by palpation. 5 mice per group. One representative of 3 experiments showing similar tumor formation kinetics is shown.
- FIGS. 20A and 20B LPD/E7 treatment eradicates established tumors.
- Intact closed symbols
- asplenic mice open symbols
- mice were SC inoculated with 0.5 ⁇ 10 6 TC-1 cells on day 0.
- mice were or IV (A) or SC (B) injected with LPD particles with ( ⁇ ) or without ( ⁇ ) 10 ⁇ g E7 peptide or left untreated ( ⁇ ).
- Tumor growth was measured 3 times per week. Mean ⁇ SD, 5 mice per group. One representative of 3 experiments showing similar tumor growth kinetics is shown.
- FIGS. 21A and 21B Tumor specific CTL activity induced by LPD/E7 treatment.
- Tumor bearing mice were IV (A) or SC (B) treated with LPD particles with ( ⁇ ) or without ( ⁇ ) 10 ⁇ g E7 peptide or E7 peptide in PBS ( ⁇ ).
- splenocytes were isolated, restimulated for 4 days and used as effectors in a chromium release assay.
- EL4 cells pulsed with E7 peptide were used as specific targets.
- Non-specific lysis was ⁇ 7% in all groups. Mean ⁇ SD, 2 mice per group. One representative of 2 experiments is shown.
- the present invention provides antigen/lipid/polycationic polypeptide salt complexes comprising an antigen, at least one lipid species and at least one polycationic polypeptide salt.
- LPD complexes are described in U.S. Pat. No. 6,008,202, which issued to Huang et al. on Dec. 28, 1999, the teachings of which are incorporated by reference.
- the teachings in U.S. Pat. No. 6,008,202 directed to LPD complexes are fully applicable to the present invention, except that it has now been surprisingly found that when an antigen is incorporated into the LPD, the antigen-LPD complex can be used as an effective vaccine to prevent and to treat cancers and other infectious diseases.
- This invention relates to lipid-comprising antigen delivery complexes having a net positive charge and/or a positively charged surface at pH 6.0-8.0. These complexes comprise lipids, antigens and optionally further comprise polycations.
- the invention further relates to a method for producing these complexes where the method may optionally include the step of purifying these formulations from excess individual components. For the production of the antigen/LPD complexes of this invention, inclusion of the purification step is a preferred embodiment.
- the lipid-comprising antigen delivery complexes of this invention are stable, capable of being produced at relatively high concentrations, and retain biological activity of the antigen component over time in storage.
- the “antigen” which is contained in the lipid-comprising drug delivery complexes of the present invention may be nucleic acids, polyanionic proteins, polysaccharides and other macromolecules which can be complexed directly with cationic lipids.
- cationic drugs e.g., large cationic protein
- anionic lipid or sequentially complexed first with anionic lipid or polymer followed by cationic lipid can be directly complexed with an anionic lipid or sequentially complexed first with anionic lipid or polymer followed by cationic lipid. The use of this process permits delivery of positive or neutral charged drug to cells by the complexes of the present invention.
- the cationic liposomes mixed with antigen or with antigen and polycation to form the complexes of the present invention may contain a cationic lipid alone or a cationic lipid in combination with a neutral lipid.
- Suitable cationic lipid species include, but are not limited to: 3- ⁇ [ 4 N-( 1 N, 8 -diguanidino spermidine)-carbamoyl] cholesterol (BGSC); 3- ⁇ [N,N-diguanidinoethyl-aminoethane)-carbamoyl] cholesterol (BGTC); N,N 1 N 2 N 3 Tetra-methyltetrapalmitylspermine (cellfectin); N-t-butyl-N′-tetradecyl-3-tetradecyl-aminopropion-amidine (CLONfectin); dimethyldioctadecyl ammonium bromide (DDAB); 1,2-dimyristyloxypropyl-3-dimethyl
- cationic lipids examples include N-t-butyl-N′-tetradecyl-3-tetradecylaminopropion-amidine (CLONfectin), 2,3-dioleoyloxy-N-[2(sperminecarboxamido)ethyl]-N,N-dimethyl-1-propanaminium trifluoroacetate (DOSPA), 1,2-bis(oleoyloxy)-3-(trimethylammonio)propane (DOTAP), N-[1-(2,3, dioleoyloxy)propyl]-N,N,N-trimethylammonium chloride) (DOTMA), cholesteryl-3- ⁇ -carboxyamidoethylenetrimethylammonium iodide, 1-dimethylamino-3-trimethylammonio-DL-2-propyl-cholesteryl carboxylate iodide, cholesteryl-3- ⁇ -carboxyamidoethyleneamine, cholesteryl-3- ⁇ -oxy
- certain cationic lipids have an increased immunostimulatory effect, i.e., increased immunostimulation activity. It has surprisingly been found that cationic lipids having shorter acyl chains have increased immunostimulation activity. In addition, it has surprisingly been found that cationic lipids having cis-unsaturated double bonds have increased immunostimulation activity.
- the cationic lipids used in the antigen-LPD complexes of the present invention are those that have shorter acyl chains and, in addition, those that have cis-unsaturated double bonds.
- preferred cationic lipids are those lipids in which bonds between the lipophilic group and the amino group are stable in aqueous solution. While such bonds found in cationic lipids include amide bonds, ester bonds, ether bonds and carbamoyl bonds, preferred cationic lipids are those having a carbamoyl bond.
- An example of a preferred cationic lipid having a carbamoyl bond is DC-Chol.
- liposomes containing more than one cationic lipid species may be used to produce the complexes of the present invention.
- liposomes comprising two cationic lipid species, lysyl-phosphatidylethanolamine and ⁇ -alanyl cholesterol ester have been disclosed (Brunette, E. et al. (1992) Nucl. Acids Res., 20:1151).
- cationic liposomes suitable for use in mixing with antigen and optionally with polycation to form the complexes of this invention
- the methods of the invention are not restricted only to the use of the cationic lipids recited above but rather, any lipid composition may be used so long as a cationic liposome is produced.
- cationic liposomes used to form the complexes of the invention may contain other lipids in addition to the cationic lipids.
- lipids include, but are not limited to, lyso lipids of which lysophosphatidylcholine (1-oleoyl lysophosphatidylcholine) is an example, cholesterol, or neutral phospholipids including dioleoyl phosphatidyl ethanolamine (DOPE) or dioleoyl phosphatidylcholine (DOPC) as well as various lipophylic surfactants, containing polyethylene glycol moieties, of which Tween-80 is one example.
- DOPE dioleoyl phosphatidyl ethanolamine
- DOPC dioleoyl phosphatidylcholine
- various lipophylic surfactants containing polyethylene glycol moieties, of which Tween-80 is one example.
- the lipid complexes of the invention may also contain negatively charged lipids as well as cationic lipids so long as the net charge of the complexes formed is positive and/or the surface of the complex is positively charged.
- Negatively charged lipids of the invention are those comprising at least one lipid species having a net negative charge at or near physiological pH or combinations of these. Suitable negatively charged lipid species include, but are not limited to, CHEMS (cholesteryl hemisuccinate), NGPE (N-glutaryl phosphatidlylethanolanine), phosphatidyl glycerol and phosphatidic acid or a similar phospholipid analog.
- the ratio of lipids may be varied to include a majority of cationic lipids in combination with cholesterol or with mixtures of lyso or neutral lipids.
- a preferred lipid is a neutral phospholipid, most preferably DOPE.
- Liposomes to be used in the production of the lipid comprising drug delivery complexes of the present invention are known to those of ordinary skill in the art.
- a review of methodologies of liposome preparation may be found in Liposome Technology (CFC Press New York 1984); Liposomes by Ostro (Marcel Dekker, 1987); Methods Biochem Anal. 33:337-462 (1988) and U.S. Pat. No. 5,283,185.
- Such methods include freeze-thaw extrusion and sonication. Both unilamellar liposomes (less than about 200 nm in average diameter) and multilamellar liposomes (greater than about 300 nm in average diameter) may be used as starting components to produce the complexes of this invention.
- the cationic lipid is present in the liposome at from about 10 to about 100 mole % of total liposomal lipid, preferably from about 20 to about 80 mole % and most preferably about 20 to about 60 mole %.
- the neutral lipid when included in the liposome, may be present at a concentration of from about 0 to about 90 mole % of the total liposomal lipid, preferably from about 20 to about 80 mole %, and most preferably from 40 to 80 mole %.
- the negatively charged lipid when included in the liposome, may be present at a concentration ranging from about 0 mole % to about 49 mole % of the total liposomal lipid, preferably from about 0 mole % to about 40 mole %.
- the liposomes contain a cationic and a neutral lipid, most preferably DC-Chol and DOPE in ratios between about 2:8 to about 6:4.
- the complexes of the present invention may contain modified lipids, protein, polycations or receptor ligands which function as a targeting factor directing the complex to a particular tissue or cell type.
- targeting factors include, but are not limited to, asialoglycoprotein, insulin, low density lipoprotein (LDL), folate and monoclonal and polyclonal antibodies directed against cell surface molecules.
- Potential targets include, but are not limited to, liver, blood cells, endothelial cells and tumor cells.
- the positive surface charge can be sterically shielded by incorporating lipophilic surfactants which contain polyethylene glycol moieties.
- the positive charge of the complexes of this invention may be affected not only by the lipid composition of the complex, but also by the pH of the solution in which the drug/lipid complexes are formed. For example, increasing pH (more basic) will gradually neutralize the positive charge of the tertiary amine of the cationic lipid DC-Chol.
- the complexes of the present invention are produced, and stored, at a pH such that the complexes have a net positive charge and/or positively charged surface.
- a preferred pH range is pH 6.0-8.0, most preferably pH 7.0-7.8.
- the polycation may be selected from organic polycations having a molecular weight of between about 300 and about 200,000. These polycations also preferably have a valence of between about 3 and about 1000 at pH 7.0.
- the polycations may be natural or synthetic amino acids, peptides, proteins, polyamines, carbohydrates and any synthetic cationic polymers.
- Non-limiting examples of polycations include polyarginine, polyornithine, protamines and polylysine, polybrene (hexadimethrine bromide), histone, cationic dendrimer, spermine, spermidine and synthetic polypeptides derived from SV40 large T antigen which has excess positive charges and represents a nuclear localization signal.
- the polycation is poly-L-lysine (PLL).
- the polycation is a polycationic polypeptide having an amino acid composition in which arginine residues comprise at least 30% of the amino acid residues of the polypeptide and lysine residues comprise less than 5% of the amino acid residues of the polypeptide.
- arginine residues comprise at least 30% of the amino acid residues of the polypeptide and lysine residues comprise less than 5% of the amino acid residues of the polypeptide.
- histidine, lysine and arginine together make up from about 45% to about 85% of the amino acid residues of the polypeptide and serine, threonine and glycine make up from about 10% to about 25% of the amino acid residues of the polypeptide.
- arginine residues constitute from about 65% to about 75% of the amino acid residues of the polypeptide and lysine residues constitute from about 0 to about 3% of the amino acid residues of the polypeptide.
- the polycationic polypeptides of the invention may also contain from about 20% to about 30% hydrophobic residues, more preferably, about 25% hydrophobic residues.
- the polycationic polypeptide to be used in producing drug/lipid/polycation complexes may be up to 500 amino acids in length, preferably about 20 to about 100 amino acids in length; more preferably, from about 25 to about 50 amino acids in length, and most preferably from about 25 to about 35 amino acids in length.
- the arginine residues present in the polycationic polypeptide are found in clusters of 3-8 contiguous arginine residues and more preferably in clusters of 4-6 contiguous arginine residues.
- the polycationic polypeptide is about 25 to about 35 amino acids in length and about 65 to about 70% of its residues are arginine residues and 0 to 3% of its residues are lysine residues.
- polycationic polypeptides to be used in formulating the complexes of the invention may be provided as naturally occurring proteins, particularly certain protamines having a high arginine to lysine ratio as discussed above, as a chemically synthesized polypeptide, as a recombinant polypeptide expressed from a nucleic acid sequence which encodes the polypeptide, or as a salt of any of the above polypeptides where such salts include, but are not limited to, phosphate, chloride and sulfate salts.
- the complexes formed by the methods of the present invention are stable for up to about one year when stored at 4° C.
- the complexes may be stored in 10% sucrose or a 5% dextrose solution upon collection from the sucrose gradient or they may be lyophilized and then reconstituted in an isotonic solution prior to use.
- the complexes are stored in solution.
- the stability of the complexes of the present invention is measured by specific assays to determine the physical stability and biological activity of the complexes over time in storage.
- the physical stability of the complexes is measured by determining the diameter and charge of the complexes by methods known to those of ordinary skill in the art, including for example, electron microscopy, gel filtration chromatography or by means of quasi-elastic light scattering using, for example, a Coulter N4SD particle size analyzer as described in the Examples.
- the physical stability of the complex is “substantially unchanged” over storage when the diameter of the stored complexes is not increased by more than 100%, preferably by not more than 50%, and most preferably by not more than 30%, over the diameter of the complexes as determined at the time the complexes were purified.
- Therapeutic formulations using the complexes of the invention preferably comprise the complexes in a physiologically compatible buffer such as, for example, phosphate buffered saline, isotonic saline or low ionic strength buffer such as 10% sucrose in H 2 O (pH 7.4-7.6) or in Hepes (pH 7-8, a more preferred pH being 7.4-7.6).
- a physiologically compatible buffer such as, for example, phosphate buffered saline, isotonic saline or low ionic strength buffer such as 10% sucrose in H 2 O (pH 7.4-7.6) or in Hepes (pH 7-8, a more preferred pH being 7.4-7.6).
- the complexes may be administered as aerosols or as liquid solutions for intratumoral, intravenous, intratracheal, intraperitoneal, and intramuscular administration.
- Tumor-associated antigen is a molecule or compound (e.g., a protein, peptide, polypeptide, lipid, glycolipid, carbohydrate and/or DNA) associated with a tumor or cancer cell and which is capable of provoking an immune response when expressed on the surface of an antigen presenting cell in the context of an MHC molecule.
- Tumor-associated antigens include self antigens, as well as other antigens that may not be specifically associated with a cancer, but nonetheless enhance an immune response to and/or reduce the growth of a tumor or cancer cell when administered to an animal. More specific embodiments are provided herein.
- a “microbial antigen,” as used herein, is an antigen of a microorganism and includes, but is not limited to, infectious virus, infectious bacteria, infectious parasites and infectious fungi.
- Microbial antigens may be intact microorganisms, and natural isolates, fragments, or derivatives thereof, synthetic compounds which are identical to or similar to naturally-occurring microbial antigens and, preferably, induce an immune response specific for the corresponding microorganism (from which the naturally-occurring microbial antigen originated).
- a compound is similar to a naturally-occurring microorganism antigen if it induces an immune response (humoral and/or cellular) similar to a naturally-occurring microorganism antigen.
- a non-limiting example of a compound that is similar to a naturally-occurring microorganism antigen is a peptide mimic of a polysaccharide antigen. More specific embodiments are provided herein.
- antigen is further intended to encompass peptide or protein analogs of known or wild-type antigens such as those described above.
- the analogs may be more soluble or more stable than wild type antigen, and may also contain mutations or modifications rendering the antigen more immunologically active.
- Also useful in the compositions and methods of the present invention are peptides or proteins which have amino acid sequences homologous with a desired antigen's amino acid sequence, where the homologous antigen induces an immune response to the respective tumor.
- the antigen in the LPD complex comprises an antigen associated with a tumor or cancer, i.e., a tumor-associated antigen.
- the tumor or cancer vaccines of the present invention further comprise at least one epitope of at least one tumor-associated antigen.
- the tumor or cancer vaccines of the present invention further comprise a plurality of epitopes from one or more tumor-associated antigens.
- the tumor-associated antigens finding use in the LPD complexes and methods of the present invention can be inherently immunogenic, or non-immunogenic, or slightly immunogenic.
- tumor-associated self antigens may be advantageously employed in the subject vaccines for therapeutic effect, since the subject compositions are capable of breaking immune tolerance against such antigens.
- exemplary antigens include, but are not limited to, synthetic, recombinant, foreign, or homologous antigens, and antigenic materials may include but are not limited to proteins, peptides, polypeptides, lipids, glycolipids, carbohydrates and DNA.
- Tumor-associated antigens suitable for use in the subject invention include both mutated and non-mutated molecules which may be indicative of single tumor type, shared among several types of tumors, and/or exclusively expressed or overexpressed in tumor cells in comparison with normal cells.
- mutated and non-mutated molecules which may be indicative of single tumor type, shared among several types of tumors, and/or exclusively expressed or overexpressed in tumor cells in comparison with normal cells.
- tumor-specific patterns of expression of carbohydrates, gangliosides, glycolipids and mucins have also been documented.
- Exemplary tumor-associated antigens for use in the subject cancer vaccines include protein products of oncogenes, tumor suppressor genes and other genes with mutations or rearrangements unique to tumor cells, reactivated embryonic gene products, oncofetal antigens, tissue-specific (but not tumor-specific) differentiation antigens, growth factor receptors, cell surface carbohydrate residues, foreign viral proteins and a number of other self proteins.
- tumor-associated antigens include, e.g., mutated antigens such as the protein products of the Ras p21 protooncogenes, tumor suppressor p53 and HER-2/neu and BCR-abl oncogenes, as well as CDK4, MUM1, Caspase 8, and Beta catenin; overexpressed antigens such as galectin 4, galectin 9, carbonic anhydrase, Aldolase A, PRAME, Her2/neu, ErbB-2 and KSA, oncofetal antigens such as alpha fetoprotein (AFP), human chorionic gonadotropin (hCG); self antigens such as carcinoembryonic antigen (CEA) and melanocyte differentiation antigens such as Mart 1/Melan A, gp100, gp75, Tyrosinase, TRP1 and TRP2; prostate associated antigens such as PSA, PAP, PSMA, PSM-P1 and PSM-P2; reactivated
- Tumor-associated antigens and their respective tumor cell targets include, e.g., cytokeratins, particularly cytokeratin 8, 18 and 19, as antigens for carcinoma.
- Epithelial membrane antigen (EMA), human embryonic antigen (HEA-125), human milk fat globules, MBr1, MBr8, Ber-EP4, 17-1A, C26 and T16 are also known carcinoma antigens.
- Desmin and muscle-specific actin are antigens of myogenic sarcomas.
- Placental alkaline phosphatase, beta-human chorionic gonadotropin, and alpha-fetoprotein are antigens of trophoblastic and germ cell tumors.
- Prostate specific antigen is an antigen of prostatic carcinomas, carcinoembryonic antigen of colon adenocarcinomas.
- HMB-45 is an antigen of melanomas.
- useful antigens could be encoded by human papilloma virus.
- Chromagranin-A and synaptophysin are antigens of neuroendocrine and neuroectodermal tumors. Of particular interest are aggressive tumors that form solid tumor masses having necrotic areas. The lysis of such necrotic cells is a rich source of antigens for antigen-presenting cells, and thus the subject therapy may find advantageous use in conjunction with conventional chemotherapy and/or radiation therapy.
- the human papillomavirus (HPV) subtype 16 E7 is used as the tumor-associated antigen. It has been found that E7 antigen-LPD complexes of the present invention are effective at preventing and treating cervical cancer.
- the present invention provides a genetically engineered E7 protein, i.e., E7m protein, having antigenic activity, but without tumorigenic activity. It has been found that the E7m-LPD complexes of the present invention induce cellular immunity to cause complete regression of established tumors and, thus, can be used as potent anti-cervical cancer vaccines.
- Tumor-associated antigens can be prepared by methods well known in the art.
- these antigens can be prepared from cancer cells either by preparing crude extracts of cancer cells (e.g., as described in Cohen et al., Cancer Res., 54:1055 (1994)), by partially purifying the antigens, by recombinant technology, or by de novo synthesis of known antigens.
- the antigen may also be in the form of a nucleic acid encoding an antigenic peptide in a form suitable for expression in a subject and presentation to the immune system of the immunized subject.
- the antigen may be a complete antigen, or it may be a fragment of a complete antigen comprising at least one epitope.
- Antigens derived from pathogens known to predispose to certain cancers may also be advantageously included in the cancer vaccines of the present invention. It is estimated that close to 16% of the worldwide incidence of cancer can be attributed to infectious pathogens; and a number of common malignancies are characterized by the expression of specific viral gene products. Thus, the inclusion of one or more antigens from pathogens implicated in causing cancer may help broaden the host immune response and enhance the prophylactic or therapeutic effect of the cancer vaccine.
- Pathogens of particular interest for use in the cancer vaccines provided herein include the hepatitis B virus (hepatocellular carcinoma), hepatitis C virus (heptomas), Epstein Barr virus (EBV) (Burkitt lymphoma, nasopharynx cancer, PTLD in immunosuppressed individuals), HTLVL (adult T cell leukemia), oncogenic human papilloma viruses types 16, 18, 33, 45 (adult cervical cancer), and the bacterium Helicobacter pylori (B cell gastric lymphoma).
- EBV Epstein Barr virus
- HTLVL adult T cell leukemia
- HTLVL adult T cell leukemia
- oncogenic human papilloma viruses types 16, 18, 33, 45 adult cervical cancer
- Helicobacter pylori B cell gastric lymphoma
- the antigen in the LPD complex comprises an antigen derived from or associated with a pathogen, i.e., a microbial antigen.
- the pathogen vaccines of the present invention further comprise at least one epitope of at least one microbial antigen.
- Pathogens which may be targeted by the subject vaccines include, but are not limited to, infectious virus, infectious bacteria, infectious parasites and infectious fungi.
- the pathogen vaccines of the present invention further comprise a plurality of epitopes from one or more microbial antigens.
- the microbial antigens finding use in the subject compositions and methods may be inherently immunogenic, or non-immunogenic, or slightly immunogenic.
- exemplary antigens include, but are not limited to, synthetic, recombinant, foreign, or homologous antigens, and antigenic materials may include but are not limited to proteins, peptides, polypeptides, lipids, glycolipids, carbohydrates and DNA.
- Exemplary viral pathogens include, but are not limited to, infectious virus that infect mammals, and more particularly humans.
- infectious virus include, but are not limited to: Retroviridae (e.g., human immunodeficiency viruses, such as HIV-1 (also referred to as HTLV-III, LAV or HTLV-III/LAV, or HIV-III; and other isolates, such as HIV-LP; Picornaviridae (e.g. polio viruses, hepatitis A virus; enteroviruses, human Coxsackie viruses, rhinoviruses, echoviruses); Calciviridae (e.g. strains that cause gastroenteritis); Togaviridae (e.g.
- Flaviridae e.g. dengue viruses, encephalitis viruses, yellow fever viruses
- Coronoviridae e.g. coronaviruses
- Rhabdoviradae e.g. vesicular stomatitis viruses, rabies viruses
- Coronaviridae e.g. coronaviruses
- Rhabdoviridae e.g. vesicular stomatitis viruses, rabies viruses
- Filoviridae e.g. ebola viruses
- Paramyxoviridae e.g.
- Orthomyxoviridae e.g. influenza viruses
- Bungaviridae e.g. Hantaan viruses, bunga viruses, phleboviruses and Nairo viruses
- Arena viridae hemorrhagic fever viruses
- Reoviridae e.g.
- reoviruses reoviruses, orbiviurses and rotaviruses
- Birnaviridae Hepadnaviridae (Hepatitis B virus); Parvovirida (parvoviruses); Papovaviridae (papilloma viruses, polyoma viruses); Adenoviridae (most adenoviruses); Herpesviridae herpes simplex virus (HSV) 1 and 2, varicella zoster virus, cytomegalovirus (CMV), herpes virus; Poxyiridae (variola viruses, vaccinia viruses, pox viruses); and Iridoviridae (e.g. African swine fever virus); and unclassified viruses (e.g.
- gram negative and gram positive bacteria may be targeted by the subject compositions and methods in vertebrate animals.
- Such gram positive bacteria include, but are not limited to Pasteurella species, Staphylococci species, and Streptococcus species.
- Gram negative bacteria include, but are not limited to, Escherichia coli, Pseudomonas species, and Salmonella species.
- infectious bacteria include but are not limited to: Helicobacter pyloris, Borella burgdorferi, Legionella pneumophilia, Mycobacteria sps (e.g. M. tuberculosis, M. avium, M. intracellulare, M. kansaii, M.
- Polypeptides of bacterial pathogens which may find use as sources of microbial antigens in the subject compositions include but are not limited to an iron-regulated outer membrane protein, (“IROMP”), an outer membrane protein (“OMP”), and an A-protein of Aeromonis salmonicida which causes furunculosis, p57 protein of Renibacterium salmoninarum which causes bacterial kidney disease (“BKD”), major surface associated antigen (“msa”), a surface expressed cytotoxin (“mpr”), a surface expressed hemolysin (“ish”), and a flagellar antigen of Yersiniosis; an extracellular protein (“ECP”), an iron-regulated outer membrane protein (“IROMP”), and a structural protein of Pasteurellosis; an OMP and a flagellar protein of Vibrosis anguillarum and V.
- IROMP iron-regulated outer membrane protein
- OMP outer membrane protein
- V an A-protein of Aeromonis salmonicida which causes furuncul
- antigens can be isolated or prepared recombinantly or by any other means known in the art.
- pathogens further include, but are not limited to, infectious fungi that infect mammals, and more particularly humans.
- infectious fungi include, but are not limited to: Cryptococcus neoformans, Histoplasma capsulatum, Coccidioides immitis, Blastomyces dermatitidis, Chlamydia trachomatis, Candida albicans .
- infectious parasites include Plasmodium such as Plasmodium falciparum, Plasmodium malariae, Plasmodium ovale , and Plasmodium vivax .
- Other infectious organisms i.e. protists
- Polypeptides of a parasitic pathogen include but are not limited to the surface antigens of Ichthyophthirius.
- compositions and methods of the present invention are useful for treating infections of nonhuman mammals.
- Many vaccines for the treatment of non-human mammals are disclosed in Bennett, K. Compendium of Veterinary Products, 3rd ed. North American Compendiums, Inc., 1995; see also WO 02/069369, the disclosure of which is expressly incorporated by reference herein.
- non-human pathogens include, but are not limited to, mouse mammary tumor virus (“MMTV”), Rous sarcoma virus (“RSV”), avian leukemia virus (“ALV”), avian myeloblastosis virus (“AMV”), murine leukemia virus (“MLV”), feline leukemia virus (“FeLV”), murine sarcoma virus (“MSV”), gibbon ape leukemia virus (“GALV”), spleen necrosis virus (“SNV”), reticuloendotheliosis virus (“RV”), simian sarcoma virus (“SSV”), Mason-Pfizer monkey virus (“MPMV”), simian retrovirus type 1 (“SRV-1”), lentiviruses such as HIV-1, HIV-2, SIV, Visna virus, feline immunodeficiency virus (“FIV”), and equine infectious anemia virus (“EIAV”), T-cell leukemia viruses such as HTLV-1, HTLV
- treatment refers to a prophylactic treatment which increases the resistance of a subject to infection with a pathogen or decreases the likelihood that the subject will become infected with the pathogen; and/or treatment after the subject has become infected in order to fight the infection, e.g., reduce or eliminate the infection or prevent it from becoming worse.
- Microbial antigens can be prepared by methods well known in the art. For example, these antigens can be prepared directly from viral and bacterial cells either by preparing crude extracts, by partially purifying the antigens, or alternatively by recombinant technology or by de novo synthesis of known antigens.
- the antigen may also be in the form of a nucleic acid encoding an antigenic peptide in a form suitable for expression in a subject and presentation to the immune system of the immunized subject. Further, the antigen may be a complete antigen, or it may be a fragment of a complete antigen comprising at least one epitope.
- Subcutaneously Injected LPD/Peptide Complex Accumulates in Local Lymphnode and Taken up by Various Immune Effector Cells.
- LPD particles As delivery to organized lymph tissue is important for successful vaccination, we wished to determine if LPD particles would make their way into draining lymph nodes following subcutaneous injection. C57BL/6 mice were footpad injected with LPD/E7 particles containing trace amounts of Cy5-labeled DNA. At 16 h after injection, popliteal lymph nodes were collected, single cell suspensions were prepared and LPD the percentage of cells that took up LPD was determined by flow cytometry. Mice injected with non-fluorescent LPD particles served as controls. After SC administration, 2.4% of all lymph node cells took up LPD particles. While only a small percentage of all lymph node cells take up LPD particles, this can be sufficient to produces effective vaccination of those cells are capable of effectively presenting the delivered antigen.
- C57BL/6 mice were footpad injected with LPD/E7 particles containing trace amounts of Cy5-labeled DNA.
- popliteal LN cells were stained for the cell-type specific surface markers CD11b (to identify macrophages and myeloid lineage DCs), CD11c (to identify dendritic cells), CD19 (to identify B cells), and NK1.1 (to identify NK cells) using fluorescently labeled antibodies and subjected to flow cytometric analysis.
- Phagocytic cells appear to be the main cell types that take up LPD/antigen particles with high percentage of NK cells (25%) and macrophages (25%) taking up particles while only 2.4% of B cells took up LPD particles. Of particular interest, 16.8% of dendritic cells took up LPD particles (Please see data in the table in Dileo et al.).
- mice were SC or IV vaccinated with LPD particles containing 0, 1, 10, or 20 ⁇ g of E7 peptide on days 0 and 5.
- mice were injected with 20 ⁇ g E7 peptide in PBS or encapsulated in SL liposomes.
- mice were injected with 20 ⁇ g E7 peptide in PBS or encapsulated in SL liposomes.
- Five days after the final vaccination splenocytes were collected, and used as effector cells in a chromium release assay. Consistent with previous reports, antigen containing SL liposomes induced significant levels of CTL activity (61% specific lysis) following SC injection only.
- Vaccination with 20 ⁇ g LPD/E7 produced the highest levels of CTL activity by both routes. Injection of 10 ⁇ g LPD/E7 particles induced intermediate levels of CTL activity in both cases, while 1 ⁇ g LPD/E7 induced significant CTL activity following IV administration only (Dileo et al.).
- mice were IV or SC vaccinated with either 20 ⁇ g E7 peptide in PBS, empty LPD, or LPD containing 20 ⁇ g of E7 peptide on days 0 and 5. Untreated mice served as controls. Five days after the last vaccination, mice were SC challenged with 0.5 ⁇ 10 6 E7 expressing TC-1 cells. Mice that received LPD/E7 particles by either route failed to develop tumors, while control mice and mice that received LPD alone or free E7 peptide developed tumors within 12 days (Dileo et al.). To determine the potential of LPD/E7 complex for use as a therapeutic strategy, subcutaneous tumors were established in C57BL/6 mice by inoculation of 0.5 ⁇ 10 6 TC-1 cells.
- mice On days 3 and 6 following inoculation, mice were injected IV or SC with LPD containing 10 ⁇ g of E7 peptide. To determine the importance of antigen delivery to the spleen in the generation of the observed immune responses, a group of mice that had their spleens surgically removed was included. Untreated mice and mice receiving empty LPD served as controls. All mice that received IV LPD/E7 peptide showed steady tumor shrinkage and complete regression within 2 weeks. SC treatment also resulted in complete regression but with slower kinetics. As expected, empty LPD administration slowed tumor progression but failed to eradicate the tumors. The anti-tumor effect in asplenic mice depended on the route of administration.
- IV treatment showed tumor growth rates similar to those observed in mice treated with LPD alone, while SC delivery resulted in tumor regression. Untreated mice showed unimpeded tumor progression (Dileo et al.). It has been shown that LPD administration to tumor bearing mice induces non-specific immune activation that can result in tumor regression. To confirm that tumor regression was due to an E7 specific response, ten days after the last treatment splenocytes were assayed for E7 specific tumor lytic activity. Consistent with previously published results, IV or SC injection of LPD without peptide induced a low level of apparent CTL activity while treatment with LPD/E7 resulted in the highest level of CTL activity in both cases (data not shown).
- LPD/E7 nanoparticles may not only provide potent anti-tumor effects in vaccination protocols, but also be effective for the treatment of advanced tumors.
- LPD/E7 is Effective in Treating Metastatic Tumor Model and Induce Tumor Specific Memory Immune Response.
- mice were vaccinated with LPD particles containing 10 ⁇ g E7 peptide or 10 ⁇ g E7 peptide in PBS on day 0 and 5.
- mice received subcutaneous tumor challenge at a dose of 1 ⁇ 10 6 TC-1 cells per mouse and the survival rate was measured. As shown in FIG. 2A , only 20% of untreated and E7-alone injected mice survived beyond 20 days after TC-1 cell injection, but the survival rate of LPD/E7 vaccinated group was 100% for the entire course of the experiment (50 days). To identify if survived mice from the LPD/E7 vaccination group exhibited the antigen specific immune response, mice were re-challenged subcutaneously with 1 ⁇ 10 5 TC-1 cells or 24JK cells. Normal unvaccinated animals receiving an equal number of TC-1 cells or 24JK cells were used as control groups.
- mice that survived from first challenge with TC-1 cells also failed to develop tumors upon re-challenge with fresh TC-1 cells, while normal animals injected with TC-1 cells and all mice injected with 24JK cells developed tumors ( FIG. 2B ).
- the data indicate that the immune response induced by LPD/E7 not only protected mice against the metastatic tumor challenge, but also provided protection for subsequent challenge.
- E7 peptide in this case, is carried by the cationic lipids, it can elicit an antitumor response. This hypothesis was independently verified by another experiment in which various LPD components were tested for antitumor activity. Indeed, E7 peptide complexed with DOTAP/chol liposomes could induce tumor regression after a single s.c. injection.
- TLR9 is responsible for the action of the immunostimulating unmethylated CpG motifs, e.g., RRCGYY (Hemmi et al., 2000; Bauer et al., 2001). It is a good guess that the adjuvant activity of LPD is mediated by TLR9. To test this hypothesis, we have obtained TLR9 ⁇ / ⁇ mice (Hemmi et al., 2000) from Professor Shizuo Akira in Japan. The mice are in the background of C57BL/6 and are syngeneic with TC-1 cells. The splenocytes from wild type or TLR9 ⁇ / ⁇ mouse injected with LPD/E7 were re-stimulated with 1 ⁇ g/ml E7 peptide for 24 h.
- the culture supernatants were collected and IFN- ⁇ levels were measured using ELISA.
- splenocytes from either wildtype or knockout mice could be stimulated with LPD/E7 to produce IFN- ⁇ to the same extend, indicating that TLR9 is not important in the process of immune stimulation. Again, it suggests that cationic lipid, rather than DNA, was the primary stimulant of the immune system.
- NK cells are involved in the first phase of tumor killing, which is followed by induction of tumor specific CTL.
- NK cells may be activated by LPD and involves in tumor cell killing.
- the antigen specific T-cell response measured by IFN- ⁇ ELISPOT assay, was approximately the same as the ones without the NK elimination. This result indicates that NK cells are only important for the antigen independent antitumor activity, but not in the antigen specific activity.
- Cationic Lipids can Activate Dendritic Cells.
- LPD is a potent vaccine delivery system/adjuvant. Following are some data we collected when studying the mechanism of the strong immunostimulation activity from LPD. We have measured by flow cytometry the expression of co-stimulatory molecules, CD86 and CD80, on DC2.4 cells as the result of stimulation by various components of LPD, including the liposome prepared from cationic lipid 1,2-dioleoyl-3-(trimethylammonium) propane (DOTAP) and cholesterol (Chol), protamine, and DNA. Plasmid DNA alone, protamine alone, and the complex of DNA/protamine did not stimulate the expression of CD80/CD86 ( FIG. 6 ). LPD stimulated DC2.4 cells expressed the highest amount of CD80/CD86.
- Lipoplex prepared from liposome (DOTAP/Chol) and DNA was as effective as the LPD, indicating that protamine is not required for DC cell stimulation.
- cholesterol is not required for DC cell stimulation ( FIG. 6 ) since LPD prepared from liposomes comprised of DOTAP alone is as effective as those prepared from liposomes comprised of DOTAP and cholesterol.
- CD80/CD86 expressions from liposome alone (DOTAP/Chol) stimulated DC2.4 cells were up to 70% of that from LPD stimulated DC2.4 cells, strongly demonstrating that the DOTAP-based cationic liposome alone can activate DCs and is responsible for the some of the LPD adjuvant activity.
- Lipofectamine® a 3:1 (w/w) liposome formulation of the polycationic lipid 2,3-dioleyloxy-N-[2(sperminecarboxamido)ethyl]-N,N-dimethyl-1-propanaminium trifluoroacetate (DOSPA) and the neutral lipid dioleoyl phosphatidylethanolamine (DOPE), and liposomes prepared from O,O′-dimyristyl-N-lysyl aspartate (DMKE) and O,O′-dimyristyl-N-lysyl-glutamate (DMKD), two newly synthesized cationic lipids by Dr.
- DOSPA polycationic lipid 2,3-dioleyloxy-N-[2(sperminecarboxamido)ethyl]-N,N-dimethyl-1-propanaminium trifluoroacetate
- DOPE neutral lipid dioleoyl phosphatidylethanol
- Lipofectin® a 1:1 (w/w) liposome formulation of cationic lipid N-[1-(2,3-dioleyloxy)propyl]-n,n,n-trimethylammonium chloride (DOTMA) and DOPE
- DMRIEC® a 1:1 (M/M) liposome formulation of cationic lipid 1,2-dimyristyloxypropyl-3-dimethyl-hydroxy ethyl ammonium bromide (DMRIE) and cholesterol
- DMRIE dimethyldioctadecylammonium bromide
- DDAB cationic lipid dimethyldioctadecylammonium bromide
- lipids with shorter (1,2-dilauroyl-sn-glycero-3-ethylphosphocholine (DLEPC-12:0), 1,2-dimyristoyl-sn-glycero-3-ethylphosphocholine (DMEPC-14:0)) or unsaturated (1,2-dioleoyl-sn-glycero-3-ethylphosphocholine (DOEPC-18:1)) acyl chains are found to be more potent than those with longer (1,2-dipalmitoyl-sn-glycero-3-ethylphosphocholine (DPEPC-16:0)) or saturated (1,2-distearoyl-sn-glycero-3-ethylphosphocholine (DSEPC-16:0)) acyl chains.
- Detergent sodium dodecyl sulfate (SDS) could not activate DC 2.4 cells for the expression of CD 80 suggesting that the DC 2.4 activation by cationic lipids with shorter hydrophobic chains were not due the possible detergent effect of shorter chain lipids on the cell membrane.
- E7 protein was expressed in E. coli , purified, detoxified, and incorporated into LPD particles. E7/LPD was then used to immunize C57BL/6 mice. The resulting antibody, tumor prevention, and tumor treatment activity from E7/LPD were compared to that of E7 alone or E7 adjuvanted with ‘Alum’. Data showed that E7/LPD induced antibody level (specific IgG) significantly higher than that of E7/Alum ( FIG. 10 ). Also, E7/LPD immunization prevented the growth of TC-1 tumor cells on mice ( FIG. 11 ); visible tumor (4 day old) on mice totally regressed when the mice were treated with E7/LPD ( FIG. 12 ).
- the resulting DNA fragment was gel purified and then cloned into the BamHI and EcoRI site of pCDNA3.1(+) vector (Invitrogen, Carlsbad, Calif.) and pET vector (Novagen, Madison, Wis.), respectively.
- the plasmid constructs were transferred into E. coli DH5a and selected against ampicillin and kanamycin, respectively.
- E7 and E7m genes were inserted into the BamH1 and EcoRI sites of pCDNA3.1(+) vector.
- the resulting plasmids were amplified in E. coli DH5a strain and purified.
- Plasmid cdc25A Sac1-luc in which luciferase gene is driven by a 1173 ( ⁇ 755 to +418) bp SacI fragment of the cdc25A promoter, is a gift from Dr. D. DiMaio from Yale University (New Haven, Conn.).
- the SacI fragment has both HPV 16 E2 protein binding site and the E2F binding site.
- Plasmid cdc25A SacI-luc, pCDNA3.1 (+) with or without E7 or E7m insert, and a CMV driven ⁇ -galactosidase gene containing plasmid were cotransfected into confluent 293 cells (5 ⁇ 10 5 /well, incubated at 37° C. and 5% CO 2 overnight, DMEM medium with 10% FBS) with Lipofectamine® (Invitrogen).
- the plasmid ratio was 2:1:10 (w/w/w) with pCDNA3.1(+) plasmid at 1 ⁇ g/well.
- Four hours after the addition of the plasmids the medium was replaced with fresh medium.
- E7 and E7m proteins were purified and used to immunize mice.
- the above data are the antibody levels when measured against E7 protein as an antigen. Similar results were obtained when measured against E7m protein.
- TC-1 cells were provided by TC Wu (Johns Hopkins University, Baltimore, Md.). These cells are C57BL6 mouse lung endothelial cells that have been transformed with the HPV16 E6 and E7 oncogenes and activated H-ras. Cells were grown in RPMI medium (Invitrogen, Carlsbad, Calif.) supplemented with 10% fetal bovine serum and 100 U/ml penicillin, and 100 mg/ml streptomycin. Cy3 labeled phophodiester oligodeoxynucleotides were purchased form Invitrogen (Carlsbad, Calif.). pNGVL3 was obtained from the National Gene Vector Laboratory (University of Michigan) and contains the CMVie promoter and no coding region.
- Plasmids were prepared using Qiagen EndoFree Giga-Prep kits (Qiagen, Valencia, Calif.).
- the MHC class I restricted peptide from the HPV 16 E7 protein (aa 49 to 57, RAHYNIVTF [SEQ. ID. NO. 5]) was synthesized by the University of Pittsburgh Peptide Synthesis Facility by solid state synthesis using an Advanced ChemTech model 200 peptide synthesizer and purified by HPLC. (Feltkamp, et al. Eur J Immunol 23, 2242-2249 (1993)).
- lipids were purchased from Avanti Polar Lipids (Alabaster Ala.).
- Small unilamellar DOTAP (1,2-Dioleoyl-3-Trimethylammonium-Propane):cholesterol (1:1 molar ratio) liposomes were prepared by thin film hydration followed by extrusion.
- LPD complexes were prepared using the procedure described by Li with modifications (Li, et al. Gene Ther 5, 930-937 (1998)). Briefly, complexes contained an 8.5:0.6:1.0 weight ratio of DOTAP/cholesterol liposomes:protamine:DNA. Liposomes and protamine (Sigma, St Louis Mo.) were mixed in 75 ⁇ l of 5.2% dextrose solution.
- SL liposomes Sterically stabilized liposomes (SL liposomes) were prepared according to Ignatius et al (29). Briefly, small unilamellar cholesterol:Palmitoyl-Oleoyl Phosphatidylcholine (POPC):PEG-PE (2:3:0.3 molar ratio) liposomes were prepared by thin film hydration with a 1 mg/ml E7 peptide containing solution followed by extrusion.
- POPC Palmitoyl-Oleoyl Phosphatidylcholine
- PEG-PE 2:3:0.3 molar ratio
- mice Six-week-old female C57BL/6 mice (Charles River Labs, Wilmington, Mass.) were used in all experiments. For vaccinations, mice were injected through the tail vein or subcutaneously with LPD particles containing 25 ⁇ g of pNGVL3 (University of Michigan) and 20 ⁇ g of E7 peptide on days 0 and 5. On day 10, mice were challenged by SC injection of 0.5 ⁇ 10 6 TC-1 cells and mice were observed for the formation of tumors by palpation twice per week.
- LPD particles 25 ⁇ g of pNGVL3 (University of Michigan) and 20 ⁇ g of E7 peptide on days 0 and 5.
- mice were challenged by SC injection of 0.5 ⁇ 10 6 TC-1 cells and mice were observed for the formation of tumors by palpation twice per week.
- SC tumors were established by injecting 0.5 ⁇ 10 6 TC-1 cells on day 0. Mice were IV injected with LPD complexes 3 and 6 days later as described in the text. Tumor size was monitored twice per week and size was determined by multiplying the two largest dimensions of the tumor. In some cases, mice were anesthetized and spleens were surgically removed 10 days prior to tumor inoculation.
- Cytolytic lymphocyte activity was measured using standard 51 Cr-release assays. Splenocytes were collected and cultured in RPMI supplemented with 10% FBS, 50 U/ml penicillin/streptomycin, 2 mM L-glutamine, 1 mM sodium pyruvate, 2 mM nonessential amino acids, 40 U/ml IL2, and 200 ng/ml MHC class I restricted E7 peptide for 4 days. Effector cells were plated into 96-well plates at various effector-to-target (E:T) cell ratios. Targets used were either EL4 cells pulsed with E7 peptide or non-pulsed EL4 cells.
- E:T effector-to-target
- mice were injected with LPD particles containing 25 ⁇ g pNGVL3, 0.1 ⁇ g Cy3 labeled oligodeoxynucleotides (ODN) and 10 ⁇ g E7 peptide in 150 ⁇ l 5% dextrose. 12, 24, and 48 h later, spleens were collected, embedded in OCT medium, frozen, and 6 ⁇ m sections were prepared and observed at 200 ⁇ magnification using a Nikon Eclipse TE300 inverted fluorescent microscope and SPOT image analysis software.
- ODN Cy3 labeled oligodeoxynucleotides
- Phycoerythrin (PE) conjugated antibodies were purchased from BD Pharmingen (San Diego Calif.). Spleens were collected 12, 24, and 48 h after administration of LPD containing fluorescein (FITC) labeled ODN. Single cell suspensions were prepared and stained for CD11b or CD11c using the M1/70 and HL3 antibodies respectively. Samples were run on an EPICS-XL benchtop cytometer (Beckman-Coulter, San Francisco) and analyzed using EXPO 32 software.
- LPD/E7 particles were taken up by antigen presenting cells.
- C57BL6 mice were IV injected with LPD/E7 particles containing trace amounts of FITC-labeled DNA.
- splenocytes were collected, stained for CD11c (to identify dendritic cells) and CD11b (to identify macrophages and myeloid lineage DCs), using PE-labeled antibodies and subjected to flow cytometric analysis ( FIG. 17 ).
- Mice injected with non-fluorescent LPD particles served as control.
- 3.9% of total splenocytes were CD11b/DNA double positive and 1.7% were CD11c/DNA positive ( FIG. 17A ).
- mice were SC or IV vaccinated with LPD particles containing 0, 1, 10, or 20 ⁇ g of E7 peptide on days 0 and 5.
- mice were injected with 20 ⁇ g E7 peptide in PBS or encapsulated in stabilized liposomes (SL liposomes). Five days after the final vaccination, splenocytes were collected, and used as effector cells in a chromium release assay.
- mice were IV or SC vaccinated with either 20 ⁇ g E7 peptide in PBS, empty LPD, or LPD containing 20 ⁇ g of E7 peptide on day days 0 and 5. Untreated mice served as controls. Five days after the last vaccination, mice were SC challenged with 0.5 ⁇ 10 5 E7 expressing TC-1 cells. Mice that received LPD/E7 particles by either route failed to develop tumors, while control mice and mice that received LPD alone or free E7 peptide developed tumors within 12 days. ( FIG. 19 )
- mice were injected IV or SC with LPD containing 10 ⁇ g of E7 peptide.
- LPD LPD containing 10 ⁇ g of E7 peptide.
- Untreated mice and mice receiving empty LPD served as controls. All mice that received IV LPD/E7 peptide showed steady tumor shrinkage and complete regression within 2 weeks ( FIG. 20 ). SC treatment also resulted in complete regression but with slower kinetics.
- Intravenous vaccination with as little as 1 ⁇ g of encapsulated peptide produces measurable antigen specific CTL activity and vaccination with 20 ⁇ g of peptide showed greater immune induction than other commonly used liposome/peptide delivery systems (SL liposomes).
- the level of immune induction is sufficient to protect mice against tumor formation and caused the complete regression of established tumors.
- IV Treatment of asplenic mice with LPD/E7 particles showed therapeutic effects similar to delivery of empty LPD particles to intact mice while the removal of the spleen showed no effect on SC administration. The differential effects of spleen removal are most likely due to the differences in the site of T cell activation depending on the route of administration. Following IV administration, T cells are activated in the spleen and its removal prevents effective priming.
- LPD particles for vaccination has some significant advantages.
- the inclusion of plasmid DNA in the particles allows for great flexibility in vaccine design. While we used empty plasmid DNA to form our LPD particles, DNA encoding any gene of interest may be substituted.
- LPD has a built in adjuvant effect, this can be modified by using DNA encoding cytokines designed to skew the immune response in a particular direction, chemotactic factors, or costimulatory molecules.
- LPD particles can be lyophilized, stored for extended periods (at least 1 year), rehydrated, and used without any loss of efficacy (Li, et al. J Pharm Sci 89, 355-364. [pii] (2000)).
Abstract
The present invention provides antigen delivery compositions and methods of using same to prevent or to treat cancers and other infectious diseases.
Description
- The present application is a continuation that claims the benefit of currently pending U.S. patent application Ser. No. 11/121,840, filed May 2, 2005 by the same inventors and having the same assignee as the present invention, and U.S. Provisional Application Ser. No. 60/567,291, filed on Apr. 30, 2004 by the same inventors and having the same assignee as the present invention, each of which is incorporated by reference herein in their entireties.
- To prevent and treat many of the deadly diseases and cancers, effective vaccines are needed. The new generation vaccine has many advantages over traditional vaccine. However, the potency of the new generation vaccine needs to be enhanced. Unfortunately, after 80 some years of development, Alum is still the only single adjuvant approved by the Food and Drug Administration (FDA) in the United States for use in humans. Therefore, novel vaccine delivery systems and/or adjuvants are desperately needed and desired.
- The present invention provides antigen delivery compositions/adjuvants and methods of using same to prevent or to treat cancers and other infectious diseases. More particularly, the present invention provides a lipid-protamine-DNA (LPD) vaccine delivery system/adjuvant and methods of using such LPD vaccine delivery system/adjuvant for the prevention and treatment of cancer and other infectious diseases. In fact, it has surprisingly been found that the LPD vaccines of the present invention can induce strong cellular immunity to cause complete regression of established tumors and to prevent the formation of new tumors.
-
FIG. 1 . One time treatment of LPD/E7 nanoparticles eradicates established tumors. C57BL/6 mice were s.c. inoculated with 1×105 TC-1 cells onday -
FIG. 2 . LPD/E7 vaccination prevents tumor establishment after i.p. injection of TC-1 cells (A) and induces tumor specific immune response (B). A. Mice were s.c. injected with LPD particles with 10 μg E7 peptide or 10 μg E7 peptide in PBS ondays day 10, the mice were i.p. challenged with 1×106 TC-1 cells and the survival rate was checked. B. 50 days after, the survived mice were s.c. rechallenged with 1×105 TC-1 or 24 JK cells. Tumor formation was monitored three times per week by palpation. -
FIG. 3 . All E7 peptide containing LPD nanoparticles can induce antigen specific anti tumor effect. Mice (n=5) were sc injected with LPD nanoparticles onday day 10, the mice were sc challenged with 1×105 TC-1 cells. Tumor formation was monitored three times per week. -
FIG. 4 . The role of TLR9 on the antigen specific immune response induced by LPD/E7 nanoparticles. The splenocytes from wild type or TLR9−/− mouse were re-stimulated with 1 μg/ml of E7 peptide for 24 h. The culture supernatants were collected and IFN-.alpha. levels were measured using ELISA. -
FIG. 5 . IFN-γ ELISPOT assay. Mice were s.c. injected with LPD nanoparticles containing 10 μg of E7 peptide or LPD nanoparticles without E7 peptide onday -
FIG. 6 . The expression of co-stimulatory molecules, CD80 and CD86, on DC2.4 cells after stimulation by LPD or the components of LPD. -
FIG. 7 . Expression of co-stimulatory molecules, CD80 and CD86, on DC2.4 cells after stimulation with different cationic liposomes. -
FIG. 8 . Hydrocarbon chain length dependence of cationic lipids on the expression of co-stimulatory molecule (CD 80) on DC 2.4 cells. -
FIG. 9 . Tumor growth kinetics on mice treated with LPD/E7 and other different formulations. The letters a, b, and c indicate that the final mean tumor sizes were significantly different between the groups, but not different within the group. -
FIG. 10 . Specific IgG level in serum after diluted for 1.000-fold. Mice (n=4-5) were immunized with E7 protein alone, E7/LPD, and E7 adjuvanted with ‘Alum’ (15 μg/mouse) (E7/Alum). The dose of E7 protein was 20 μg/mouse. As control, one group of mice was left untreated. Mice were immunized onday day 28, mice were bled via tail vein. ANOVA analysis on the three treatments showed a p value of 0.001. * indicates that the value from E7/LPD is significantly different from that of the others. -
FIG. 11 . Immunization with E7/LPD prevented TC-1 tumor cell growth in C57BL/6 mice (n=6). Mice were immunized onday FIG. 1 . On day 21, TC-1 cells (5×105) were injected subcutaneously. The growth of the tumors was monitored for 15 days. Showing is % of tumor free mice as a function of time. Statistic analysis showed that, the line for E7/Alum is different from that for E7/LPD (p=0.02). -
FIG. 12 . Treatment with E7/LPD caused regression of tumors. Mice (n=5) were subcutaneously injected with TC-1 cells (5×105/mouse) onday 0. Onday 4, they were treated with E7 alone, E7/LPD, or E7/Alum. Dosage is same as inFIG. 1 . Showed is the tumor growth kinetics. Onday 25, the tumor size from E7/LPD treated mice is significantly smaller than that from other treatments (p=5×10−6, ANOVA). -
FIG. 13 . Relative RLU in 293 cells transfected with a CMV driven β-galactosidase gene containing plasmid, cdc25A Sac1-luc, and pCDNA3(+) with or without E7/E7m gene. * indicates that the value for pCDNA-E7 is different from that of the others (p=0.002, ANOVA). Also, the value for pCDNA3 is not different from that for pCDNA-E7m (p=0.19). -
FIG. 14 . Specific IgG levels in mice immunized with E7m, E7m/LPD, E7, and E7/LPD. Mice (n=5-6) were immunized onday day 28, the value for E7m/LPD is lower than that for E7/LPD (p=0.02); onday 60, the values from these two treatments are similar (p=0.53). For E7m/LPD, the value fromday 28 is similar to that from day 60 (p=0.81); for E7/LPD, these two values are different (p=0.004). -
FIG. 15 . E7m/LPD and E7/LPD are equally effective in treating tumor. Mice (n=5 or 10, 10 for E7/LPD and E7m/LPD) were injected with TC-1 cells (5×105/mouse) onday 0. Onday -
FIG. 16 . Distribution of LPD/E7 particles in the spleen following IV administration. Spleens from mice that were injected with LPD/E7 particles containing Cy3 labeled ODN were visualized at the indicated times after administration. -
FIGS. 17A and 17B . Uptake of LPD/E7 particles by CD11b+ and CD11c+ cells. Mice were injected with LPD particles containing 25 μg pNGVL3, 0.1 μg FITC labeled ODN and 10 μg E7 peptide in 150μl 5% dextrose. (A) Splenocytes were collected 24 h later, stained with PE labeled anti-CD11b or CD11c antibodies and analyzed by flow cytometry. (B) Spleens were collected at the indicated times post injection and the percent of all CD11b+ (▪) and CD11c+ () that were DNA positive was determined. Mean ±SD, n=3. One representative of 3 experiments is shown. -
FIGS. 18A and 18B . Tumor specific CTL activity induced by LPD/E7 vaccination. Mice were IV (A) or SC (B) injected with either LPD particles containing 0 (♦), 1 (▴), 10 (▪), or 20 () μg of E7 peptide, SL liposomes containing 20 μg E7 peptide (∘.largecircle.), or 20 μg E7 peptide in PBS (*) ondays -
FIGS. 19A and 19B . LPD/E7 vaccination prevents tumor establishment. Mice were IV (A) or SC (B) injected with LPD particles with () or without (▪) 20 μg E7 peptide, or 20 μg E7 peptide in PBS (♦) ondays day 10, the mice were SC challenged with 0.5×106 TC-1 cells. Tumor formation was monitored twice per week by palpation. 5 mice per group. One representative of 3 experiments showing similar tumor formation kinetics is shown. -
FIGS. 20A and 20B . LPD/E7 treatment eradicates established tumors. Intact (closed symbols) or asplenic mice (open symbols) were SC inoculated with 0.5×106 TC-1 cells onday 0. Ondays -
FIGS. 21A and 21B . Tumor specific CTL activity induced by LPD/E7 treatment. Tumor bearing mice were IV (A) or SC (B) treated with LPD particles with (▴) or without (▪) 10 μg E7 peptide or E7 peptide in PBS (). Ten days after the last treatment, splenocytes were isolated, restimulated for 4 days and used as effectors in a chromium release assay. EL4 cells pulsed with E7 peptide were used as specific targets. Non-specific lysis was <7% in all groups. Mean ±SD, 2 mice per group. One representative of 2 experiments is shown. - As mentioned, the present invention provides antigen/lipid/polycationic polypeptide salt complexes comprising an antigen, at least one lipid species and at least one polycationic polypeptide salt. LPD complexes are described in U.S. Pat. No. 6,008,202, which issued to Huang et al. on Dec. 28, 1999, the teachings of which are incorporated by reference. The teachings in U.S. Pat. No. 6,008,202 directed to LPD complexes are fully applicable to the present invention, except that it has now been surprisingly found that when an antigen is incorporated into the LPD, the antigen-LPD complex can be used as an effective vaccine to prevent and to treat cancers and other infectious diseases.
- This invention relates to lipid-comprising antigen delivery complexes having a net positive charge and/or a positively charged surface at pH 6.0-8.0. These complexes comprise lipids, antigens and optionally further comprise polycations. The invention further relates to a method for producing these complexes where the method may optionally include the step of purifying these formulations from excess individual components. For the production of the antigen/LPD complexes of this invention, inclusion of the purification step is a preferred embodiment. The lipid-comprising antigen delivery complexes of this invention are stable, capable of being produced at relatively high concentrations, and retain biological activity of the antigen component over time in storage.
- The “antigen” which is contained in the lipid-comprising drug delivery complexes of the present invention may be nucleic acids, polyanionic proteins, polysaccharides and other macromolecules which can be complexed directly with cationic lipids. However, cationic drugs (e.g., large cationic protein) can be directly complexed with an anionic lipid or sequentially complexed first with anionic lipid or polymer followed by cationic lipid. The use of this process permits delivery of positive or neutral charged drug to cells by the complexes of the present invention.
- The cationic liposomes mixed with antigen or with antigen and polycation to form the complexes of the present invention may contain a cationic lipid alone or a cationic lipid in combination with a neutral lipid. Suitable cationic lipid species include, but are not limited to: 3-β[4N-(1N,8-diguanidino spermidine)-carbamoyl] cholesterol (BGSC); 3-β[N,N-diguanidinoethyl-aminoethane)-carbamoyl] cholesterol (BGTC); N,N1N2N3Tetra-methyltetrapalmitylspermine (cellfectin); N-t-butyl-N′-tetradecyl-3-tetradecyl-aminopropion-amidine (CLONfectin); dimethyldioctadecyl ammonium bromide (DDAB); 1,2-dimyristyloxypropyl-3-dimethyl-hydroxy ethyl ammonium bromide (DMRIE); 2,3-dioleoyloxy-N-[2(sperminecarboxamido)ethyl]-N,N-dimethyl-1-propanaminium trifluorocetate) (DOSPA); 1,3-dioleoyloxy-2-(6-carboxyspermyl)-propylamide (DOSPER); 4-(2,3-bis-palmitoyloxy-propyl)-1-methyl-1H-imidazole (DPIM) N,N,N′,N′-tetramethyl-N,N′-bis(2-hydroxyethyl)-2,3 dioleoyloxy-1,4-butanediammonium iodide) (Tfx-50); 1,2 bis(oleoyloxy)-3-(trimethylammonio) propane (DOTAP); N-1-(2,3-dioleoyloxy) propyl-N,N,N-trimethyl ammonium chloride (DOTMA) or other N—(N,N-1-dialkoxy)-alkyl-N,N,N-trisubstituted ammonium surfactants; 1,2 dioleoyl-3-(4′-trimethylammonio) butanol-sn-glycerol (DOBT) or cholesteryl (4′trimethylammonia) butanoate (ChOTB) where the trimethylammonium group is connected via a butanol spacer arm to either the double chain (for DOTB) or cholesteryl group (for ChOTB); DORI (DL-1,2-dioleoyl-3-dimethylaminopropyl-p-hydroxyethylammonium) or DORIE (DL-1,2-O-dioleoyl-3-dimethylaminopropyl-p-hydroxyethylammonium) (DORIE) or analogs thereof as disclosed in WO 93/03709; 1,2-dioleoyl-3-succinyl-sn-glycerol choline ester (DOSC); cholesteryl hemisuccinate ester (ChOSC); lipopolyamines such as dioctadecylamidoglycylspermine (DOGS) and dipalmitoyl phosphatidylethanolamylspermine (DPPES) or the cationic lipids disclosed in U.S. Pat. No. 5,283,185, cholesteryl-3β-carboxylamido-ethylenetrimethylammonium iodide, 1-dimethylamino-3-trimethylammonio-DL-2-propylcholesteryl carboxylate iodide, cholesteryl-3-β-carboxyamidoethyleneamine, cholesteryl-3-β-oxysuccinamido-ethylenetrimethylammonium iodide, 1-dimethylamino-3-trimethylammonio-DL-2-propyl-cholesteryl-3-β-oxysuccinate iodide, 2-(2-trimethylammonio)-ethylmethylamino ethyl-cholesteryl-3-β-oxysuccinate iodide, 3-β-N—(N′,N′-dimethylaminoethane) carbamoyl cholesterol (DC-chol), and 3-β-N-(polyethyleneimine)-carbamoylcholesterol.
- Examples of preferred cationic lipids include N-t-butyl-N′-tetradecyl-3-tetradecylaminopropion-amidine (CLONfectin), 2,3-dioleoyloxy-N-[2(sperminecarboxamido)ethyl]-N,N-dimethyl-1-propanaminium trifluoroacetate (DOSPA), 1,2-bis(oleoyloxy)-3-(trimethylammonio)propane (DOTAP), N-[1-(2,3, dioleoyloxy)propyl]-N,N,N-trimethylammonium chloride) (DOTMA), cholesteryl-3-β-carboxyamidoethylenetrimethylammonium iodide, 1-dimethylamino-3-trimethylammonio-DL-2-propyl-cholesteryl carboxylate iodide, cholesteryl-3-β-carboxyamidoethyleneamine, cholesteryl-3-β-oxysuccinamidoethylenetrimethyl-ammonium iodide, 1-dimethylamino-3-trimethylammonio-DL-2-propyl-cholesteryl-3-β-oxysuccinate iodide, 2-(2-trimethylammonio)ethylmethylamino ethyl-cholesteryl-3-β-oxysuccinateiodide, 3-β-N—(N′,N′dimethyl-aminoethane)-carbamoyl-cholesterol (DC-chol), and 3-β-N-(polyethyleneimine)-carbamoyl cholesterol.
- In certain embodiments, it has been found that certain cationic lipids have an increased immunostimulatory effect, i.e., increased immunostimulation activity. It has surprisingly been found that cationic lipids having shorter acyl chains have increased immunostimulation activity. In addition, it has surprisingly been found that cationic lipids having cis-unsaturated double bonds have increased immunostimulation activity. As such, in preferred embodiments, the cationic lipids used in the antigen-LPD complexes of the present invention are those that have shorter acyl chains and, in addition, those that have cis-unsaturated double bonds.
- Since an attribute of the complexes of the invention is their stability during storage (i.e., their ability to maintain a small diameter and retain biological activity over time following their formation), it will be understood by those of ordinary skill in the art that preferred cationic lipids are those lipids in which bonds between the lipophilic group and the amino group are stable in aqueous solution. While such bonds found in cationic lipids include amide bonds, ester bonds, ether bonds and carbamoyl bonds, preferred cationic lipids are those having a carbamoyl bond. An example of a preferred cationic lipid having a carbamoyl bond is DC-Chol. Those of skill in the art would readily understand that liposomes containing more than one cationic lipid species may be used to produce the complexes of the present invention. For example, liposomes comprising two cationic lipid species, lysyl-phosphatidylethanolamine and β-alanyl cholesterol ester have been disclosed (Brunette, E. et al. (1992) Nucl. Acids Res., 20:1151).
- It is to be further understood that in considering cationic liposomes suitable for use in mixing with antigen and optionally with polycation, to form the complexes of this invention, the methods of the invention are not restricted only to the use of the cationic lipids recited above but rather, any lipid composition may be used so long as a cationic liposome is produced.
- Thus, in addition to cationic lipids, cationic liposomes used to form the complexes of the invention may contain other lipids in addition to the cationic lipids. These lipids include, but are not limited to, lyso lipids of which lysophosphatidylcholine (1-oleoyl lysophosphatidylcholine) is an example, cholesterol, or neutral phospholipids including dioleoyl phosphatidyl ethanolamine (DOPE) or dioleoyl phosphatidylcholine (DOPC) as well as various lipophylic surfactants, containing polyethylene glycol moieties, of which Tween-80 is one example. The lipid complexes of the invention may also contain negatively charged lipids as well as cationic lipids so long as the net charge of the complexes formed is positive and/or the surface of the complex is positively charged. Negatively charged lipids of the invention are those comprising at least one lipid species having a net negative charge at or near physiological pH or combinations of these. Suitable negatively charged lipid species include, but are not limited to, CHEMS (cholesteryl hemisuccinate), NGPE (N-glutaryl phosphatidlylethanolanine), phosphatidyl glycerol and phosphatidic acid or a similar phospholipid analog.
- It is further contemplated that in the cationic liposomes utilized to form the complexes of the invention, the ratio of lipids may be varied to include a majority of cationic lipids in combination with cholesterol or with mixtures of lyso or neutral lipids. When the cationic lipid of choice is to be combined with another lipid, a preferred lipid is a neutral phospholipid, most preferably DOPE.
- Methods for producing the liposomes to be used in the production of the lipid comprising drug delivery complexes of the present invention are known to those of ordinary skill in the art. A review of methodologies of liposome preparation may be found in Liposome Technology (CFC Press New York 1984); Liposomes by Ostro (Marcel Dekker, 1987); Methods Biochem Anal. 33:337-462 (1988) and U.S. Pat. No. 5,283,185. Such methods include freeze-thaw extrusion and sonication. Both unilamellar liposomes (less than about 200 nm in average diameter) and multilamellar liposomes (greater than about 300 nm in average diameter) may be used as starting components to produce the complexes of this invention.
- In the cationic liposomes utilized to produce the drug/lipid complexes of this invention, the cationic lipid is present in the liposome at from about 10 to about 100 mole % of total liposomal lipid, preferably from about 20 to about 80 mole % and most preferably about 20 to about 60 mole %. The neutral lipid, when included in the liposome, may be present at a concentration of from about 0 to about 90 mole % of the total liposomal lipid, preferably from about 20 to about 80 mole %, and most preferably from 40 to 80 mole %. The negatively charged lipid, when included in the liposome, may be present at a concentration ranging from about 0 mole % to about 49 mole % of the total liposomal lipid, preferably from about 0 mole % to about 40 mole %. In a preferred embodiment, the liposomes contain a cationic and a neutral lipid, most preferably DC-Chol and DOPE in ratios between about 2:8 to about 6:4. It is further understood that the complexes of the present invention may contain modified lipids, protein, polycations or receptor ligands which function as a targeting factor directing the complex to a particular tissue or cell type. Examples of targeting factors include, but are not limited to, asialoglycoprotein, insulin, low density lipoprotein (LDL), folate and monoclonal and polyclonal antibodies directed against cell surface molecules. Potential targets include, but are not limited to, liver, blood cells, endothelial cells and tumor cells. Furthermore, to enhance the circulatory half-life of the complexes, the positive surface charge can be sterically shielded by incorporating lipophilic surfactants which contain polyethylene glycol moieties.
- It is to be further understood that the positive charge of the complexes of this invention may be affected not only by the lipid composition of the complex, but also by the pH of the solution in which the drug/lipid complexes are formed. For example, increasing pH (more basic) will gradually neutralize the positive charge of the tertiary amine of the cationic lipid DC-Chol. In a preferred embodiment, the complexes of the present invention are produced, and stored, at a pH such that the complexes have a net positive charge and/or positively charged surface. A preferred pH range is pH 6.0-8.0, most preferably pH 7.0-7.8.
- When a polycation is to be mixed with nucleic acid and cationic liposomes, the polycation may be selected from organic polycations having a molecular weight of between about 300 and about 200,000. These polycations also preferably have a valence of between about 3 and about 1000 at pH 7.0. The polycations may be natural or synthetic amino acids, peptides, proteins, polyamines, carbohydrates and any synthetic cationic polymers. Non-limiting examples of polycations include polyarginine, polyornithine, protamines and polylysine, polybrene (hexadimethrine bromide), histone, cationic dendrimer, spermine, spermidine and synthetic polypeptides derived from SV40 large T antigen which has excess positive charges and represents a nuclear localization signal. In one embodiment, the polycation is poly-L-lysine (PLL).
- In another more preferred embodiment, the polycation is a polycationic polypeptide having an amino acid composition in which arginine residues comprise at least 30% of the amino acid residues of the polypeptide and lysine residues comprise less than 5% of the amino acid residues of the polypeptide. In addition, preferably histidine, lysine and arginine together make up from about 45% to about 85% of the amino acid residues of the polypeptide and serine, threonine and glycine make up from about 10% to about 25% of the amino acid residues of the polypeptide. More preferably, arginine residues constitute from about 65% to about 75% of the amino acid residues of the polypeptide and lysine residues constitute from about 0 to about 3% of the amino acid residues of the polypeptide.
- In addition to the above recited percentages of arginine and lysine residues, the polycationic polypeptides of the invention may also contain from about 20% to about 30% hydrophobic residues, more preferably, about 25% hydrophobic residues. The polycationic polypeptide to be used in producing drug/lipid/polycation complexes may be up to 500 amino acids in length, preferably about 20 to about 100 amino acids in length; more preferably, from about 25 to about 50 amino acids in length, and most preferably from about 25 to about 35 amino acids in length.
- In one embodiment, the arginine residues present in the polycationic polypeptide are found in clusters of 3-8 contiguous arginine residues and more preferably in clusters of 4-6 contiguous arginine residues.
- In another embodiment, the polycationic polypeptide is about 25 to about 35 amino acids in length and about 65 to about 70% of its residues are arginine residues and 0 to 3% of its residues are lysine residues.
- The polycationic polypeptides to be used in formulating the complexes of the invention may be provided as naturally occurring proteins, particularly certain protamines having a high arginine to lysine ratio as discussed above, as a chemically synthesized polypeptide, as a recombinant polypeptide expressed from a nucleic acid sequence which encodes the polypeptide, or as a salt of any of the above polypeptides where such salts include, but are not limited to, phosphate, chloride and sulfate salts.
- The complexes formed by the methods of the present invention are stable for up to about one year when stored at 4° C. The complexes may be stored in 10% sucrose or a 5% dextrose solution upon collection from the sucrose gradient or they may be lyophilized and then reconstituted in an isotonic solution prior to use. In a preferred embodiment, the complexes are stored in solution. The stability of the complexes of the present invention is measured by specific assays to determine the physical stability and biological activity of the complexes over time in storage. The physical stability of the complexes is measured by determining the diameter and charge of the complexes by methods known to those of ordinary skill in the art, including for example, electron microscopy, gel filtration chromatography or by means of quasi-elastic light scattering using, for example, a Coulter N4SD particle size analyzer as described in the Examples. The physical stability of the complex is “substantially unchanged” over storage when the diameter of the stored complexes is not increased by more than 100%, preferably by not more than 50%, and most preferably by not more than 30%, over the diameter of the complexes as determined at the time the complexes were purified.
- Therapeutic formulations using the complexes of the invention preferably comprise the complexes in a physiologically compatible buffer such as, for example, phosphate buffered saline, isotonic saline or low ionic strength buffer such as 10% sucrose in H2O (pH 7.4-7.6) or in Hepes (pH 7-8, a more preferred pH being 7.4-7.6). The complexes may be administered as aerosols or as liquid solutions for intratumoral, intravenous, intratracheal, intraperitoneal, and intramuscular administration.
- Methods for preparing and purifying the antigen-LPD complexes of the present invention are disclosed in U.S. Pat. No. 6,008,202, the teachings of which are incorporated by reference.
- A “tumor-associated antigen,” as used herein is a molecule or compound (e.g., a protein, peptide, polypeptide, lipid, glycolipid, carbohydrate and/or DNA) associated with a tumor or cancer cell and which is capable of provoking an immune response when expressed on the surface of an antigen presenting cell in the context of an MHC molecule. Tumor-associated antigens include self antigens, as well as other antigens that may not be specifically associated with a cancer, but nonetheless enhance an immune response to and/or reduce the growth of a tumor or cancer cell when administered to an animal. More specific embodiments are provided herein.
- A “microbial antigen,” as used herein, is an antigen of a microorganism and includes, but is not limited to, infectious virus, infectious bacteria, infectious parasites and infectious fungi. Microbial antigens may be intact microorganisms, and natural isolates, fragments, or derivatives thereof, synthetic compounds which are identical to or similar to naturally-occurring microbial antigens and, preferably, induce an immune response specific for the corresponding microorganism (from which the naturally-occurring microbial antigen originated). In a preferred embodiment, a compound is similar to a naturally-occurring microorganism antigen if it induces an immune response (humoral and/or cellular) similar to a naturally-occurring microorganism antigen. Compounds or antigens that are similar to a naturally-occurring microorganism antigen are well known to those of ordinary skill in the art. A non-limiting example of a compound that is similar to a naturally-occurring microorganism antigen is a peptide mimic of a polysaccharide antigen. More specific embodiments are provided herein.
- The term “antigen” is further intended to encompass peptide or protein analogs of known or wild-type antigens such as those described above. The analogs may be more soluble or more stable than wild type antigen, and may also contain mutations or modifications rendering the antigen more immunologically active. Also useful in the compositions and methods of the present invention are peptides or proteins which have amino acid sequences homologous with a desired antigen's amino acid sequence, where the homologous antigen induces an immune response to the respective tumor.
- In one embodiment, the antigen in the LPD complex comprises an antigen associated with a tumor or cancer, i.e., a tumor-associated antigen. As such, in a preferred embodiment, the tumor or cancer vaccines of the present invention further comprise at least one epitope of at least one tumor-associated antigen. In another preferred embodiment, the tumor or cancer vaccines of the present invention further comprise a plurality of epitopes from one or more tumor-associated antigens. The tumor-associated antigens finding use in the LPD complexes and methods of the present invention can be inherently immunogenic, or non-immunogenic, or slightly immunogenic. As demonstrated herein, even tumor-associated self antigens may be advantageously employed in the subject vaccines for therapeutic effect, since the subject compositions are capable of breaking immune tolerance against such antigens. Exemplary antigens include, but are not limited to, synthetic, recombinant, foreign, or homologous antigens, and antigenic materials may include but are not limited to proteins, peptides, polypeptides, lipids, glycolipids, carbohydrates and DNA.
- Tumor-associated antigens suitable for use in the subject invention include both mutated and non-mutated molecules which may be indicative of single tumor type, shared among several types of tumors, and/or exclusively expressed or overexpressed in tumor cells in comparison with normal cells. In addition to proteins and glycoproteins, tumor-specific patterns of expression of carbohydrates, gangliosides, glycolipids and mucins have also been documented. Exemplary tumor-associated antigens for use in the subject cancer vaccines include protein products of oncogenes, tumor suppressor genes and other genes with mutations or rearrangements unique to tumor cells, reactivated embryonic gene products, oncofetal antigens, tissue-specific (but not tumor-specific) differentiation antigens, growth factor receptors, cell surface carbohydrate residues, foreign viral proteins and a number of other self proteins.
- Specific embodiments of tumor-associated antigens include, e.g., mutated antigens such as the protein products of the Ras p21 protooncogenes, tumor suppressor p53 and HER-2/neu and BCR-abl oncogenes, as well as CDK4, MUM1,
Caspase 8, and Beta catenin; overexpressed antigens such asgalectin 4, galectin 9, carbonic anhydrase, Aldolase A, PRAME, Her2/neu, ErbB-2 and KSA, oncofetal antigens such as alpha fetoprotein (AFP), human chorionic gonadotropin (hCG); self antigens such as carcinoembryonic antigen (CEA) and melanocyte differentiation antigens such asMart 1/Melan A, gp100, gp75, Tyrosinase, TRP1 and TRP2; prostate associated antigens such as PSA, PAP, PSMA, PSM-P1 and PSM-P2; reactivated embryonic gene products such asMAGE 1,MAGE 3,MAGE 4,GAGE 1,GAGE 2, BAGE, RAGE, and other cancer testis antigens such as NY-ESO1, SSX2 and SCP1; mucins such as Muc-1 and Muc-2; gangliosides such as GM2, GD2 and GD3, neutral glycolipids and glycoproteins such as Lewis (y) and globo-H; and glycoproteins such as Tn, Thompson-Freidenreich antigen (TF) and sTn. Also included as tumor-associated antigens herein are whole cell and tumor cell lysates as well as immunogenic portions thereof, as well as immunoglobulin idiotypes expressed on monoclonal proliferations of B lymphocytes for use against B cell lymphomas. - Tumor-associated antigens and their respective tumor cell targets include, e.g., cytokeratins, particularly
cytokeratin - In fact, in a preferred embodiment, the human papillomavirus (HPV)
subtype 16 E7 is used as the tumor-associated antigen. It has been found that E7 antigen-LPD complexes of the present invention are effective at preventing and treating cervical cancer. In addition, the present invention provides a genetically engineered E7 protein, i.e., E7m protein, having antigenic activity, but without tumorigenic activity. It has been found that the E7m-LPD complexes of the present invention induce cellular immunity to cause complete regression of established tumors and, thus, can be used as potent anti-cervical cancer vaccines. - Tumor-associated antigens can be prepared by methods well known in the art. For example, these antigens can be prepared from cancer cells either by preparing crude extracts of cancer cells (e.g., as described in Cohen et al., Cancer Res., 54:1055 (1994)), by partially purifying the antigens, by recombinant technology, or by de novo synthesis of known antigens. The antigen may also be in the form of a nucleic acid encoding an antigenic peptide in a form suitable for expression in a subject and presentation to the immune system of the immunized subject. Further, the antigen may be a complete antigen, or it may be a fragment of a complete antigen comprising at least one epitope.
- Antigens derived from pathogens known to predispose to certain cancers may also be advantageously included in the cancer vaccines of the present invention. It is estimated that close to 16% of the worldwide incidence of cancer can be attributed to infectious pathogens; and a number of common malignancies are characterized by the expression of specific viral gene products. Thus, the inclusion of one or more antigens from pathogens implicated in causing cancer may help broaden the host immune response and enhance the prophylactic or therapeutic effect of the cancer vaccine. Pathogens of particular interest for use in the cancer vaccines provided herein include the hepatitis B virus (hepatocellular carcinoma), hepatitis C virus (heptomas), Epstein Barr virus (EBV) (Burkitt lymphoma, nasopharynx cancer, PTLD in immunosuppressed individuals), HTLVL (adult T cell leukemia), oncogenic human papilloma viruses types 16, 18, 33, 45 (adult cervical cancer), and the bacterium Helicobacter pylori (B cell gastric lymphoma). Other medically relevant microorganisms that may serve as antigens in mammals and more particularly humans are described extensively in the literature, e.g., C. G. A Thomas, Medical Microbiology, Bailliere Tindall, Great Britain 1983, the entire contents of which is hereby incorporated by reference.
- In another embodiment, the antigen in the LPD complex comprises an antigen derived from or associated with a pathogen, i.e., a microbial antigen. As such, in a preferred embodiment, the pathogen vaccines of the present invention further comprise at least one epitope of at least one microbial antigen. Pathogens which may be targeted by the subject vaccines include, but are not limited to, infectious virus, infectious bacteria, infectious parasites and infectious fungi. In another preferred embodiment, the pathogen vaccines of the present invention further comprise a plurality of epitopes from one or more microbial antigens.
- The microbial antigens finding use in the subject compositions and methods may be inherently immunogenic, or non-immunogenic, or slightly immunogenic. Exemplary antigens include, but are not limited to, synthetic, recombinant, foreign, or homologous antigens, and antigenic materials may include but are not limited to proteins, peptides, polypeptides, lipids, glycolipids, carbohydrates and DNA.
- Exemplary viral pathogens include, but are not limited to, infectious virus that infect mammals, and more particularly humans. Examples of infectious virus include, but are not limited to: Retroviridae (e.g., human immunodeficiency viruses, such as HIV-1 (also referred to as HTLV-III, LAV or HTLV-III/LAV, or HIV-III; and other isolates, such as HIV-LP; Picornaviridae (e.g. polio viruses, hepatitis A virus; enteroviruses, human Coxsackie viruses, rhinoviruses, echoviruses); Calciviridae (e.g. strains that cause gastroenteritis); Togaviridae (e.g. equine encephalitis viruses, rubella viruses); Flaviridae (e.g. dengue viruses, encephalitis viruses, yellow fever viruses); Coronoviridae (e.g. coronaviruses); Rhabdoviradae (e.g. vesicular stomatitis viruses, rabies viruses); Coronaviridae (e.g. coronaviruses); Rhabdoviridae (e.g. vesicular stomatitis viruses, rabies viruses); Filoviridae (e.g. ebola viruses); Paramyxoviridae (e.g. parainfluenza viruses, mumps virus, measles virus, respiratory syncytial virus); Orthomyxoviridae (e.g. influenza viruses); Bungaviridae (e.g. Hantaan viruses, bunga viruses, phleboviruses and Nairo viruses); Arena viridae (hemorrhagic fever viruses); Reoviridae (e.g. reoviruses, orbiviurses and rotaviruses); Birnaviridae; Hepadnaviridae (Hepatitis B virus); Parvovirida (parvoviruses); Papovaviridae (papilloma viruses, polyoma viruses); Adenoviridae (most adenoviruses); Herpesviridae herpes simplex virus (HSV) 1 and 2, varicella zoster virus, cytomegalovirus (CMV), herpes virus; Poxyiridae (variola viruses, vaccinia viruses, pox viruses); and Iridoviridae (e.g. African swine fever virus); and unclassified viruses (e.g. the etiological agents of Spongiform encephalopathies, the agent of delta hepatitis (thought to be a defective satellite of hepatitis B virus), the agents of non-A, non-B hepatitis (class 1=internally transmitted; class 2=parenterally transmitted (i.e. Hepatitis C); Norwalk and related viruses, and astroviruses).
- Also, gram negative and gram positive bacteria may be targeted by the subject compositions and methods in vertebrate animals. Such gram positive bacteria include, but are not limited to Pasteurella species, Staphylococci species, and Streptococcus species. Gram negative bacteria include, but are not limited to, Escherichia coli, Pseudomonas species, and Salmonella species. Specific examples of infectious bacteria include but are not limited to: Helicobacter pyloris, Borella burgdorferi, Legionella pneumophilia, Mycobacteria sps (e.g. M. tuberculosis, M. avium, M. intracellulare, M. kansaii, M. gordonae), Staphylococcus aureus, Neisseria gonorrhoeae, Neisseria meningitidis, Listeria monocytogenes, Streptococcus pyogenes (Group A Streptococcus), Streptococcus agalactiae (Group B Streptococcus), Streptococcus (viridans group), Streptococcus faecalis, Streptococcus bovis, Streptococcus (anaerobic sps.), Streptococcus pneumoniae, pathogenic Campylobacter sp., Enterococcus sp., Haemophilus infuenzae, Bacillus antracis, corynebacterium diphtheriae, corynebacterium sp., Erysipelothrix rhusiopathiae, Clostridium perfringers, Clostridium tetani, Enterobacter aerogenes, Klebsiella pneumoniae, Pasturella multocida, Bacteroides sp., Fusobacterium nucleatum, Streptobacillus moniliformis, Treponema pallidium, Treponema pertenue, Leptospira, Rickettsia, and Actinomyces israelli.
- Polypeptides of bacterial pathogens which may find use as sources of microbial antigens in the subject compositions include but are not limited to an iron-regulated outer membrane protein, (“IROMP”), an outer membrane protein (“OMP”), and an A-protein of Aeromonis salmonicida which causes furunculosis, p57 protein of Renibacterium salmoninarum which causes bacterial kidney disease (“BKD”), major surface associated antigen (“msa”), a surface expressed cytotoxin (“mpr”), a surface expressed hemolysin (“ish”), and a flagellar antigen of Yersiniosis; an extracellular protein (“ECP”), an iron-regulated outer membrane protein (“IROMP”), and a structural protein of Pasteurellosis; an OMP and a flagellar protein of Vibrosis anguillarum and V. ordalii; a flagellar protein, an OMP protein, aroA, and purA of Edwardsiellosis ictaluri and E. tarda; and surface antigen of Ichthyophthirius; and a structural and regulatory protein of Cytophaga columnari; and a structural and regulatory protein of Rickettsia. Such antigens can be isolated or prepared recombinantly or by any other means known in the art.
- Examples of pathogens further include, but are not limited to, infectious fungi that infect mammals, and more particularly humans. Examples of infectious fungi include, but are not limited to: Cryptococcus neoformans, Histoplasma capsulatum, Coccidioides immitis, Blastomyces dermatitidis, Chlamydia trachomatis, Candida albicans. Examples of infectious parasites include Plasmodium such as Plasmodium falciparum, Plasmodium malariae, Plasmodium ovale, and Plasmodium vivax. Other infectious organisms (i.e. protists) include Toxoplasma gondii. Polypeptides of a parasitic pathogen include but are not limited to the surface antigens of Ichthyophthirius.
- Other medically relevant microorganisms that serve as antigens in mammals and more particularly humans are described extensively in the literature, e.g., see C. G. A Thomas, Medical Microbiology, Bailliere Tindall, Great Britain 1983, the entire contents of which is hereby incorporated by reference. In addition to the treatment of infectious human diseases and human pathogens, the compositions and methods of the present invention are useful for treating infections of nonhuman mammals. Many vaccines for the treatment of non-human mammals are disclosed in Bennett, K. Compendium of Veterinary Products, 3rd ed. North American Compendiums, Inc., 1995; see also WO 02/069369, the disclosure of which is expressly incorporated by reference herein.
- Exemplary non-human pathogens include, but are not limited to, mouse mammary tumor virus (“MMTV”), Rous sarcoma virus (“RSV”), avian leukemia virus (“ALV”), avian myeloblastosis virus (“AMV”), murine leukemia virus (“MLV”), feline leukemia virus (“FeLV”), murine sarcoma virus (“MSV”), gibbon ape leukemia virus (“GALV”), spleen necrosis virus (“SNV”), reticuloendotheliosis virus (“RV”), simian sarcoma virus (“SSV”), Mason-Pfizer monkey virus (“MPMV”), simian retrovirus type 1 (“SRV-1”), lentiviruses such as HIV-1, HIV-2, SIV, Visna virus, feline immunodeficiency virus (“FIV”), and equine infectious anemia virus (“EIAV”), T-cell leukemia viruses such as HTLV-1, HTLV-II, simian T-cell leukemia virus (“STLV”), and bovine leukemia virus (“BLV”), and foamy viruses such as human foamy virus (“HFV”), simian foamy virus (“SFV”) and bovine foamy virus (“BFV”).
- In preferred embodiments, “treatment,” “treat,” and “treating,” as used herein with reference to infectious pathogens, refer to a prophylactic treatment which increases the resistance of a subject to infection with a pathogen or decreases the likelihood that the subject will become infected with the pathogen; and/or treatment after the subject has become infected in order to fight the infection, e.g., reduce or eliminate the infection or prevent it from becoming worse.
- Microbial antigens can be prepared by methods well known in the art. For example, these antigens can be prepared directly from viral and bacterial cells either by preparing crude extracts, by partially purifying the antigens, or alternatively by recombinant technology or by de novo synthesis of known antigens. The antigen may also be in the form of a nucleic acid encoding an antigenic peptide in a form suitable for expression in a subject and presentation to the immune system of the immunized subject. Further, the antigen may be a complete antigen, or it may be a fragment of a complete antigen comprising at least one epitope.
- 1. Subcutaneously Injected LPD/Peptide Complex Accumulates in Local Lymphnode and Taken up by Various Immune Effector Cells.
- As delivery to organized lymph tissue is important for successful vaccination, we wished to determine if LPD particles would make their way into draining lymph nodes following subcutaneous injection. C57BL/6 mice were footpad injected with LPD/E7 particles containing trace amounts of Cy5-labeled DNA. At 16 h after injection, popliteal lymph nodes were collected, single cell suspensions were prepared and LPD the percentage of cells that took up LPD was determined by flow cytometry. Mice injected with non-fluorescent LPD particles served as controls. After SC administration, 2.4% of all lymph node cells took up LPD particles. While only a small percentage of all lymph node cells take up LPD particles, this can be sufficient to produces effective vaccination of those cells are capable of effectively presenting the delivered antigen. To determine what cell types were taking up LPD/E7 particles, C57BL/6 mice were footpad injected with LPD/E7 particles containing trace amounts of Cy5-labeled DNA. At 16 h after injection, popliteal LN cells were stained for the cell-type specific surface markers CD11b (to identify macrophages and myeloid lineage DCs), CD11c (to identify dendritic cells), CD19 (to identify B cells), and NK1.1 (to identify NK cells) using fluorescently labeled antibodies and subjected to flow cytometric analysis. Phagocytic cells appear to be the main cell types that take up LPD/antigen particles with high percentage of NK cells (25%) and macrophages (25%) taking up particles while only 2.4% of B cells took up LPD particles. Of particular interest, 16.8% of dendritic cells took up LPD particles (Please see data in the table in Dileo et al.).
- 2. LPD/E7 Complexes Induce an E7 Specific Immune Response.
- To determine if LPD/E7 particles induce enhanced immunization versus traditional liposome/peptide vaccines, mice were SC or IV vaccinated with LPD particles containing 0, 1, 10, or 20 μg of E7 peptide on
days - 3. LPD/E7 Induces Both Protective and Therapeutic Immunities Against HPV+ Tumor.
- To determine if the induced immune response is adequate to provide protective immunity, mice were IV or SC vaccinated with either 20 μg E7 peptide in PBS, empty LPD, or LPD containing 20 μg of E7 peptide on
days - On
days - 4. A Single s.c. Injection of LPD/E7 can Induce Regression of Large Advanced Tumor.
- To determine how late the LPD/E7 nanoparticle treatment can still be effective, subcutaneous tumors were established in C57BL/6 mice by inoculation of 1×105 TC-1 cells. On
days FIG. 1 ). LPD treatment on 12 days after TC-1 cell inoculation stopped tumor growth after 20 days. The experiment had to be terminated at 25 days because the size of the tumors in the untreated control group had grown to be too large. The average diameter of tumor onday 12 was more than 7 mm and this time point was at the middle of the entire course of the experiment. These data indicate that LPD/E7 nanoparticles may not only provide potent anti-tumor effects in vaccination protocols, but also be effective for the treatment of advanced tumors. - 5. LPD/E7 is Effective in Treating Metastatic Tumor Model and Induce Tumor Specific Memory Immune Response.
- To identify the effect of LPD/E7 nanoparticle vaccination on the metastatic cervical cancer, we established metastatic tumor model with TC-1 cells. If TC-1
cells 1×106 cells) were injected intraperitoneally, numerous metastatic tumor nodules were observed in the peritoneum in a few days later; many were also found in organs such as liver, spleen, kidney and lymph nodes. Inoculated mice died within 20 days after TC-1 cell injection (FIG. 2A ). To determine if LPD/E7 vaccination induced anti-tumor immunity against i.p. injected TC-1 cells, mice were vaccinated with LPD particles containing 10 μg E7 peptide or 10 μg E7 peptide in PBS onday day 10, mice received subcutaneous tumor challenge at a dose of 1×106 TC-1 cells per mouse and the survival rate was measured. As shown inFIG. 2A , only 20% of untreated and E7-alone injected mice survived beyond 20 days after TC-1 cell injection, but the survival rate of LPD/E7 vaccinated group was 100% for the entire course of the experiment (50 days). To identify if survived mice from the LPD/E7 vaccination group exhibited the antigen specific immune response, mice were re-challenged subcutaneously with 1×105 TC-1 cells or 24JK cells. Normal unvaccinated animals receiving an equal number of TC-1 cells or 24JK cells were used as control groups. Mice that survived from first challenge with TC-1 cells also failed to develop tumors upon re-challenge with fresh TC-1 cells, while normal animals injected with TC-1 cells and all mice injected with 24JK cells developed tumors (FIG. 2B ). The data indicate that the immune response induced by LPD/E7 not only protected mice against the metastatic tumor challenge, but also provided protection for subsequent challenge. - 6. Immunological Characterizations of LPD/E7 Peptide.
- Previous experiments showed that LPD particles formulated with ODN-1668 (containing unmethylated CpG motif), but not ODN-1668GC (containing identical sequence as 1668 except the CpG in the motif was replaced with GpC), could induce TH1 cytokines and show anti-tumor activity (Whitmore et al, 2001). These experiments were done with LPD particles without any specific tumor antigen. Whether the same result would be true for an antigen specific vaccine activity was not known. We prepared LPD/E7 complex using either ODN-1668 or ODN-1668GC, but no plasmid DNA, and injected them to animals and to see if any protective immunity was developed in the animal against subsequent challenge of TC-1 cells. As can be seen in
FIG. 3 , all formulations containing E7 peptide had prevented the growth of tumor; whereas no formulations without E7 peptide had any activity. The data indicate that the antitumor activity was antigen dependent. Furthermore, since formulations with or without the CpG motif had the same activity, it suggested that the unmethylated CpG motif played little if any role in the induction of antitumor immune responses. This was a somewhat surprising result, because we had previously shown that CpG motifs are necessary for an antigen independent antitumor activity of LPD (Whitmore et al, 2001). Apparently, when the antigen is present, the antigen dependent immune response dominates the independent response. Moreover, the data also suggest that DNA or ODN is not necessary for the antitumor immune response. As long as the antigen, E7 peptide in this case, is carried by the cationic lipids, it can elicit an antitumor response. This hypothesis was independently verified by another experiment in which various LPD components were tested for antitumor activity. Indeed, E7 peptide complexed with DOTAP/chol liposomes could induce tumor regression after a single s.c. injection. - TLR9 is responsible for the action of the immunostimulating unmethylated CpG motifs, e.g., RRCGYY (Hemmi et al., 2000; Bauer et al., 2001). It is a good guess that the adjuvant activity of LPD is mediated by TLR9. To test this hypothesis, we have obtained TLR9 −/− mice (Hemmi et al., 2000) from Professor Shizuo Akira in Japan. The mice are in the background of C57BL/6 and are syngeneic with TC-1 cells. The splenocytes from wild type or TLR9−/− mouse injected with LPD/E7 were re-stimulated with 1 μg/ml E7 peptide for 24 h. The culture supernatants were collected and IFN-γ levels were measured using ELISA. As can be seen in
FIG. 4 , splenocytes from either wildtype or knockout mice could be stimulated with LPD/E7 to produce IFN-γ to the same extend, indicating that TLR9 is not important in the process of immune stimulation. Again, it suggests that cationic lipid, rather than DNA, was the primary stimulant of the immune system. - According to our preliminary data, approximately 25% of Lymphnode NK cells have taken up s.c. injected LPD. Our previous work using LPD without E7 peptide also indicates that NK cells are involved in the first phase of tumor killing, which is followed by induction of tumor specific CTL. Thus, there is a real possibility that NK cells may be activated by LPD and involves in tumor cell killing. To identify whether the NK cells are necessary for the antigen specific immune response, we have eliminated the NK cells by treating the animals with anti-NK1.1 antibody. As can be seen in
FIG. 5 , the antigen specific T-cell response, measured by IFN-γ ELISPOT assay, was approximately the same as the ones without the NK elimination. This result indicates that NK cells are only important for the antigen independent antitumor activity, but not in the antigen specific activity. - 7. Cationic Lipids can Activate Dendritic Cells.
- Previously we have shown that LPD is a potent vaccine delivery system/adjuvant. Following are some data we collected when studying the mechanism of the strong immunostimulation activity from LPD. We have measured by flow cytometry the expression of co-stimulatory molecules, CD86 and CD80, on DC2.4 cells as the result of stimulation by various components of LPD, including the liposome prepared from
cationic lipid 1,2-dioleoyl-3-(trimethylammonium) propane (DOTAP) and cholesterol (Chol), protamine, and DNA. Plasmid DNA alone, protamine alone, and the complex of DNA/protamine did not stimulate the expression of CD80/CD86 (FIG. 6 ). LPD stimulated DC2.4 cells expressed the highest amount of CD80/CD86. Lipoplex prepared from liposome (DOTAP/Chol) and DNA was as effective as the LPD, indicating that protamine is not required for DC cell stimulation. In addition, cholesterol is not required for DC cell stimulation (FIG. 6 ) since LPD prepared from liposomes comprised of DOTAP alone is as effective as those prepared from liposomes comprised of DOTAP and cholesterol. Finally, it was found that CD80/CD86 expressions from liposome alone (DOTAP/Chol) stimulated DC2.4 cells were up to 70% of that from LPD stimulated DC2.4 cells, strongly demonstrating that the DOTAP-based cationic liposome alone can activate DCs and is responsible for the some of the LPD adjuvant activity. Therefore, a few other cationic liposomes were also tested for their ability to stimulate the expression of CD80/CD86 by DC2.4 cells. To our surprise, as shown inFIG. 7 , the ability to stimulate the expression of CD80/CD86 on DC2.4 cells by different cationic liposomes varies greatly. Lipofectamine®, a 3:1 (w/w) liposome formulation of thepolycationic lipid 2,3-dioleyloxy-N-[2(sperminecarboxamido)ethyl]-N,N-dimethyl-1-propanaminium trifluoroacetate (DOSPA) and the neutral lipid dioleoyl phosphatidylethanolamine (DOPE), and liposomes prepared from O,O′-dimyristyl-N-lysyl aspartate (DMKE) and O,O′-dimyristyl-N-lysyl-glutamate (DMKD), two newly synthesized cationic lipids by Dr. Yong-Serk Park, strongly stimulated the expression of CD80/CD86 by CD2.4 cells, whereas Lipofectin®, a 1:1 (w/w) liposome formulation of cationic lipid N-[1-(2,3-dioleyloxy)propyl]-n,n,n-trimethylammonium chloride (DOTMA) and DOPE, DMRIEC®, a 1:1 (M/M) liposome formulation ofcationic lipid 1,2-dimyristyloxypropyl-3-dimethyl-hydroxy ethyl ammonium bromide (DMRIE) and cholesterol, and liposome prepared from cationic lipid dimethyldioctadecylammonium bromide (DDAB) and cholesterol did not show any significant stimulation on the expression of CD80/CD86 by DC2.4 cells. - The ability of different cationic lipids to stimulate the expression of
CD 80 on DC 2.4 cells varied significantly. Both hydrophilic head and the lipophilic tail of the lipids have significant effect on this ability. For example, the DXEPC lipids with the ethyl phosphocholine (EPC) head groups are, in general, more potent than the DXTAP lipids with trimethylammonium propane (TAP) head group. The effect of the hydrocarbon tail region of the lipids on the DC cell stimulation also was systematically investigated (FIG. 8 ). Within the lipids bearing one particular head group structure, lipids with shorter (1,2-dilauroyl-sn-glycero-3-ethylphosphocholine (DLEPC-12:0), 1,2-dimyristoyl-sn-glycero-3-ethylphosphocholine (DMEPC-14:0)) or unsaturated (1,2-dioleoyl-sn-glycero-3-ethylphosphocholine (DOEPC-18:1)) acyl chains are found to be more potent than those with longer (1,2-dipalmitoyl-sn-glycero-3-ethylphosphocholine (DPEPC-16:0)) or saturated (1,2-distearoyl-sn-glycero-3-ethylphosphocholine (DSEPC-16:0)) acyl chains. Similar trends were observed with lipids having TAP head groups also with 1,2-distearoyl-3-trimethylammonium propane (DSTAP-18:0) and 1,2-palmitoyl-3-trimethylammonium propane (DPTAP-16:0) showing much lower expression of CD80 on DC 2.4 cells compared to that of 1,2-myristoyl-3-trimethylammonium propane (DMTAP-14:0) and 1,2-oleoyl-3-trimethylammonium propane (DOTAP-18:1). Detergent sodium dodecyl sulfate (SDS) could not activate DC 2.4 cells for the expression ofCD 80 suggesting that the DC 2.4 activation by cationic lipids with shorter hydrophobic chains were not due the possible detergent effect of shorter chain lipids on the cell membrane. - To further prove that both DNA and cationic liposome are required for the full activity of LPD, an in vivo tumor therapy study was carried out. As shown in
FIG. 9 , 20 days after treatment with E7 peptide-incorporated LPD (LPD/E7), the tumor (injected 6 days before the onset of treatment) almost totally regressed. Liposome/E7 and lipoplex/E7 (LD/E7) showed effect to some extent but significantly weaker than that of the LPD/E7. Tumors in mice treated with other formulations including DNA/E7, protamine/E7, LP/E7, PD/E7, and E7 alone kept growing rapidly with the final tumor size comparable to those on the untreated naive mice. Therefore, the result of this tumor therapy study again demonstrated that both DNA and cationic liposome are required for the full immunostimulation activity of LPD. It is interesting to note that in the tumor model, protamine becomes functionally important, as the activity of LPE/E7 was significantly greater than that of LD/E7. It is speculated that by condensing DNA, protamine helped to bring DNA inside the liposomes. E7 peptide was thought to bind to DNA via electrostatic interaction (Dileo et al., 2003). In LPD/E7, the E7 peptide might locate inside the liposome and should be protected from enzymatic degradation after injection. On the other hand, E7 might only be loosely bound in the LD/E7 particles. In fact, the peptide incorporation efficiency of LPD/E7 was about 80%, whereas for LD/E7 and L/E7, it was about 65%. - 8. Genetically Engineered
HPV 16 E7 Protein as a Potential Cervical Cancer Vaccine. - Previously, we showed that a seven amino acid peptide from
HPV 16 E7 protein, when incorporated into LPD nanoparticles, induced strong anti-tumor response the can prevent and treat tumors grafted on mice. In the present study, we hypothesized that the LPD particles could also be used as a carrier for E7 protein to induce strong antibody and anti-tumor responses. We also hypothesized that by introducing mutations on E7 protein, we can delete the oncogenic activity of E7 but keep its antigenic activity. - To investigate whether strong immune responses can be elicited when E7 protein is incorporated into LPD nanoparticles as a vaccine, E7 protein was expressed in E. coli, purified, detoxified, and incorporated into LPD particles. E7/LPD was then used to immunize C57BL/6 mice. The resulting antibody, tumor prevention, and tumor treatment activity from E7/LPD were compared to that of E7 alone or E7 adjuvanted with ‘Alum’. Data showed that E7/LPD induced antibody level (specific IgG) significantly higher than that of E7/Alum (
FIG. 10 ). Also, E7/LPD immunization prevented the growth of TC-1 tumor cells on mice (FIG. 11 ); visible tumor (4 day old) on mice totally regressed when the mice were treated with E7/LPD (FIG. 12 ). - To engineer the E7 protein to delete its oncogenic activity, and hopefully, without disrupting its immunogenicity. The following experiments were carried out. For the engineering of mutated E7 protein, an overlapping PCR was used. Amino acids D21 and C94 on E7 protein were changed to G21 and G94 by changing their codons from GAT to GGT and TGT to GGT, respectively. The four primers used were P1, 5-TTGGGATCCACCATGCATGGAGATACACCTAC-3 [SEQ. ID. NO. 1]; P2, 5-CGGAATTCATTCTTATGGTTTCTGAGAACCGATGGGGCACACA-3 [SEQ. ID. NO. 2]; P3, 5-GAGACAACTGGTCTCTACTGTTAT-3 [SEQ. ID. NO. 3]; and P4, 5-ACAGTAGAGACCAGTTGTCTCTGG-3 [SEQ. ID. NO. 4]. Using pET-E7 as the template, two separate PCRs were completed using primer P1/P4 and P2/P3 as the primer pairs, respectively. The PCR products were purified using QiaQuick PCR purification Kit (Valencia, Calif.). Another PCR was completed using P1 and P2 as the primers and equal molar of the products from the two previous PCRs as the templates. The PCR conditions were 94° C. for 5 min followed by 35 cycles of 94° C., 0.5 min, 56° C., 1 min, and 72° C., 0.5 min. Another 5 min of incubation at 72° C. was included prior to the end of the PCR reaction. Taq DNA polymerase and dNTP were from Promega (Madision, Wis.). After purification, the PCR product was then ligated to the pGEM®-T vector from Promega. The ligation reaction was then transferred into E. coli DH5a strain. Positive colonies were selected using LB/ampicillin/IPTG/X-Gal plates. After confirmation of mutations on the E7 gene of the pGEM®-T-E7m, the plasmid was digested with BamHI and EcoRI, whose restriction sites are on primer P1 and P2, respectively. The resulting DNA fragment was gel purified and then cloned into the BamHI and EcoRI site of pCDNA3.1(+) vector (Invitrogen, Carlsbad, Calif.) and pET vector (Novagen, Madison, Wis.), respectively. The plasmid constructs were transferred into E. coli DH5a and selected against ampicillin and kanamycin, respectively.
- An indirect method was used to verify that E7m lost its ability to bind to pRB protein and therefore is unable to activated E2F driven genes. E7 and E7m genes were inserted into the BamH1 and EcoRI sites of pCDNA3.1(+) vector. The resulting plasmids were amplified in E. coli DH5a strain and purified. Plasmid cdc25A Sac1-luc, in which luciferase gene is driven by a 1173 (−755 to +418) bp SacI fragment of the cdc25A promoter, is a gift from Dr. D. DiMaio from Yale University (New Haven, Conn.). The SacI fragment has both
HPV 16 E2 protein binding site and the E2F binding site. Plasmid cdc25A SacI-luc, pCDNA3.1 (+) with or without E7 or E7m insert, and a CMV driven β-galactosidase gene containing plasmid were cotransfected into confluent 293 cells (5×105/well, incubated at 37° C. and 5% CO2 overnight, DMEM medium with 10% FBS) with Lipofectamine® (Invitrogen). The plasmid ratio was 2:1:10 (w/w/w) with pCDNA3.1(+) plasmid at 1 μg/well. Four hours after the addition of the plasmids, the medium was replaced with fresh medium. After another 44 h, the incubation was stopped. Cells were washed with cold PBS (10 mM, pH 7.4) for twice and lysed. Luciferase activity, β-galactosidase expression, and total protein amount were then determined. Relative light unit normalized to galactosidase protein level and total protein amount was reported. As shown inFIG. 13 , when 293 cells were co-transfected with E2F responsive element driven luciferase gene encoding plasmid (cdc25A Sac I-luc) and an E7 protein encoding plasmid (pCDNA-E7), significantly higher luciferase expression was observed than when cdc25A Sac I-luc was co-transfected with an empty plasmid (pCDNA3) (p=0.02). However, when pCDNA-E7m was cotransfected with cdc25A Sac I-luc, the resulting luciferase level was comparable to that when cdc25A Sac I-luc and pCDNA3 were co-transfected (p=0.19). Taken together, these date suggest that the mutations on E7m may abolish its ability to bind to pRB and thus the oncogenic activity. - To investigate whether the mutations introduced on E7 affect the mutated protein's ability to induce antibody and antitumor responses, E7 and E7m proteins were purified and used to immunize mice. The resulting specific antibody levels and tumor treatment abilities were compared. Shown in
FIG. 14 are the specific antibody levels in serum on day 27 andday 60. Again, both E7/LPD and E7m/LPD induced significantly higher IgG level than E7 and E7m alone without LPD. Interestingly, on day 27, the IgG level from E7/LPD was higher than that from E7m/LPD (p=0.019); whereas onday 60, the IgG level from E7/LPD was comparable to that for E7m/LPD (p=0.53). This is due to the significant decreased IgG level in E7/LPD immunized mice as time passed (p=0.004). The above data are the antibody levels when measured against E7 protein as an antigen. Similar results were obtained when measured against E7m protein. - Treatment of tumor bearing mice with E7m/LPD is as effective as with E7/LPD in causing tumor regression (
FIG. 15 ). - In summary, mutations in the E7 protein have been successfully introduced. The resulting mutated E7m protein losses its oncogenic property, but is as immunogenic as the original E7 protein.
- A. Materials and Methods
- 1. DNA, Cell Lines and Peptides
- TC-1 cells were provided by TC Wu (Johns Hopkins University, Baltimore, Md.). These cells are C57BL6 mouse lung endothelial cells that have been transformed with the HPV16 E6 and E7 oncogenes and activated H-ras. Cells were grown in RPMI medium (Invitrogen, Carlsbad, Calif.) supplemented with 10% fetal bovine serum and 100 U/ml penicillin, and 100 mg/ml streptomycin. Cy3 labeled phophodiester oligodeoxynucleotides were purchased form Invitrogen (Carlsbad, Calif.). pNGVL3 was obtained from the National Gene Vector Laboratory (University of Michigan) and contains the CMVie promoter and no coding region. Plasmids were prepared using Qiagen EndoFree Giga-Prep kits (Qiagen, Valencia, Calif.). The MHC class I restricted peptide from the
HPV 16 E7 protein (aa 49 to 57, RAHYNIVTF [SEQ. ID. NO. 5]) was synthesized by the University of Pittsburgh Peptide Synthesis Facility by solid state synthesis using anAdvanced ChemTech model 200 peptide synthesizer and purified by HPLC. (Feltkamp, et al. Eur J Immunol 23, 2242-2249 (1993)). - 2. Liposome and LPD Preparation
- All lipids were purchased from Avanti Polar Lipids (Alabaster Ala.). Small unilamellar DOTAP (1,2-Dioleoyl-3-Trimethylammonium-Propane):cholesterol (1:1 molar ratio) liposomes were prepared by thin film hydration followed by extrusion. LPD complexes were prepared using the procedure described by Li with modifications (Li, et al.
Gene Ther 5, 930-937 (1998)). Briefly, complexes contained an 8.5:0.6:1.0 weight ratio of DOTAP/cholesterol liposomes:protamine:DNA. Liposomes and protamine (Sigma, St Louis Mo.) were mixed in 75 μl of 5.2% dextrose solution. 75 μl of a solution containing plasmid DNA and E7 peptide was slowly added by dropwise addition with constant mixing. Complexes were incubated for 20 min at room temperature prior to injection. LPD/E7 particle size was determined by dynamic light scattering using a Coulter N4 plus (Beckman Coulter, San Francisco) and found to be indistinguishable from LPD particles (110±30 nm and 123±40 nm, respectively n=3). Peptide encapsulation efficiency was determined using FITC-labeled E7 peptide and was found to be 83±4% (n=3). - Sterically stabilized liposomes (SL liposomes) were prepared according to Ignatius et al (29). Briefly, small unilamellar cholesterol:Palmitoyl-Oleoyl Phosphatidylcholine (POPC):PEG-PE (2:3:0.3 molar ratio) liposomes were prepared by thin film hydration with a 1 mg/ml E7 peptide containing solution followed by extrusion.
- 3. Immunizations/Treatments
- Six-week-old female C57BL/6 mice (Charles River Labs, Wilmington, Mass.) were used in all experiments. For vaccinations, mice were injected through the tail vein or subcutaneously with LPD particles containing 25 μg of pNGVL3 (University of Michigan) and 20 μg of E7 peptide on
days day 10, mice were challenged by SC injection of 0.5×106 TC-1 cells and mice were observed for the formation of tumors by palpation twice per week. - For therapy experiments, SC tumors were established by injecting 0.5×106 TC-1 cells on
day 0. Mice were IV injected withLPD complexes - 4. CTL Assays
- Cytolytic lymphocyte activity was measured using standard 51Cr-release assays. Splenocytes were collected and cultured in RPMI supplemented with 10% FBS, 50 U/ml penicillin/streptomycin, 2 mM L-glutamine, 1 mM sodium pyruvate, 2 mM nonessential amino acids, 40 U/ml IL2, and 200 ng/ml MHC class I restricted E7 peptide for 4 days. Effector cells were plated into 96-well plates at various effector-to-target (E:T) cell ratios. Targets used were either EL4 cells pulsed with E7 peptide or non-pulsed EL4 cells. Targets were labeled with 200 μCi 51Cr (NEN Life Sciences, Boston Mass.) for 18 h at 37° C. Before mixing with effectors, the targets were washed two times with medium, and resuspended at 2×105 cells/ml. The lysis reaction was carried out for 4 h at 37° C., after which the plates were centrifuged, and 100 μl of medium from each well were assayed for 51Cr content in a scintillation counter. Specific lysis was calculated using the following equation: % specific lysis=(experimental release-spontaneous release)/(maximum release-spontaneous release)×100.
- 5. Histology
- To visualize LPD distribution, mice were injected with LPD particles containing 25 μg pNGVL3, 0.1 μg Cy3 labeled oligodeoxynucleotides (ODN) and 10 μg E7 peptide in 150
μl 5% dextrose. 12, 24, and 48 h later, spleens were collected, embedded in OCT medium, frozen, and 6 μm sections were prepared and observed at 200× magnification using a Nikon Eclipse TE300 inverted fluorescent microscope and SPOT image analysis software. - 6. Flow Cytometry
- Phycoerythrin (PE) conjugated antibodies were purchased from BD Pharmingen (San Diego Calif.). Spleens were collected 12, 24, and 48 h after administration of LPD containing fluorescein (FITC) labeled ODN. Single cell suspensions were prepared and stained for CD11b or CD11c using the M1/70 and HL3 antibodies respectively. Samples were run on an EPICS-XL benchtop cytometer (Beckman-Coulter, San Francisco) and analyzed using EXPO 32 software.
- B. Results
- 1. LPD/Peptide Complexes Accumulate in the Spleen and are Taken Up by APCs
- As delivery to organized lymph tissue is important for successful vaccination, we wished to visualize the distribution of LPD particles within the spleen. To this end, C57BL6 mice were IV injected with LPD/E7 particles containing trace amounts of Cy3-labeled DNA. At 12, 24, and 48 h after injection, spleens were collected, sectioned and the distribution of fluorescence was observed. Mice injected with non-fluorescent LPD particles served as controls. After IV administration, LPD particles rapidly accumulate in the marginal zones of the spleen. (
FIG. 16 ) At 24 h, the majority of the fluorescence was still located in the marginal zones but began to be seen in the white pulp. By 48 h, fluorescence was less intense and was found in a diffuse pattern. Control mice showed no fluorescence. - To determine if LPD/E7 particles are taken up by antigen presenting cells, C57BL6 mice were IV injected with LPD/E7 particles containing trace amounts of FITC-labeled DNA. At 12, 24, and 48 h after injection, splenocytes were collected, stained for CD11c (to identify dendritic cells) and CD11b (to identify macrophages and myeloid lineage DCs), using PE-labeled antibodies and subjected to flow cytometric analysis (
FIG. 17 ). Mice injected with non-fluorescent LPD particles served as control. At 24 h, 3.9% of total splenocytes were CD11b/DNA double positive and 1.7% were CD11c/DNA positive (FIG. 17A ). However, these numbers represent approximately 18% (3.9% of 21.6%) and 30% (1.7% of 5.7%) of all CD11b and CD11c positive cells respectively (FIG. 17B ). Similar percentages were observed at 12 and 48 h. Control mice and splenocytes stained with isotype control antibodies showed <0.5% positive cells for both CD11b and CD11c. - 2. LPD/E7 Complexes Induce an E7 Specific Immune Response
- Previous work has shown that the induction of E7 specific CTL activity is important for tumor control (Cheng, et al. J Clin Invest 108, 669-678 (2001); and Cheng, et al. J Virol 75, 2368-2376 (2001)). To determine if LPD/E7 particles induces significant CTL activity, mice were SC or IV vaccinated with LPD particles containing 0, 1, 10, or 20 μg of E7 peptide on
days FIG. 18 ) (Ignatius, et al. Blood 96, 3505-3513 (2000)). Vaccination with 20 μg LPD/E7 produced the highest levels of CTL activity by both routes (92% and 72% specific lysis by IV and SC respectively). Injection of 10 μg LPD/E7 particles induced intermediate levels of CTL activity in both cases, while 1 μg LPD/E7 induced significant CTL activity following IV administration only. Free E7 peptide showed no CTL induction by either route. - 3. LPD/E7 Vaccination Protects Mice from HPV+ Tumor Formation
- To determine if the induce immune response is adequate to provide protective immunity, mice were IV or SC vaccinated with either 20 μg E7 peptide in PBS, empty LPD, or LPD containing 20 μg of E7 peptide on
day days FIG. 19 ) - 4. LPD/E7 Complexes can be Used to Eradicated Established HPV+ Tumors
- To determine the potential of LPD/E7 complexes for use as a therapeutic strategy, subcutaneous tumors were established in C57BL6 mice by inoculation of 0.5×106 TC-1 cells. On
days FIG. 20 ). SC treatment also resulted in complete regression but with slower kinetics. As expected, empty LPD administration slowed tumor progression but failed to eradicate the tumors. The anti-tumor effect in asplenic mice depended on the route of administration. IV treatment showed tumor growth rates similar to those observed in mice treated with LPD alone, while SC delivery resulted in tumor regression. Untreated mice showed unimpeded tumor progression. - It has been shown that LPD administration to tumor bearing mice induces non-specific immune activation that can result in tumor regression (Whitmore, et al., Gene Ther. 6, 1867-1875 (1999); and Whitmore, et al., Cancer Immunol Immunother. 50, 503-514 (2001)). To confirm that tumor regression was due to an E7 specific response, ten days after the last treatment splenocytes were assayed for E7 specific tumor lytic activity. Consistent with previously published results, IV or SC injection of LPD without peptide induced a low level of apparent CTL activity while treatment with LPD/E7 resulted in the highest level of CTL activity in both cases (
FIG. 21 ). Cells from untreated mice showed no lytic activity. - C. Discussion
- Following IV administration, peptide containing LPD particles traffic to the spleen where they accumulate in the APC rich marginal zones (Basak, et al., Blood 99, 2869-2879 (2002); and McIlroy, et al., Blood 97, 3470-3477 (2001)). Flow cytometry identified the cells that take up LPD/E7 complexes as mainly CD11b and CD11c positive cells. Approximately 27% of all CD11c and 16% of CD11b positive cells show LPD uptake as soon as 12 h after injection and remained positive for at least 48 h. Over time these particles or the cells that have internalized them appear to traffic into the white pulp where immune activation can occur. These observations are consistent with recently published studies by Moron, et al. which suggest that CD11c+CD11b+ cells in the marginal zone internalize VLPs and subsequently traffic to T-cell areas of the spleen (Moron, et al., J Exp Med 195, 1233-1245 (2002))
- While only a small number of APCs presenting an antigen are needed to initiate an immune response, most tumor antigens represent self antigens and are inherently less immunogenic than virally encoded tumor antigens (Porgador, et al., J Exp Med 188, 1075-1082 (1998)). The ability of LPD particles to deliver antigen to a large number of APCs should be beneficial when delivering epitopes from these antigens.
- Intravenous vaccination with as little as 1 μg of encapsulated peptide produces measurable antigen specific CTL activity and vaccination with 20 μg of peptide showed greater immune induction than other commonly used liposome/peptide delivery systems (SL liposomes). The level of immune induction is sufficient to protect mice against tumor formation and caused the complete regression of established tumors. IV Treatment of asplenic mice with LPD/E7 particles showed therapeutic effects similar to delivery of empty LPD particles to intact mice while the removal of the spleen showed no effect on SC administration. The differential effects of spleen removal are most likely due to the differences in the site of T cell activation depending on the route of administration. Following IV administration, T cells are activated in the spleen and its removal prevents effective priming. The fact that removal of the spleen does not completely remove the IV therapeutic effect could be the result of LPD uptake by APCs in other lymphatic tissues, such as lung or hepatic lymph nodes, or to the anti-tumor effect of LPD mediated by their ability to induce the production of Th1 cytokines (IL-12, IFNγ, and TNF.alpha.) that possess direct anti-tumor activities (Whitmore, et al.,
Gene Ther 6, 1867-1875 (1999)). While the spleen plays a role in the production of these cytokines, a large amount of this production occurs in the liver and lung (Whitmore, et al.Cancer Immunol Immunother 50, 503-514 (2001)). However, when LPD/E7 is given SC the particles will drain into the local lymph nodes where successful priming can occur and removal of the spleen has no effect. The fact that IV vaccination consistently induced higher CTL activities than SC injection in combination with the observations in asplenic mice shows that antigen delivery to the spleen is important for the enhanced vaccination observed here. - These results seem to be in contrast with those obtained by others using liposome/peptide complexes for vaccination (Ignatius, et al. Blood 96, 3505-3513 (2000); and Ludewig, et al., Vaccine 19, 23-32 (2000)). In these studies, no immune response was observed upon IV administration. This discrepancy may be due to differences in liposome formulation used. LPD lipopolyplexes are more stable than non-polycation containing lipoplexes (Li, et al.
Gene Ther 5, 930-937 (1998)). It has been reported that prolonged stability results in liposome accumulation in the spleen (Tam, et al. Gene Ther 7, 1867-1874 (2000)). In the absence of extended circulation, other formulations may be rapidly degraded and fail to deliver sufficient amounts of antigen to the spleen. - The use of LPD particles for vaccination has some significant advantages. The inclusion of plasmid DNA in the particles allows for great flexibility in vaccine design. While we used empty plasmid DNA to form our LPD particles, DNA encoding any gene of interest may be substituted. For example, while LPD has a built in adjuvant effect, this can be modified by using DNA encoding cytokines designed to skew the immune response in a particular direction, chemotactic factors, or costimulatory molecules.
- The biophysical properties of the LPD formulation are also an advantage. Others have reported successful vaccination using liposome based peptide delivery strategies, however these systems are more complex and usually require higher doses of peptide or the inclusion of helper peptides or other stimulatory molecules (Ludewig, et al., Vaccine 19, 23-32 (2000)). From a pharmaceutical point of view, LPD particles can be lyophilized, stored for extended periods (at least 1 year), rehydrated, and used without any loss of efficacy (Li, et al. J Pharm Sci 89, 355-364. [pii] (2000)). These unique properties make large scale “off the shelf” applications possible for cancers with known immunodominant epitopes such as cervical cancer, prostate cancer and various her2/neu expressing cancers (Terasawa, et al.
Clin Cancer Res 8, 41-53 (2002); Knutson, et al.,Clin Breast Cancer 2, 73-79 (2001); Munger, et al.,Oncogene 20, 7888-7898 (2001); and Zeng, G.,J Immunother 24, 195-204 (2001)). - In compliance with 37 C.F.R. § 1.821(e), the applicants request that the compliant computer readable “Sequence Listing” that is already on file for corresponding U.S. patent application Ser. No. 11/121,840 be used with the present application. The paper copy of the “Sequence Listing” in the present application is identical to the computer readable copy filed with corresponding U.S. patent application Ser. No. 11/121,840.
- While the present invention has been disclosed by reference to the details of preferred embodiments of the invention, it is to be understood that the disclosure is intended as an illustrative rather than in a limiting sense, as it is contemplated that modifications will readily occur to those skilled in the art, within the spirit of the invention and the scope of the amended claims.
Claims (21)
1. A method of inducing an immune response in a subject comprising administering to the subject an antigen/lipid complex comprising an antigen and a non-steroidal cationic lipid having a structure represented by the formula:
wherein in R1 is a quaternary ammonium group, Y1 is chosen from a hydrocarbon chain, an ester, a ketone, and a peptide, R2 and R3 are independently chosen from a saturated fatty acid, an unsaturated fatty acid, an ester-linked hydrocarbon, phosphor-diesters, and combinations thereof;
to form an antigen/lipid complex to induce an immune response to treat or prevent disease in the subject.
2. The method of claim 1 wherein said cationic lipid is selected from the group consisting of 1,2-myristoyl-3-trimethylammonium propane (DMTAP), 1,2-distearoyl-3-trimethylammonium propane (DSTAP), 1,2-palmitoyl-3-trimethylammonium propane (DPTAP), 1,2-oleoyl-3-trimethylammonium propane (DOTAP), 1,2-dipalmitoyl-sn-glycero-3-ethylphosphocholine (DPEPC), 1,2-distearoyl-sn glycerol-3-ethylphosphocholine (DSEPC), 1,2-dimyristoyl-sn-glycero-3-ethylphophocholine (DMEPC), 1,2-dilauroyl-sn-glycero-3-ethylphosphocholine (DLEPC), 1,2-dioleoyl-sn-glycero-3-ethylphosphocholine (DOEPC), O,O′-dimyristyl-N-lysyl-aspartate (DMKE), O,O′-dimyristyl-N-lysyl-glutamate (DMKD), 2,3-dioleyloxy-N-[2(sperminecarboxamido)ethyl]-N,N-dimethyl-1-propanaminium trifluoracetate (DOSPA), N-[1-(2,3-dioleyloxy)propyl]-n,n,n-trimethylammonium chloride (DOTMA), their structural variants and derivatives, and combinations thereof.
3. A method for stimulating an immune response to a tumor in a subject comprising administering to the subject the complex of claim 1 wherein said antigen is a tumor-associated antigen thereby stimulating an immune response to a tumor in the subject.
4. A method for inhibiting the growth of a tumor cell in a subject, said method comprising administering to a subject the complex of claim 1 wherein said antigen is a tumor-associated antigen, or a tumor-associated antigen modified to retain its antigenic activity but to eliminate its tumorigenic activity, thereby preventing or inhibiting the growth of a tumor cell in said subject.
5. The method of claim 1 wherein the antigen is derived from pathogens associated with cancer risk wherein said pathogens are selected from the group consisting of hepatitis B virus, hepatitis C virus, Epstein Barr virus, HTLVL, oncogenic human papilloma viruses types 16, 18, 33, 45 and the bacterium Helicobacter pylori.
6. The method of claim 3 , wherein the tumor associated antigen is selected from the group consisting of mutated antigens, overexpressed antigens found in tumors, melanocyte differentiation antigens, prostate associated antigens, reactivated embryonic gene products, human papilloma virus antigens, oncofetal antigens, self antigens, cancer testis antigens, mucins, gangliosides, whole cell and tumor cell lysates, immunogenic portions of whole cell and tumor cell lysates, immunoglobulin idiotypes expressed on monoclonal proliferations of B lymphocytes, and combinations thereof.
7. The method of claim 6 wherein said human papilloma virus antigen is an HPV 16 E7 protein or peptide.
8. The method of claim 7 wherein said HPV 16 E7 protein or peptide has been modified to retain its antigenic activity but to eliminate its tumorigenic activity.
9. The method of claim 1 , wherein said antigen/lipid complex includes at least one additional component selected from the group consisting of a cationic salt, an adjuvant, an immunostimulant, a cholesterol, a surfactant, a polymer, and combinations thereof.
10. A method of inducing an immune response to treat or prevent an infectious disease in a subject comprising administering to the subject an antigen/lipid complex comprising an antigen and a non-steroidal cationic lipid having a structure represented by the formula:
wherein in R1 is a quaternary ammonium group, Y1 is chosen from a hydrocarbon chain, an ester, a ketone, and a peptide, R2 and R3 are independently chosen from a saturated fatty acid, an unsaturated fatty acid, an ester-linked hydrocarbon, phosphor-diesters, and combinations thereof;
to form an antigen/lipid complex to induce an immune response to treat or prevent an infectious disease in the subject.
11. The method of claim 10 wherein the cationic lipid selected from the group consisting of 1,2-myristoyl-3-trimethylammonium propane (DMTAP), 1,2-distearoyl-3-trimethylammonium propane (DSTAP), 1,2-palmitoyl-3-trimethylammonium propane (DPTAP), 1,2-oleoyl-3-trimethylammonium propane (DOTAP), 1,2-dipalmitoyl-sn-glycero-3-ethylphosphocholine (DPEPC), 1,2-distearoyl-sn glycerol-3-ethylphosphocholine (DSEPC), 1,2-dimyristoyl-sn-glycero-3-ethylphophocholine (DMEPC), 1,2-dilauroyl-sn-glycero-3-ethylphosphocholine (DLEPC), 1,2-dioleoyl-sn-glycero-3-ethylphosphocholine (DOEPC), O,O′-dimyristyl-N-lysyl-aspartate (DMKE), O,O′-dimyristyl-N-lysyl-glutamate (DMKD), 2,3-dioleyloxy-N-[2(sperminecarboxamido)ethyl]-N,N-dimethyl-1-propanaminium trifluoracetate (DOSPA), N-[1-(2,3-dioleyloxy)propyl]-n,n,n-trimethylammonium chloride (DOTMA), and combinations thereof.
12. The method of claim 10 wherein said antigen is a viral or microbial antigen.
13. The method of claim 12 wherein said viral antigen is selected from the group consisting of retroviridae, picornaviridae, orthomyxoviridae, herpesviridae, hepatitis A, hepatitis B, hepatitis C, Epstein Barr virus, HTLVL, oncogenic human papilloma viruses types 16, 18, 33, and 45, and combinations thereof.
14. The method of claim 12 wherein said microbial antigen is selected from the group consisting of Mycobacteria species, Pasteurella species, Staphylocci species, Streptococcus species, Pseudomonas species, Salmonella species, Helicobacter pylori, and combinations thereof.
15. The method of claim 10 wherein said antigen is a protein or peptide associated with a virus or microbe.
16. The method of claim 10 wherein said antigen is a protein or peptide associated with a virus or microbe, and the protein or peptide is modified to retain its antigenic activity but to eliminate its pathogenic activity.
17. The method of claim 10 , wherein the cationic lipid includes structural variants and derivatives thereof.
18. An antigen/lipid complex comprising an antigen and a non-steroidal cationic lipid having a structure represented by the formula:
wherein in R1 is a quaternary ammonium group, Y1 is chosen from a hydrocarbon chain, an ester, a ketone, and a peptide, R2 and R3 are independently chosen from a saturated fatty acid, an unsaturated fatty acid, an ester-linked hydrocarbon, phosphor-diesters, and combinations thereof;
to form an antigen/lipid complex.
19. The complex of claim 18 wherein the cationic lipid is selected from the group consisting of 1,2-myristoyl-3-trimethylammonium propane (DMTAP), 1,2-distearoyl-3-trimethylammonium propane (DSTAP), 1,2-palmitoyl-3-trimethylammonium propane (DPTAP), 1,2-oleoyl-3-trimethylammonium propane (DOTAP), 1,2-dipalmitoyl-sn-glycero-3-ethylphosphocholine (DPEPC), 1,2-distearoyl-sn glycerol-3-ethylphosphocholine (DSEPC), 1,2-dimyristoyl-sn-glycero-3-ethylphophocholine (DMEPC), 1,2-dilauroyl-sn-glycero-3-ethylphosphocholine (DLEPC), 1,2-dioleoyl-sn-glycero-3-ethylphosphocholine (DOEPC), O,O′-dimyristyl-N-lysyl-aspartate (DMKE), O,O′-dimyristyl-N-lysyl-glutamate (DMKD), 2,3-dioleyloxy-N-[2(sperminecarboxamido)ethyl]-N,N-dimethyl-1-propanaminium trifluoracetate (DOSPA), N-[1-(2,3-dioleyloxy)propyl]-n,n,n-trimethylammonium chloride (DOTMA), and combinations thereof.
20. The complex of claim 18 further including an additive selected from the group consisting of cationic salt, adjuvant, immunostimulant, cholesterol, surfactant, polymer, and combinations thereof, to improve the stability or activity of the combination.
21. The complex of claim 18 wherein the cationic lipid includes structural variants and derivatives thereof.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US11/944,912 US20080131455A1 (en) | 2004-04-30 | 2007-11-26 | Antigen Delivery Compositions And Methods Of Use |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US56729104P | 2004-04-30 | 2004-04-30 | |
US11/121,840 US7303881B2 (en) | 2004-04-30 | 2005-05-02 | Antigen delivery compositions and methods of use |
US11/944,912 US20080131455A1 (en) | 2004-04-30 | 2007-11-26 | Antigen Delivery Compositions And Methods Of Use |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/121,840 Continuation US7303881B2 (en) | 2004-04-30 | 2005-05-02 | Antigen delivery compositions and methods of use |
Publications (1)
Publication Number | Publication Date |
---|---|
US20080131455A1 true US20080131455A1 (en) | 2008-06-05 |
Family
ID=35541619
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/121,840 Active 2026-02-09 US7303881B2 (en) | 2004-04-30 | 2005-05-02 | Antigen delivery compositions and methods of use |
US11/944,912 Abandoned US20080131455A1 (en) | 2004-04-30 | 2007-11-26 | Antigen Delivery Compositions And Methods Of Use |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/121,840 Active 2026-02-09 US7303881B2 (en) | 2004-04-30 | 2005-05-02 | Antigen delivery compositions and methods of use |
Country Status (1)
Country | Link |
---|---|
US (2) | US7303881B2 (en) |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20060003955A1 (en) * | 1994-07-15 | 2006-01-05 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
US20090017057A1 (en) * | 2007-03-22 | 2009-01-15 | Pds Biotechnology Corporation | Stimulation of an immune response by cationic lipids |
WO2013039989A1 (en) * | 2011-09-12 | 2013-03-21 | Pds Biotechnology Corporation | Particluate vaccine formulations |
US11612652B2 (en) | 2015-11-13 | 2023-03-28 | Pds Biotechnology Corporation | Lipids as synthetic vectors to enhance antigen processing and presentation ex-vivo in dendritic cell therapy |
US11801257B2 (en) | 2008-04-17 | 2023-10-31 | Pds Biotechnology Corporation | Stimulation of an immune response by enantiomers of cationic lipids |
US11904015B2 (en) | 2012-09-21 | 2024-02-20 | Pds Biotechnology Corporation | Vaccine compositions and methods of use |
Families Citing this family (40)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7576066B2 (en) | 2002-07-03 | 2009-08-18 | Coley Pharmaceutical Group, Inc. | Nucleic acid compositions for stimulating immune responses |
US7569553B2 (en) | 2002-07-03 | 2009-08-04 | Coley Pharmaceutical Group, Inc. | Nucleic acid compositions for stimulating immune responses |
US7605138B2 (en) | 2002-07-03 | 2009-10-20 | Coley Pharmaceutical Group, Inc. | Nucleic acid compositions for stimulating immune responses |
US7807803B2 (en) | 2002-07-03 | 2010-10-05 | Coley Pharmaceutical Group, Inc. | Nucleic acid compositions for stimulating immune responses |
US20040053880A1 (en) | 2002-07-03 | 2004-03-18 | Coley Pharmaceutical Group, Inc. | Nucleic acid compositions for stimulating immune responses |
DE10347710B4 (en) | 2003-10-14 | 2006-03-30 | Johannes-Gutenberg-Universität Mainz | Recombinant vaccines and their use |
FR2862306B1 (en) * | 2003-11-17 | 2008-05-30 | Aventis Pasteur | VACCINE COMPOSITION |
US7303881B2 (en) * | 2004-04-30 | 2007-12-04 | Pds Biotechnology Corporation | Antigen delivery compositions and methods of use |
WO2006118327A1 (en) * | 2005-04-27 | 2006-11-09 | Oxygenix Co Ltd | Cationic amino acid type lipid |
DE102005046490A1 (en) | 2005-09-28 | 2007-03-29 | Johannes-Gutenberg-Universität Mainz | New nucleic acid molecule comprising promoter, a transcriptable nucleic acid sequence, a first and second nucleic acid sequence for producing modified RNA with transcriptional stability and translational efficiency |
US8753878B2 (en) * | 2006-12-22 | 2014-06-17 | Ewos S.A. | Process and formulation for immunizing fish in aquaculture systems |
WO2008091569A2 (en) * | 2007-01-23 | 2008-07-31 | Dtherapeutics, Llc | Devices, systems, and methods for promoting endothelialization |
WO2009120247A2 (en) * | 2007-12-27 | 2009-10-01 | The Ohio State University Research Foundation | Lipid nanoparticle compositions and methods of making and using the same |
WO2009105283A1 (en) * | 2008-02-24 | 2009-08-27 | Govt. Of The United States Of America, As Represented By The Sec., Dept. Of Health And Human Service | Use of immunogenic compositions for the treatment or prevention of pathogen infections |
MX2010012326A (en) * | 2008-05-19 | 2010-12-01 | Univ North Carolina | Methods and compositions comprising novel cationic lipids. |
CA2761917C (en) * | 2009-05-14 | 2018-06-12 | Sanofi Pasteur | Method for detoxification of lipopolysaccharide (lps) or of lipid a of gram-negative bacteria |
HUE029284T2 (en) | 2010-07-06 | 2017-02-28 | Glaxosmithkline Biologicals Sa | Immunisation of large mammals with low doses of rna |
WO2012006373A1 (en) | 2010-07-06 | 2012-01-12 | The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. | Systems and methods for magnetized stent having growth-promoting properties |
NZ606591A (en) | 2010-07-06 | 2015-02-27 | Novartis Ag | Cationic oil-in-water emulsions |
MX2013000164A (en) | 2010-07-06 | 2013-03-05 | Novartis Ag | Liposomes with lipids having an advantageous pka- value for rna delivery. |
ES2934240T3 (en) | 2010-07-06 | 2023-02-20 | Glaxosmithkline Biologicals Sa | Virion-like delivery particles for self-replicating RNA molecules |
PT3243526T (en) | 2010-07-06 | 2020-03-04 | Glaxosmithkline Biologicals Sa | Delivery of rna to trigger multiple immune pathways |
MX2013002336A (en) | 2010-08-31 | 2013-03-18 | Novartis Ag | Pegylated liposomes for delivery of immunogen-encoding rna. |
HUE059214T2 (en) | 2010-08-31 | 2022-10-28 | Glaxosmithkline Biologicals Sa | Small liposomes for delivery of immunogen-encoding rna |
BR112013008700B8 (en) | 2010-10-11 | 2022-10-04 | Novartis Ag | SELF-REPLICATING RNA MOLECULE, ALPHAVIRUS REPLICON PARTICLE, COMPOSITION, RECOMBINANT DNA MOLECULE, USE OF SELF-REPLICATING RNA MOLECULE |
DE102011018499A1 (en) | 2011-04-23 | 2012-10-25 | Emc Microcollections Gmbh | Topical nanoparticle vaccine for the immune stimulation of dendritic cells in the skin |
AU2012261237B2 (en) | 2011-05-24 | 2017-06-01 | BioNTech SE | Individualized vaccines for cancer |
EP3332802A1 (en) | 2011-07-06 | 2018-06-13 | GlaxoSmithKline Biologicals SA | Immunogenic combination compositions and uses thereof |
EP2729125B1 (en) | 2011-07-06 | 2017-12-13 | GlaxoSmithKline Biologicals SA | Oil-in-water emulsions that contain nucleic acids |
EP2729124B1 (en) | 2011-07-06 | 2018-10-24 | GlaxoSmithKline Biologicals SA | Cationic oil-in-water emulsions |
AU2012325997C1 (en) * | 2011-10-18 | 2018-07-05 | Dicerna Pharmaceuticals, Inc. | Amine cationic lipids and uses thereof |
US20130131008A1 (en) * | 2011-10-25 | 2013-05-23 | Board Of Regents, The University Of Texas System | Lipophilic monophosphorylated derivatives and nanoparticles |
WO2013143555A1 (en) | 2012-03-26 | 2013-10-03 | Biontech Ag | Rna formulation for immunotherapy |
JP6484558B2 (en) | 2012-11-28 | 2019-03-13 | バイオエヌテック エールエヌアー ファーマシューティカルズ ゲーエムベーハーBiontech Rna Pharmaceuticals Gmbh | Combination of cancer vaccine |
WO2014180490A1 (en) | 2013-05-10 | 2014-11-13 | Biontech Ag | Predicting immunogenicity of t cell epitopes |
WO2016045732A1 (en) | 2014-09-25 | 2016-03-31 | Biontech Rna Pharmaceuticals Gmbh | Stable formulations of lipids and liposomes |
WO2016128060A1 (en) | 2015-02-12 | 2016-08-18 | Biontech Ag | Predicting t cell epitopes useful for vaccination |
WO2017059902A1 (en) | 2015-10-07 | 2017-04-13 | Biontech Rna Pharmaceuticals Gmbh | 3' utr sequences for stabilization of rna |
KR20200096800A (en) * | 2017-12-05 | 2020-08-13 | 피디에스 바이오테크놀러지 코퍼레이션 | Methods and compositions comprising cationic lipids for stimulating type I interferon genes |
CN113350521B (en) * | 2021-04-08 | 2022-11-29 | 上海大学 | LPD nano liposome and preparation method and application thereof |
Citations (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5264618A (en) * | 1990-04-19 | 1993-11-23 | Vical, Inc. | Cationic lipids for intracellular delivery of biologically active molecules |
US5283185A (en) * | 1991-08-28 | 1994-02-01 | University Of Tennessee Research Corporation | Method for delivering nucleic acids into cells |
US5334761A (en) * | 1992-08-28 | 1994-08-02 | Life Technologies, Inc. | Cationic lipids |
US6008202A (en) * | 1995-01-23 | 1999-12-28 | University Of Pittsburgh | Stable lipid-comprising drug delivery complexes and methods for their production |
US6214804B1 (en) * | 1989-03-21 | 2001-04-10 | Vical Incorporated | Induction of a protective immune response in a mammal by injecting a DNA sequence |
US6419931B1 (en) * | 1991-08-26 | 2002-07-16 | Epimmune Inc. | Compositions and methods for eliciting CTL immunity |
US6464980B1 (en) * | 1993-08-06 | 2002-10-15 | Epimmune Inc. | MAGE-1 c-terminal immunogenic peptides |
US20030008813A1 (en) * | 1999-12-17 | 2003-01-09 | Felgner Philip L. | Intracellular protein delivery compositions and methods of use |
US6586409B1 (en) * | 1999-03-26 | 2003-07-01 | Vical Incorporated | Adjuvant compositions and methods for enhancing immune responses to polynucleotide-based vaccines |
US6649170B1 (en) * | 1999-05-12 | 2003-11-18 | Statens Serum Institut | Adjuvant combinations for immunization composition and vaccines |
US6693086B1 (en) * | 1998-06-25 | 2004-02-17 | National Jewish Medical And Research Center | Systemic immune activation method using nucleic acid-lipid complexes |
US6710035B2 (en) * | 1989-03-21 | 2004-03-23 | Vical Incorporated | Generation of an immune response to a pathogen |
US6780421B1 (en) * | 1994-11-14 | 2004-08-24 | Aventis Pasteur Sa | Adjuvant for a vaccine composition |
US20050025822A1 (en) * | 2003-05-30 | 2005-02-03 | Wong Frances M.P. | Method of pulmonary administration of an agent |
US20050245446A1 (en) * | 2002-05-08 | 2005-11-03 | Hailes Helen C | Materials for the delivery of biologically-active material to cells |
US20060008472A1 (en) * | 2004-04-30 | 2006-01-12 | Leaf Huang | Antigen delivery compositions and methods of use |
US7001614B2 (en) * | 1996-08-19 | 2006-02-21 | The United States Of America As Represented By The Department Of Health And Human Services | Liposome complexes for increased systemic delivery |
US20060051405A1 (en) * | 2004-07-19 | 2006-03-09 | Protiva Biotherapeutics, Inc. | Compositions for the delivery of therapeutic agents and uses thereof |
US20060083780A1 (en) * | 2004-06-07 | 2006-04-20 | Protiva Biotherapeutics, Inc. | Cationic lipids and methods of use |
US20060165708A1 (en) * | 2001-06-29 | 2006-07-27 | Chugai Seiyaku Kabushiki Kaisha | Cancer vaccine containing cancer antigen based on tumor suppressor gene wt1 product and cationic liposomes |
US20060182793A1 (en) * | 2003-07-22 | 2006-08-17 | Cytos Biotechnology Ag | Cpg-packaged liposomes |
US7105574B1 (en) * | 1999-03-26 | 2006-09-12 | Vical Incorporated | Adjuvant compositions and methods for enhancing immune responses to polynucleotide-based vaccines |
US20060204566A1 (en) * | 1996-08-19 | 2006-09-14 | Government Of The Us, As Represented By The Secretary, Deprtment Of Health And Human Services | Novel liposome complexes for increased systemic delivery |
US20060223769A1 (en) * | 1998-06-25 | 2006-10-05 | National Jewish Medical And Research Center | Vaccines using nucleic acid-lipid complexes |
US20060275777A1 (en) * | 2005-06-03 | 2006-12-07 | Waelti Ernst R | Novel strategies for protein vaccines |
US20070059318A1 (en) * | 2005-08-15 | 2007-03-15 | Balu-Iyer Sathy V | Lipid nano particulates containing antigens as cancer vaccines |
US20080014254A1 (en) * | 2004-11-26 | 2008-01-17 | Michael Platscher | Stable Crystal Modifications of Dotap Chloride |
-
2005
- 2005-05-02 US US11/121,840 patent/US7303881B2/en active Active
-
2007
- 2007-11-26 US US11/944,912 patent/US20080131455A1/en not_active Abandoned
Patent Citations (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6710035B2 (en) * | 1989-03-21 | 2004-03-23 | Vical Incorporated | Generation of an immune response to a pathogen |
US6214804B1 (en) * | 1989-03-21 | 2001-04-10 | Vical Incorporated | Induction of a protective immune response in a mammal by injecting a DNA sequence |
US5459127A (en) * | 1990-04-19 | 1995-10-17 | Vical, Inc. | Cationic lipids for intracellular delivery of biologically active molecules |
US5264618A (en) * | 1990-04-19 | 1993-11-23 | Vical, Inc. | Cationic lipids for intracellular delivery of biologically active molecules |
US6419931B1 (en) * | 1991-08-26 | 2002-07-16 | Epimmune Inc. | Compositions and methods for eliciting CTL immunity |
US5283185A (en) * | 1991-08-28 | 1994-02-01 | University Of Tennessee Research Corporation | Method for delivering nucleic acids into cells |
US5334761A (en) * | 1992-08-28 | 1994-08-02 | Life Technologies, Inc. | Cationic lipids |
US6464980B1 (en) * | 1993-08-06 | 2002-10-15 | Epimmune Inc. | MAGE-1 c-terminal immunogenic peptides |
US6780421B1 (en) * | 1994-11-14 | 2004-08-24 | Aventis Pasteur Sa | Adjuvant for a vaccine composition |
US6008202A (en) * | 1995-01-23 | 1999-12-28 | University Of Pittsburgh | Stable lipid-comprising drug delivery complexes and methods for their production |
US20060204566A1 (en) * | 1996-08-19 | 2006-09-14 | Government Of The Us, As Represented By The Secretary, Deprtment Of Health And Human Services | Novel liposome complexes for increased systemic delivery |
US7001614B2 (en) * | 1996-08-19 | 2006-02-21 | The United States Of America As Represented By The Department Of Health And Human Services | Liposome complexes for increased systemic delivery |
US20040157791A1 (en) * | 1998-06-25 | 2004-08-12 | Dow Steven W. | Systemic immune activation method using nucleic acid-lipid complexes |
US6693086B1 (en) * | 1998-06-25 | 2004-02-17 | National Jewish Medical And Research Center | Systemic immune activation method using nucleic acid-lipid complexes |
US20060223769A1 (en) * | 1998-06-25 | 2006-10-05 | National Jewish Medical And Research Center | Vaccines using nucleic acid-lipid complexes |
US6586409B1 (en) * | 1999-03-26 | 2003-07-01 | Vical Incorporated | Adjuvant compositions and methods for enhancing immune responses to polynucleotide-based vaccines |
US7105574B1 (en) * | 1999-03-26 | 2006-09-12 | Vical Incorporated | Adjuvant compositions and methods for enhancing immune responses to polynucleotide-based vaccines |
US6649170B1 (en) * | 1999-05-12 | 2003-11-18 | Statens Serum Institut | Adjuvant combinations for immunization composition and vaccines |
US20030008813A1 (en) * | 1999-12-17 | 2003-01-09 | Felgner Philip L. | Intracellular protein delivery compositions and methods of use |
US20060165708A1 (en) * | 2001-06-29 | 2006-07-27 | Chugai Seiyaku Kabushiki Kaisha | Cancer vaccine containing cancer antigen based on tumor suppressor gene wt1 product and cationic liposomes |
US20050245446A1 (en) * | 2002-05-08 | 2005-11-03 | Hailes Helen C | Materials for the delivery of biologically-active material to cells |
US20050025822A1 (en) * | 2003-05-30 | 2005-02-03 | Wong Frances M.P. | Method of pulmonary administration of an agent |
US20060182793A1 (en) * | 2003-07-22 | 2006-08-17 | Cytos Biotechnology Ag | Cpg-packaged liposomes |
US20060008472A1 (en) * | 2004-04-30 | 2006-01-12 | Leaf Huang | Antigen delivery compositions and methods of use |
US7303881B2 (en) * | 2004-04-30 | 2007-12-04 | Pds Biotechnology Corporation | Antigen delivery compositions and methods of use |
US20060083780A1 (en) * | 2004-06-07 | 2006-04-20 | Protiva Biotherapeutics, Inc. | Cationic lipids and methods of use |
US20060051405A1 (en) * | 2004-07-19 | 2006-03-09 | Protiva Biotherapeutics, Inc. | Compositions for the delivery of therapeutic agents and uses thereof |
US20080014254A1 (en) * | 2004-11-26 | 2008-01-17 | Michael Platscher | Stable Crystal Modifications of Dotap Chloride |
US20060275777A1 (en) * | 2005-06-03 | 2006-12-07 | Waelti Ernst R | Novel strategies for protein vaccines |
US20070059318A1 (en) * | 2005-08-15 | 2007-03-15 | Balu-Iyer Sathy V | Lipid nano particulates containing antigens as cancer vaccines |
Cited By (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8129351B2 (en) * | 1994-07-15 | 2012-03-06 | The University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
US20060003955A1 (en) * | 1994-07-15 | 2006-01-05 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
US20090017057A1 (en) * | 2007-03-22 | 2009-01-15 | Pds Biotechnology Corporation | Stimulation of an immune response by cationic lipids |
US11911359B2 (en) | 2007-03-22 | 2024-02-27 | Pds Biotechnology Corporation | Stimulation of an immune response by cationic lipids |
US8877206B2 (en) | 2007-03-22 | 2014-11-04 | Pds Biotechnology Corporation | Stimulation of an immune response by cationic lipids |
US11801257B2 (en) | 2008-04-17 | 2023-10-31 | Pds Biotechnology Corporation | Stimulation of an immune response by enantiomers of cationic lipids |
WO2013039989A1 (en) * | 2011-09-12 | 2013-03-21 | Pds Biotechnology Corporation | Particluate vaccine formulations |
EP2755680A4 (en) * | 2011-09-12 | 2015-04-15 | Pds Biotechnology Corp | Particluate vaccine formulations |
EP2755680A1 (en) * | 2011-09-12 | 2014-07-23 | PDS Biotechnology Corporation | Particluate vaccine formulations |
US11904015B2 (en) | 2012-09-21 | 2024-02-20 | Pds Biotechnology Corporation | Vaccine compositions and methods of use |
US11911465B2 (en) | 2012-09-21 | 2024-02-27 | Pds Biotechnology Corporation | Vaccine compositions and methods of use |
US11612652B2 (en) | 2015-11-13 | 2023-03-28 | Pds Biotechnology Corporation | Lipids as synthetic vectors to enhance antigen processing and presentation ex-vivo in dendritic cell therapy |
US11638753B2 (en) | 2015-11-13 | 2023-05-02 | PDS Biotechnology Corporalion | Lipids as synthetic vectors to enhance antigen processing and presentation ex-vivo in dendritic cell therapy |
Also Published As
Publication number | Publication date |
---|---|
US7303881B2 (en) | 2007-12-04 |
US20060008472A1 (en) | 2006-01-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US7303881B2 (en) | Antigen delivery compositions and methods of use | |
US11801257B2 (en) | Stimulation of an immune response by enantiomers of cationic lipids | |
US20220031650A1 (en) | Stimulation of an immune response by cationic lipids | |
US20230285551A1 (en) | Lipids as synthetic vectors to enhance antigen processing and presentation ex-vivo in dendritic cell therapy | |
US20230052399A1 (en) | Methods to alter the tumor microenvironment for effective cancer immunotherapy |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |